An official website of the United States government
NCTN Catalog
The information presented here is estimated and for informational purposes only. Please consult the specific biospecimen resource for more detailed and precise inventory data.
Found 925 results.
| NCTN Groups & Access | Organ Site/Path DX | Protocol Number & Title | Total Patient Accrual | Specimen Types |
|---|---|---|---|---|
| ALLIANCE | Lung | 8833: Dihydro-5-azacytidine in malignant mesothelioma | Fixed Tissue Block (9), Fixed Tissue Slide (9) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 8852: Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma | Fixed Tissue Block (25), Fixed Tissue Slide (137), H&E Stained Slide (196) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 8854: Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma | Fixed Tissue Block (4), Fixed Tissue Slide (36), H&E Stained Slide (37) | |
| ALLIANCE | Breast | 8861: Monitoring CA 15-3 Antigen in Patients during & after Adjuvant Therapy for Stage II, Node Positve Ca of the Breast | Plasma (791) | |
| ALLIANCE | Lung | 8933: Trimetrexate for Malignant Mesothelioma: Phase II | Fixed Tissue Block (6) | |
| ALLIANCE | Lung | 8964: Pathology Review of Long Term Survivors in Small Cell Lung Cancer: A Case Control Study | Fixed Tissue Block (69) | |
| ALLIANCE | Lymphoma - Hodgkin's | 9051: A Phase II Study of Etoposide, Vinblastine, Doxorubicin EVA, and Subtotal Nodal Radiation in Poor Risk, Early Stage Hodgkin’s Disease | Fixed Tissue Block (8) | |
| ALLIANCE | Lymphoma - NOS | 9061: Clinical Significance of Bcl-2 Rearranements in Lymphoma Utilizing the Polymerase Chain Reaction | Fixed Tissue Block (19), Fixed Tissue Slide (4) | |
| ALLIANCE | Lung | 9064: Analysis of Neuroendocrine 211 Markers on Tissue Blocks in Patients with Stage IliA NOn-Small Cell Lung Cancer | Fixed Tissue Block (63) | |
| ALLIANCE | Breast | 9082: A Randomized Comparative Study of High Dose CPA/cDDP/BCNU and ABMT versus Standard Dose CPA/cDDP/BCNU as Consolidation to Adjuvant CAF for Patients with Operable Stage II or Stage III Breast Cancer Involving > 10 Axillary Lymph Nodes, Phase III | Fixed Tissue Block (16) | |
| ALLIANCE | Lung | 9131: Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma | Fixed Tissue Block (33), Fixed Tissue Slide (3), H&E Stained Slide (5) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 9150: High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma | Fixed Tissue Block (6) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 9153: Prolonged Follow-up After Initial Therapy With 2-Chlorodeoxyadenosine in Patients With Indolent Non-Hodgkin Lymphoma | Fixed Tissue Block (12) | |
| ALLIANCE | Gastric | 9195: Trial of Adjuvant Chemoradiation After Gastric Resection For Adenocarcinoma, Phase III | Fixed Tissue Block (24), Fixed Tissue Slide (6), H&E Stained Slide (4) | |
| ALLIANCE | Lung | 9234: High-dose paclitaxel plus G-CSF for malignant mesothelioma | Fixed Tissue Block (8) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 9251: Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia | Fixed Tissue Block (8), Fixed Tissue Slide (62), H&E Stained Slide (81) | |
| ALLIANCE | Lung | 9267: Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer | Fixed Tissue Block (156), Fixed Tissue Slide (100), H&E Stained Slide (150) | |
| ALLIANCE | Breast | 9342: Phase III study of Taxol at three dose levels in the treatment of patients with metastatic breast cancer | Fixed Tissue Block (160), Fixed Tissue Slide (211) | |
| ALLIANCE | Breast | 9343: Evaluation of Lumpectomy, Tamoxifen, & Irradiation of the Breast Compared with Llumpectomy + Tamoxifen in Women 70 Years of Age or Older who have Carcinoma of the Breast that is Less Than or Equal to 2cm & Clinicaly Negative Axillary Nodes | Digital Slide Images (70), Fixed Tissue Block (377), Fixed Tissue Slide (466), H&E Stained Slide (201) | |
| ALLIANCE | Breast | 9344: Doxorubicin Dose Escalation, with or without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen for Node Positive Breast Cancer: A Phase III Intergroup Study | 3,121 | Digital Slide Images (2,450), Fixed Tissue Block (2,801), Fixed Tissue Slide (1,000) |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 9351: Phase II study of high dose CHOP in previously untreated low intermediate, high intermediate, and high risk non-Hodgkin’s lymphoma: IWF grade E,F,G,H | Fixed Tissue Block (12), Fixed Tissue Slide (82), H&E Stained Slide (89) | |
| ALLIANCE | Lymphoma - Hodgkin's | 9391: RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease | Fixed Tissue Block (5), Fixed Tissue Slide (3), H&E Stained Slide (5) | |
| ALLIANCE | Breast | 9394: Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes | 636 | Fixed Tissue Block (132), Fixed Tissue Slide (69), H&E Stained Slide (3) |
| ALLIANCE | Colon | 9395: Phase III intergroup prospectively randomized trail of perioperative 5-FU after curative resection followed by 5-FU/Levamisole for patients with colon cancer | Fixed Tissue Block (40), Fixed Tissue Slide (3), H&E Stained Slide (35) | |
| ALLIANCE | Breast | 9443: | Fixed Tissue Block (56), Fixed Tissue Slide (2), H&E Stained Slide (11) | |
| ALLIANCE | Prostate | 9480: A Phase III Study of Three Different Doses of Suramin (NSC# 34936) Administered with a Fixed Dosing Schedule in Patients with Advanced Prostate Cancer | Plasma (360), Serum (14), Urine (371) | |
| ALLIANCE | Colon | 9481: Phase III study of hepatic artery floxuridine (FUDR), leucovorin (LV), and dexamethasone (DEX) versus systemic 5-fluorouracil (5-FU) and leucovorin (LV) as treatment for hepatic metastases from colorectal cancer | Fixed Tissue Block (5), H&E Stained Slide (56) | |
| ALLIANCE | Breast | 9484: Linkage of molecular and epidmiological breast cancer investigations with treatment data: A specialized registry | Fixed Tissue Slide (6) | |
| ALLIANCE | Rectum | 9491: Postoperative evaluation of 5-FU by bolus injection vs. 5-FU by prolonged venous infusion prior to and following combined prolonged venous infusion plus pelvic XRT plus bolus 5-FU plus Leucovorin in patients with rectal cancer | Fixed Tissue Block (7), Fixed Tissue Slide (6), H&E Stained Slide (4) | |
| ALLIANCE | Breast | 9494: | Fixed Tissue Block (36), Fixed Tissue Slide (13), H&E Stained Slide (3) | |
| ALLIANCE | Breast | 9496: Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer | Fixed Tissue Block (2) | |
| ALLIANCE | Lung | 9530: Gemcitabine for malignant mesothelioma: A phase II trial | Fixed Tissue Block (5) | |
| ALLIANCE | Lymphoma - NOS | 9550: | Fixed Tissue Slide (9), H&E Stained Slide (12) | |
| ALLIANCE | Lymphoma - NOS | 9551: Phase II study of 9-aminocamptothecin in previously treated lymphomas | Fixed Tissue Block (2), Fixed Tissue Slide (33) | |
| ALLIANCE via Navigator | Colon | 9581: Phase III randomized study of adjuvant immunotherapy with monoclonal antibody 17-1A versus no adjuvant therapy following resection for stage II (modified astler-coller B2) adenocarcinoma of the colon | Digital Slide Images (1,350), Fixed Tissue Block (1,099), Fixed Tissue Slide (1,094), H&E Stained Slide (1,331) | |
| ALLIANCE via Navigator | Lung | 9633: A phase III study of adjuvant chemotherapy after resection for patients with T2 N0 stage I non-small cell carcinoma of the lung | Digital Slide Images (169), Fixed Tissue Block (223) | |
| ALLIANCE | Prostate | 9663: Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy | Fixed Tissue Block (135), Plasma (162), RNA (109), Whole Bone Marrow (105) | |
| ALLIANCE | Colon | 9667: Biologic Correlates to Response and Survival in Colon Cancer | Fixed Tissue Block (110), Fixed Tissue Slide (34), H&E Stained Slide (100) | |
| ALLIANCE | Prostate | 9682: Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer | Fixed Tissue Block (14), Fixed Tissue Slide (44), H&E Stained Slide (3) | |
| ALLIANCE | Prostate | 9687: Surgery in Treating Patients With Prostate Cancer | Fixed Tissue Block (1), Fixed Tissue Slide (35), H&E Stained Slide (18) | |
| ALLIANCE via Navigator | Leukemia - Acute myelocytic | 9710: Phase III randomized study of concurrent tretinoin & chemotherapy with or without arsenic trioxide (As2O3)(NSC # 706363) as initial consolidation therapy followed by maintenance therapy with intermittent tretinoin versus intermittent tretinoin plus mercaptopurine and methotrexate for patients with untreated acute promyelocytic leukemia | 229 | Cell Slide (186), Cells (226), DNA (5), RNA (138), Serum (9) |
| ALLIANCE | Leukemia - Acute myelocytic | 9710: Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients With Untreated Acute Promyelocytic Leukemia | 229 | Cell Slide (186), Cells (226), DNA (5), RNA (138), Serum (9) |
| ALLIANCE via Navigator | Leukemia - Acute myelocytic | 9720: Phase III study of MDR modulation with PSC-833 (NSC#648265) followed by immunotherapy with rIL-2 (NSC#373364) vs. no further therapy in previously untreated patients with AML >= 60 years | 664 | Cell Slide (395), Cells (661), DNA (363), Serum (1) |
| ALLIANCE | Leukemia - Acute myelocytic | 9720: Multidrug Resistance Studies in Acute Myeloid Leukemia | 664 | Cell Slide (395), Cells (661), DNA (363), Serum (1) |
| ALLIANCE via Navigator | Breast | 9741: A randomized phase III trial of sequential chemotherapy using doxorubicin, paclitaxel, and cyclophosphamide followed by paclitaxel at 14 or 21 days intervals in women with node postitive stage II/IIIA breast cancer | Digital Slide Images (1,400), Fixed Tissue Block (1,408), Fixed Tissue Slide (289), H&E Stained Slide (1,605) | |
| ALLIANCE | Lung | 9761: Detection of Occult Micrometastases in Patients With Clinical Stage I NSCLC: A Prospective Analysis | Fixed Tissue Block (341) | |
| ALLIANCE | Prostate | 9782: Hormone Therapy in Treating Patients With Prostate Cancer | DNA (1), Plasma (70) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 9793: Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma | Digital Slide Images (30), Fixed Tissue Block (69), Fixed Tissue Slide (122), H&E Stained Slide (96) | |
| ALLIANCE | Lung | 9795: Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed | Fixed Tissue Block (45), H&E Stained Slide (43) | |
| ALLIANCE via Navigator | Breast | 9840: A phase III study of paclitaxel via weekly 1 hour infusion versus standard 3 hour infusion every 3 weeks with herceptin (trastuzumab) (NSC #688097) in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer | Fixed Tissue Block (253), Fixed Tissue Slide (323), H&E Stained Slide (366), Plasma (13) | |
| ALLIANCE via Navigator | Leukemia - Acute myelocytic | 10201: A phase III study of daunorubicin and cytarabine +/- G3139 (Genasense |, oblimersen sodium, NSC # 683428, IND #58842), a BCL2 antisense oligonuecleotide, in previously untreated patients with acute myeloid leukemia (AML) >/= 60 years | 495 | Cell Slide (418), Cells (494), DNA (186), Plasma (1), RNA (179), Serum (19) |
| ALLIANCE | Leukemia - Acute myelocytic | 10201: A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) > / = 60 Years | 495 | Cell Slide (418), Cells (494), DNA (186), Plasma (1), RNA (179), Serum (19) |
| ALLIANCE | Leukemia - Acute myelocytic | 10503: Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia | 545 | Cell Slide (361), Cells (524), DNA (2), Saliva (164), Serum (17) |
| ALLIANCE | Leukemia - Acute myelocytic | 10503: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) | 545 | Cell Slide (361), Cells (524), DNA (2), Saliva (164), Serum (17) |
| ALLIANCE | Leukemia - Acute myelocytic | 10603: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML) | 1,194 | Cell Slide (924), Cells (1,148), Plasma (169), Saliva (476), Serum (2) |
| ALLIANCE | Leukemia - Acute myelocytic | 10603: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) | 1,194 | Cell Slide (924), Cells (1,148), Plasma (169), Saliva (476), Serum (2) |
| ALLIANCE | Leukemia - Acute lymphocytic | 10701: A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Fixed Tissue Slide (20), Plasma (43) | |
| ALLIANCE via Navigator | Leukemia - Acute myelocytic | 19808: Phase III randomized study of induction chemotherapy with or without MDR-modulation with PSC-833 (NSC # 648265, IND # 41121) followed by cytogenetic risk-adapted intensification therapy followed by immunotherapy with rIL-2 (NSC# 373364, IND # 1969) vs. observation in previously untreated patients with AML < 60 years | 733 | Cell Slide (683), Cells (732), DNA (355), RNA (238), Serum (12) |
| ALLIANCE | Leukemia - Acute myelocytic | 19808: Multidrug Resistance Studies in Acute Myeloid Leukemia | 733 | Cell Slide (683), Cells (732), DNA (355), RNA (238), Serum (12) |
| ALLIANCE | Lung | 30101: RANDOMIZED PHASE II STUDY OF MAINTENANCE PEMETREXED VERSUS OBSERVATION FOR PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA WITHOUT PROGRESSION AFTER FIRST-LINE CHEMOTHERAPY | Fixed Tissue Block (3), Fixed Tissue Slide (27), H&E Stained Slide (25) | |
| ALLIANCE | Lung | 30106: Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: phase II trial | Buffy Coat (10), DNA (21), Fixed Tissue Block (12), Fixed Tissue Slide (22), H&E Stained Slide (22), Plasma (26), Serum (20), Whole Blood (7) | |
| ALLIANCE | Lung | 30107: Vatalanib in malignant mesothelioma: a phase II trial | Cells (23), DNA (15), Plasma (37), Serum (29) | |
| ALLIANCE | Lung | 30203: Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer | Fixed Tissue Block (55), Fixed Tissue Slide (98), H&E Stained Slide (58), Serum (131) | |
| ALLIANCE | Lung | 30304: Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer | DNA (7), Plasma (7), Whole Blood (4) | |
| ALLIANCE | Lung | 30306: Cisplatin, Irinotecan and Bevacizumab (NSC# 704865) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study | 76 | Buffy Coat (10), Digital Slide Images (45), DNA (61), Fixed Tissue Block (9), Fixed Tissue Slide (30), H&E Stained Slide (49), Plasma (61), Whole Blood (51) |
| ALLIANCE | Lung | 30307: A Phase II Study of BAY 43-9006 (NSC #724772) in Patients With Malignant Mesothelioma | 51 | Digital Slide Images (44), Fixed Tissue Block (12), Fixed Tissue Slide (30), H&E Stained Slide (52), Plasma (51) |
| ALLIANCE | Lung | 30406: Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma | Buffy Coat (157), Digital Slide Images (171), DNA (165), Fixed Tissue Block (50), Fixed Tissue Slide (98), H&E Stained Slide (167), Plasma (170), Whole Blood (9) | |
| ALLIANCE | Lung | 30407: A Randomized Phase II Study of Radiation Therapy, Pemetrexed and Carboplatin With or Without Cetuximab in Stage III Non-Small Cell Lung Cancer | Fixed Tissue Block (31), Fixed Tissue Slide (74), H&E Stained Slide (33) | |
| ALLIANCE | Lung | 30504: Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study | Plasma (84) | |
| ALLIANCE | Lung | 30506: A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients with Early Stage Non-Small Cell Lung Cancer Associated with Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data | Fixed Tissue Block (10), Fixed Tissue Slide (19), Frozen Tissue (39), H&E Stained Slide (21) | |
| ALLIANCE | Lung | 30601: A Phase II Study of Dasatinib (NSC #732517) in Patients With Previously Treated Malignant Mesothelioma | Buffy Coat (41), Digital Slide Images (26), Fixed Tissue Block (13), Fixed Tissue Slide (31), H&E Stained Slide (31), Plasma (41), Serum (39) | |
| ALLIANCE | Lung | 30602: Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer | Buffy Coat (33), DNA (33), Plasma (32), Serum (33), Whole Blood (1) | |
| ALLIANCE | Lung | 30605: A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer | Digital Slide Images (52), Fixed Tissue Block (18), Fixed Tissue Slide (28), H&E Stained Slide (58) | |
| ALLIANCE | Lung | 30607: Randomized phase III double-blind placebo-controlled trial of sunitinib (NSC#736511, IND #74019) as maintenance therapy in non-progressing patients following an initial four cycles of platinum-based combination chemotherapy in advanced stage IIIB/IV non-small cell lung cancer | Buffy Coat (179), DNA (179), Plasma (184) | |
| ALLIANCE | Lung | 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide | Plasma (445) | |
| ALLIANCE | Lung | 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer | Buffy Coat (105), DNA (82), Plasma (107), Serum (2) | |
| ALLIANCE | Lung | 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer | Buffy Coat (331), Digital Slide Images (500), DNA (332), Fixed Tissue Block (220), Fixed Tissue Slide (401), Plasma (317), Urine (228) | |
| ALLIANCE | Lung | 30901: Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients with Malignant Pleural Mesothelioma without Progression After First-Line Chemotherapy | Buffy Coat (42), DNA (42), Fixed Tissue Block (25), Fixed Tissue Slide (9), H&E Stained Slide (10), Plasma (45), Serum (45) | |
| ALLIANCE | Lung | 39810: Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2 | Fixed Tissue Block (1) | |
| ALLIANCE via Navigator | Breast | 40101: Cyclophosphamide and doxorubicin (CA x 4 cycles) versus paclitaxel ( 4 cycles) as adjuvant therapy for breast cancer in women with 0-3 positive axillary lymph nodes: a phase III randomized study | Buffy Coat (1,343), Digital Slide Images (300-400), DNA (2,481), Fixed Tissue Block (2,223), Plasma (2,427), Serum (22), Whole Blood (488) | |
| ALLIANCE | Breast | 40105: Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design | Fixed Tissue Block (11), Fixed Tissue Slide (11), H&E Stained Slide (12) | |
| ALLIANCE | Breast | 40302: Endocrine Therapy with or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or Without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer | Digital Slide Images (154), Fixed Tissue Block (182), Fixed Tissue Slide (19), H&E Stained Slide (106), Plasma (1), Serum (267) | |
| ALLIANCE | Breast | 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone with or without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer | Buffy Coat (635), Digital Slide Images (471), DNA (639), Fixed Tissue Block (479), Fixed Tissue Slide (30), H&E Stained Slide (478), Serum (649) | |
| ALLIANCE | Breast | 40503: Endocrine Therapy with or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer | Buffy Coat (315), Digital Slide Images (219), DNA (313), Fixed Tissue Block (235), Fixed Tissue Slide (11), H&E Stained Slide (225), Plasma (333), Serum (335) | |
| ALLIANCE | Breast | 40601: Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer | Buffy Coat (246), Digital Slide Images (833), DNA (244), Fixed Tissue Block (302), Frozen Tissue (296), H&E Stained Slide (31), Serum (273) | |
| ALLIANCE | Breast | 40603: Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer | Buffy Coat (374), Digital Slide Images (425), DNA (374), Fixed Tissue Block (436), H&E Stained Slide (559) | |
| ALLIANCE | Breast | 40903: Phase II Study Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in SITU (DCIS) | Buffy Coat (80), DNA (80), Fixed Tissue Block (15), Fixed Tissue Slide (1), Plasma (79) | |
| ALLIANCE | Breast | 49801: Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ | Fixed Tissue Block (164), Fixed Tissue Slide (56), H&E Stained Slide (53), Plasma (90) | |
| ALLIANCE | Breast | 49806: Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer | Fixed Tissue Block (5) | |
| ALLIANCE | Breast | 49808: A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T +/- H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or None in Women with Her-2+ Stage IIIA, IIIB or Regional Stage IV Breast Cancer | Fixed Tissue Block (5), Fixed Tissue Slide (2), H&E Stained Slide (3) | |
| ALLIANCE via Navigator | Breast | 49907: A randomized trial of adjuvant chemotherapy with standard regimens, cyclophosphamide, methotrexate and fluorouracil - (CMF) or doxorubicin and cyclophosphamide - (AC), versus capecitabine in women 65 years and older with node positive or node negative breast cancer | Digital Slide Images (320), Fixed Tissue Block (392) | |
| ALLIANCE | Breast | 49910: S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast Cancer | Fixed Tissue Block (3), Fixed Tissue Slide (2), H&E Stained Slide (3) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 50002: Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Fixed Tissue Block (25), Fixed Tissue Slide (18), H&E Stained Slide (24) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 50103: Phase II Study Of Dose-Adjusted Epoch-Rituximab (EPOCH-R) Chemotherapy For Patients With Previously Untreated Aggressive CD20+ B-Cell Non-Hodgkin's Lymphoma (NHL) | Digital Slide Images (73), Fixed Tissue Block (18), Fixed Tissue Slide (65), H&E Stained Slide (71) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 50201: A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma | Fixed Tissue Block (1), Fixed Tissue Slide (7), H&E Stained Slide (7) | |
| ALLIANCE | Lymphoma - NOS | 50202: Intensive Chemotherapy And Immunotherapy In Patients With Newly Diagnosed Primary CNS Lymphoma | Digital Slide Images (43), Fixed Tissue Block (22), Fixed Tissue Slide (38), H&E Stained Slide (44) | |
| ALLIANCE | Lymphoma - Hodgkin's | 50203: Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma | Digital Slide Images (102), Fixed Tissue Block (6), Fixed Tissue Slide (53), H&E Stained Slide (95) | |
| ALLIANCE | Lymphoma - Hodgkin's | 50206: A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | Fixed Tissue Block (3), Fixed Tissue Slide (25), H&E Stained Slide (24) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 50401: A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory | Buffy Coat (88), Digital Slide Images (94), DNA (88), Fixed Tissue Block (76), Fixed Tissue Slide (34), H&E Stained Slide (81), Plasma (87) | |
| ALLIANCE | Lymphoma - NOS | 50402: Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab | Digital Slide Images (54), Fixed Tissue Block (34), Fixed Tissue Slide (4), H&E Stained Slide (57) | |
| ALLIANCE | Lymphoma - NOS | 50403: Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma | Digital Slide Images (137), Fixed Tissue Block (111), Fixed Tissue Slide (87) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 50404: A Phase II Trial of Rituximab + Oblimersen Sodium (GenasenseTM, G3139, NSC #683428, IND #58842) in Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL) | Fixed Tissue Slide (1), H&E Stained Slide (1) | |
| ALLIANCE | Lymphoma - NOS | 50501: A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (Revlimid™, CC-5013) (NSC #703813) for Relapsed/Refractory Mantle Cell Lymphoma | Digital Slide Images (25), Fixed Tissue Block (3), Fixed Tissue Slide (4), H&E Stained Slide (2) | |
| ALLIANCE | Lymphoma - Hodgkin's | 50502: A Randomized Double-Blinded Placebo Controlled Phase II Study of the Anti-CD30 Antibody, SGN-30 (NSC #731636), in Combination With Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD) for Patients With Relapsed/Refractory Hodgkin Lymphoma | Buffy Coat (25), Digital Slide Images (30), DNA (26), Fixed Tissue Block (26), Fixed Tissue Slide (5), H&E Stained Slide (27), Plasma (25) | |
| ALLIANCE | Lymphoma - Hodgkin's | 50602: Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | Buffy Coat (25), DNA (25), Fixed Tissue Block (22), Fixed Tissue Slide (8), H&E Stained Slide (11), Plasma (26), Serum (24) | |
| ALLIANCE | Lymphoma - Hodgkin's | 50604: Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma | Buffy Coat (25), Digital Slide Images (142), DNA (25), Fixed Tissue Block (32), Fixed Tissue Slide (19), H&E Stained Slide (24), Plasma (26), Serum (80) | |
| ALLIANCE | Lymphoma - NOS | 50701: A phase II trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma | Buffy Coat (58), Digital Slide Images (58), DNA (49), Fixed Tissue Block (52), Fixed Tissue Slide (34), H&E Stained Slide (59), Plasma (62) | |
| ALLIANCE | Lymphoma - Hodgkin's | 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL) | Digital Slide Images (64), Fixed Tissue Block (74), Fixed Tissue Slide (50), H&E Stained Slide (49), Plasma (39), Serum (39) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 50803: A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL) | Buffy Coat (58), Digital Slide Images (62), DNA (58), Fixed Tissue Block (50), Fixed Tissue Slide (39), H&E Stained Slide (61), Plasma (60) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 50901: A Phase II Trial of Ofatumumab (CALGB IND #112390) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL) | Buffy Coat (39), Cells (5), Digital Slide Images (47), DNA (40), Fixed Tissue Block (31), Fixed Tissue Slide (14), H&E Stained Slide (37) | |
| ALLIANCE | Lymphoma - NOS | 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients with Untreated Follicular Lymphoma | Buffy Coat (234), Digital Slide Images (120), DNA (234), Fixed Tissue Block (103), Fixed Tissue Slide (172), H&E Stained Slide (117), Plasma (174), Serum (333) | |
| ALLIANCE | Lymphoma - NOS | 51101: A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma | Digital Slide Images (72), Fixed Tissue Block (40), Fixed Tissue Slide (29), H&E Stained Slide (32) | |
| ALLIANCE | Lymphoma - Hodgkin's | 59804: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma | Fixed Tissue Block (12), Fixed Tissue Slide (77), H&E Stained Slide (81) | |
| ALLIANCE | Lymphoma - NOS | 59901: 506U78 in Treating Patients With Lymphoma | Fixed Tissue Block (1), Fixed Tissue Slide (15), H&E Stained Slide (18) | |
| ALLIANCE | Lymphoma - Non-Hodgkin's | 59903: Randomized Phase II Study of Dose-Adjusted EPOCH vs. NHL-15 Chemotherapy for Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma (NHL) | Digital Slide Images (58), Fixed Tissue Block (35), Fixed Tissue Slide (42), H&E Stained Slide (58) | |
| ALLIANCE | Lymphoma - NOS | 59906: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma | Fixed Tissue Block (3), Fixed Tissue Slide (21), H&E Stained Slide (24) | |
| ALLIANCE | Hematologic - NOS | 59908: Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma | Fixed Tissue Block (1), Fixed Tissue Slide (3), H&E Stained Slide (3) | |
| ALLIANCE | Lymphoma - NOS | 59909: A Phase II Study Of Intensive Induction Chemotherapy Followed By Autologous Stem Cell Transplantation Plus Immunotherapy For Mantle Cell Lymphoma | Digital Slide Images (75), Fixed Tissue Block (13), H&E Stained Slide (2) | |
| ALLIANCE | Multiple (not organ based) | 60301: Pharmacokinetic and phase I study of sorafenib (BAY 43-9006, NSC 724772, IND #69896) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction | Fixed Tissue Block (12) | |
| ALLIANCE | Multiple (not organ based) | 70604: A randomized, phase III study of standard dosing versus longer dosing interval of zoledronic acid in metastatic cancer | Buffy Coat (1,339), DNA (1,341), Serum (758) | |
| ALLIANCE via Navigator | Breast | 70806: Vitamin D and breast cancer markers | Serum (265) | |
| ALLIANCE | Prostate | 70807: The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance | Buffy Coat (515), Digital Slide Images (350), DNA (517), Fixed Tissue Slide (222), Plasma (568), Serum (480) | |
| ALLIANCE | Breast | 79805: Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease | Serum (65) | |
| ALLIANCE | Prostate | 79806: Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels | Fixed Tissue Block (3), Fixed Tissue Slide (17), H&E Stained Slide (9) | |
| ALLIANCE | Colon | 80001: Sentinel Node Staging of Resectable Colon Cancer | Fixed Tissue Block (71), Fixed Tissue Slide (77), H&E Stained Slide (75) | |
| ALLIANCE | Rectum | 80002: Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer | Fixed Tissue Block (2), H&E Stained Slide (1) | |
| ALLIANCE | Gastrointestinal stromal tumor | 80004: STI571 Response Predictors in Gastrointestinal Stromal Tumors | Fixed Tissue Block (202), Fixed Tissue Slide (30) | |
| ALLIANCE | Gastric | 80101: Phase III intergroup trial of adjuvant chemoradiation after resection of gastric or gastroesophageal adenocarcinoma | Buffy Coat (302), Digital Slide Images (77), DNA (265), Fixed Tissue Block (314), Fixed Tissue Slide (145), H&E Stained Slide (296), Plasma (379), Serum (1), Whole Blood (66) | |
| ALLIANCE via Navigator | GI - NOS | 80203: Phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with and without cetuximab (C225) for patients with untreated matastatis adenocarcinoma of the colon or rectum | Buffy Coat (6), Digital Slide Images (206), DNA (184), Fixed Tissue Block (155), Fixed Tissue Slide (208), H&E Stained Slide (192), Plasma (79), Serum (155), Whole Blood (79) | |
| ALLIANCE via Navigator | Pancreas | 80303: A randomized phase III trial of gemcitabine plus bevacizumab (NSC #704865 IND #7921) versus gemcitabine plus placebo in patients with advanced pancreatic cancer | Buffy Coat (47), DNA (390), Plasma (348), Serum (254), Urine (355), Whole Blood (247) | |
| ALLIANCE | Bladder | 80403: Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | Buffy Coat (179), DNA (176), Plasma (178) | |
| ALLIANCE | GI - NOS | 80405: Phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum | Buffy Coat (1,944), DNA (2,062), Plasma (1,842), Serum (329), Whole Blood (91) | |
| ALLIANCE | Pancreas | 80701: Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors | Fixed Tissue Block (42), Fixed Tissue Slide (41), H&E Stained Slide (40) | |
| ALLIANCE | Colon | 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer | Buffy Coat (840), DNA (840), Fixed Tissue Block (758), Fixed Tissue Slide (184), H&E Stained Slide (184), Plasma (1,922), Serum (1,942) | |
| ALLIANCE | Liver | 80802: Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) | Buffy Coat (209), DNA (209), Plasma (231), Serum (221) | |
| ALLIANCE | Esophageal | 80803: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer | Digital Slide Images (101), Fixed Tissue Block (33), Fixed Tissue Slide (45), H&E Stained Slide (1) | |
| ALLIANCE via Navigator | Colon | 89803: Phase III intergroup trial of irinotecan (CPT-11) (NSC # 616348) plus fluorouracil/leucovorin (5-FU/Lv) versus fluorouracil/leucovorin alone after curative resection for patients with stage III colon cancer | Digital Slide Images (655), Fixed Tissue Block (758) | |
| ALLIANCE | Anus | 89808: Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer | Fixed Tissue Block (24), Fixed Tissue Slide (7), H&E Stained Slide (15) | |
| ALLIANCE | Rectum | 89901: A Phase I/II Study of Preoperative Oxaliplatin (NSC# 266046), 5-Fluorouracil, and External Beam Radiation Therapy in Locally Advanced Rectal Cancer | Fixed Tissue Block (14), Fixed Tissue Slide (17), H&E Stained Slide (23) | |
| ALLIANCE | GU - NOS | 90102: A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma | Fixed Tissue Block (33), H&E Stained Slide (10) | |
| ALLIANCE | Bladder | 90104: A Randomized Phase III Study Comparing Sequential Chemotherapy (AG-TP) to Cisplatin and Gemcitabine (GC) as Adjuvant Treatment After Cystectomy for Transitional Cell Carcinoma of the Bladder | Fixed Tissue Block (18), Fixed Tissue Slide (9), H&E Stained Slide (2) | |
| ALLIANCE | Prostate | 90202: A randomized double-blind, placebo-controlled phase III study of early versus standard zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone | Serum (545) | |
| ALLIANCE | Prostate | 90202: A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone | 22 | Serum (546) |
| ALLIANCE | Prostate | 90203: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer | Buffy Coat (598), Digital Slide Images (350), DNA (549), Fixed Tissue Block (70), Fixed Tissue Slide (119), Frozen Tissue (204), H&E Stained Slide (602), Plasma (624), Serum (629) | |
| ALLIANCE via Navigator | Kidney | 90206: A randomized phase III trial of interferon alpha-2B or interferon alpha-2B plus bevacizumab in patients with advanced renal cell carcinoma | Digital Slide Images (620), Fixed Tissue Block (325), Fixed Tissue Slide (290), Plasma (623), Serum (46), Urine (606) | |
| ALLIANCE | Prostate | 90401: A randomized double-blinded placebo controlled phase III trial comparing docetaxel and prednisone with and without bevacizumab (IND #7921, NSC #704865) in men with hormone refractory prostate cancer | Buffy Coat (794), DNA (825), Plasma (824), Serum (832), Whole Blood (117) | |
| ALLIANCE | Bladder | 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma | Buffy Coat (424), Digital Slide Images (250), DNA (417), Fixed Tissue Block (324), Fixed Tissue Slide (9), H&E Stained Slide (226), Plasma (431), Serum (420) | |
| ALLIANCE | Kidney | 90802: Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors | Buffy Coat (65), DNA (63), Fixed Tissue Block (50), Fixed Tissue Slide (20), Plasma (66), Urine (65) | |
| ALLIANCE | Prostate | 99809: Phase II Trial of Androgen Suppression for 6 Months Combined With External Beam Radiotherapy (EBRT) With Brachytherapy (BT) Boost for Intermediate Risk Prostate Cancer | Digital Slide Images (60), Fixed Tissue Block (4), Fixed Tissue Slide (6), H&E Stained Slide (52) | |
| ALLIANCE | Prostate | 99811: Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | Fixed Tissue Slide (3), H&E Stained Slide (32) | |
| ALLIANCE | Prostate | 99904: Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer | Fixed Tissue Block (101), Fixed Tissue Slide (38), H&E Stained Slide (31), Plasma (12), Serum (12), Whole Blood (12) | |
| ALLIANCE | Myeloma | 100104: A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND # 70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma | 463 | Cell Slide (2), Cells (449), Serum (40) |
| ALLIANCE | Myeloma | 100104: A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma | 463 | Cell Slide (2), Cells (449), Serum (40) |
| ALLIANCE | Hematologic - NOS | 109901: Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells | Fixed Tissue Block (4), H&E Stained Slide (22) | |
| ALLIANCE | Lung | 140202: | Digital Slide Images (207), Fixed Tissue Block (353) | |
| ALLIANCE | Breast | 150007: Contrast-Enhanced Breast MRI For Evaluation Of Patients Undergoing Neoadjuvant Treatment For Locally-Advanced Breast Cancer (I-SPY 1/ACRIN 6657) | Buffy Coat (170), Digital Slide Images (32), Fixed Tissue Block (260), Plasma (170), Serum (266), Whole Blood (24) | |
| ALLIANCE | Lung | 159902: Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer | Fixed Tissue Block (232), Fixed Tissue Slide (116), H&E Stained Slide (135) | |
| ALLIANCE | Melanoma | 500001: Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | Fixed Tissue Block (4) | |
| ALLIANCE | Melanoma | 500103: A Phase III Randomized Study of Four Weeks High Dose IFNa2b in Stage T3-T4 or N1 (microscopic) Melanoma | Fixed Tissue Block (50), Fixed Tissue Slide (31), H&E Stained Slide (31) | |
| ALLIANCE | Melanoma | 500104: Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma | Fixed Tissue Block (8), H&E Stained Slide (3) | |
| ALLIANCE | Melanoma | 500105: Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma | Fixed Tissue Block (233), Fixed Tissue Slide (106), H&E Stained Slide (97) | |
| ALLIANCE | Melanoma | 509801: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma | Fixed Tissue Block (7), Fixed Tissue Slide (4) | |
| ALLIANCE | Multiple (not organ based) | 90802 : Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND# 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors | Buffy Coat (64), DNA (63), Fixed Tissue Block (50), Fixed Tissue Slide (21), Plasma (65), Urine (63) | |
| ALLIANCE | Breast | A011106: ALTernate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study | Buffy Coat (1,296), DNA (937), Fixed Tissue Block (1,449), Fixed Tissue Slide (1,449), Frozen Tissue (1,449), H&E Stained Slide (1), Plasma (1,588), RNA (627), Serum (1,222), Whole Blood (1) | |
| ALLIANCE | Breast | A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy | Buffy Coat (334), Cells (299), Fixed Tissue Block (176), Fixed Tissue Slide (94), H&E Stained Slide (14), Plasma (335) | |
| ALLIANCE | Breast | A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial | Buffy Coat (2,149), Fixed Tissue Block (1,266), Fixed Tissue Slide (858), Plasma (2,138), Urine (2,159) | |
| ALLIANCE | Lymphoma - Diffuse large B-cell | A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype | Buffy Coat (65), Fixed Tissue Block (48), Fixed Tissue Slide (129), H&E Stained Slide (1), Plasma (1) | |
| ALLIANCE | Lung | Z4031: Use of Proteomic Analysis of Serum Samples for Detection of Non-Small Cell Lung Cancer | Buffy Coat (1,017), DNA (602), Fixed Tissue Block (473), Fixed Tissue Slide (277), Frozen Tissue (652), RNA (645), Serum (1,009) | |
| ALLIANCE via Navigator | Lung | Z0030: Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in the Patient with N0 or N1 (less than hilar) Non-Small Cell Carcinoma | Buffy Coat (284), DNA (171), Frozen Tissue (291), RNA (173), Serum (6) | |
| ALLIANCE | Head & Neck | Z0360: A Trial of Lymphatic Mapping and Sentinel Node Lymphadenectomy for Patients with T1 or T2 Clinically N0 Oral Cavity Squamous Cell Carcinoma | Buffy Coat (134), DNA (19), Fixed Tissue Block (26), Fixed Tissue Slide (123), Frozen Tissue (73), Plasma (2), RNA (26), Serum (143) | |
| ALLIANCE via Navigator | Breast | Z1031: A randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25 mg daily), letrozole (2.5 mg), or anastrozole (1 mg) in postmenopausal women with clinical stage II and III estrogen receptor positive breast cancer | Buffy Coat (500), DNA (524), Fixed Tissue Block (578), Fixed Tissue Slide (354), Frozen Tissue (576), Plasma (577), RNA (519), Serum (577), Whole Blood (146) | |
| ALLIANCE via Navigator | Breast | Z1041: A randomized phase III trial comparing a neoadjuvant regimen of FEC-75 followed by paclitaxel plus trastuzumab with a neoadjuvant regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER-2 positive operable breast cancer | Buffy Coat (172), DNA (69), Fixed Tissue Block (106), Fixed Tissue Slide (221), Frozen Tissue (82), Plasma (173), RNA (17), Serum (173), Whole Blood (32) | |
| ALLIANCE | Breast | Z11102: Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC) | Buffy Coat (117), Fixed Tissue Block (108), Fixed Tissue Slide (171), Frozen Tissue (27) | |
| ALLIANCE | Esophageal | Z4051: A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus | Fixed Tissue Block (4), Fixed Tissue Slide (44), Serum (78), Whole Blood (1) | |
| ALLIANCE | Lung | Z4099: A randomized phase III study of sublobar resection (+/- brachytherapy) versus stereotactic body radiation therapy in high risk patients with stage I non-small cell lung cancer (NSCLC) | Buffy Coat (7), Frozen Tissue (2), Plasma (8), Serum (8), Whole Blood (1) | |
| ALLIANCE | Pancreas | Z5041: A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma | Buffy Coat (112), Fixed Tissue Block (3), Fixed Tissue Slide (65), Frozen Tissue (68), Plasma (34), Serum (34), Whole Blood (4) | |
| ALLIANCE | Rectum | Z6041: A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for uT2uN0 Rectal Cancer | Fixed Tissue Block (59), Fixed Tissue Slide (22), Frozen Tissue (1) | |
| ALLIANCE via Navigator | Rectum | Z6051: A phase III prosepctive randomized trial comparing laparoscopic-assisted resection versus open resection for rectal cancer | Fixed Tissue Block (9), Fixed Tissue Slide (94), Frozen Tissue (138) | |
| ALLIANCE | Gastrointestinal stromal tumor | Z9000: A Phase II Study of Adjuvant STI571 (Gleevec™) Therapy in Patients Following Completely Resected High-risk Primary GastroIntestinal Stromal Tumor (GIST) | Buffy Coat (221), DNA (4), Fixed Tissue Block (86), Fixed Tissue Slide (74), Frozen Tissue (4), RNA (8), Serum (417) | |
| ALLIANCE via Navigator | Gastrointestinal stromal tumor | Z9001: A phase III randomized double-blind study of adjuvant STI571 (Gleevec) versus placebo in patients following the resection of primary gastrointestinal stromal tumor (GIST) | Buffy Coat (585), DNA (336), Fixed Tissue Block (357), Fixed Tissue Slide (297), Frozen Tissue (11), Plasma (3), RNA (10), Serum (587), Whole Blood (2) | |
| ALLIANCE | Sarcoma - NOS | Z9031: A Phase III Randomized Study of Preoperative Radiation plus Surgery versus Surgery Alone for Patients with Retroperitoneal Sarcomas (RPS) | Buffy Coat (13), Fixed Tissue Block (2), Fixed Tissue Slide (9), Frozen Tissue (4), Plasma (13), Serum (13) | |
| CCTG via Navigator | Lung | BR.10: A Phase III prospective randomized study of adjuvant chemotherapy with vinorelbine and cisplatin in completely resected non-small cell lung cancer with companion tumour marker evaluation | 532 | Fixed Tissue Block (451), Fixed Tissue Slide (454) |
| CCTG via Navigator | Lung | BR.19: A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer | 503 | Fixed Tissue Block (376), Fixed Tissue Slide (414) |
| CCTG via Navigator | Breast | MA.17 / MA17R: A Double Blind Randomization To Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study) | 5,187 | Fixed Tissue Block (873), Fixed Tissue Slide (451) |
| CCTG via Navigator | Breast | MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer | 7,576 | DNA (4,254), Fixed Tissue Block (3,920), Fixed Tissue Slide (4,029), Plasma (3,635), Whole Blood (3,573) |
| CCTG via Navigator | Prostate | PR.11: A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer (START) | 180 | Fixed Tissue Block (82), Fixed Tissue Slide (66) |
| COG | Hematologic - NOS | 162: Previously Untreated "Average Risk" | Fixed Tissue Block (1) | |
| COG | Hematologic - NOS | 251: Chemotherapy vs BMT | Cell Slide (1) | |
| COG | Leukemia - Acute lymphocytic | 1882: Treatment of Newly Diagnosed A.L.L. in Children With a Poor Prognosis Excluding Infants and Patients With Lymphoma -Leukemia or FAB L3 Blasts | 1,542 | Buffy Coat (24), Cell Slide (99), Fixed Tissue Block (3), Frozen Tissue (2), Plasma (1), Serum (4), Urine (1), Whole Bone Marrow (245) |
| COG | Leukemia - Acute lymphocytic | 1922: Randomized Comparison of Intravenous vs Oral Mercaptopurine and Dexamethasone vs Prednisone for Favorable and Intermediate A.L.L. | 1,080 | Buffy Coat (3), Fixed Tissue Block (1), Whole Blood (1), Whole Bone Marrow (111) |
| COG | Neuroblastoma | 3881: Biology and Therapy of Good, Intermediate, and Selected Poor Prognosis Neuroblastoma | 784 | Fixed Tissue (2), Fixed Tissue Block (9), Frozen Tissue (19) |
| COG | Neuroblastoma | 3891: Conventional Dose Chemoradiotherapy vs Ablative Chemoradiotherapy With Autologous BMT for High-Risk Neuroblastoma | 560 | Cells (1), Fixed Tissue (2), Fixed Tissue Block (14), Frozen Tissue (30), Serum (1), Whole Bone Marrow (1) |
| COG | Lymphoma - NOS | 5941: A Pilot Study For The Treatment of Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma | 220 | Buffy Coat (2), Cell Slide (20), DNA (1), Fixed Tissue (3), Fixed Tissue Block (8), Frozen Tissue (19), RNA (1), Serum (17), Whole Bone Marrow (15) |
| COG | Multiple (not organ based) | 6901: IRS IV for Stage 1 Disease(IRSG-9198) | 348 | Buffy Coat (1), Cell Slide (2), Fixed Tissue (1), Fixed Tissue Block (32), Frozen Tissue (63), Serum (3), Whole Blood (4), Whole Bone Marrow (4) |
| COG | Multiple (not organ based) | 6902: IRS IV for Stage 2 and Stage 3 Disease(IRSG-9198) | 640 | Buffy Coat (9), Fixed Tissue (1), Fixed Tissue Block (74), Frozen Tissue (143), Plasma (1), Serum (1), Urine (1), Whole Blood (9), Whole Bone Marrow (6) |
| COG | Multiple (not organ based) | 6903: IRS IV for Stage 4 and/or Clinical Group IV Disease, All Patients With Metastasis(IRSG-9198) | 152 | Buffy Coat (1), Fixed Tissue Block (14), Frozen Tissue (24) |
| COG | Multiple (not organ based) | 6941: IRS-V Pilot Study of Topotecan for Stage 4/Clinical Group IV Disease(IRSG-9497) | Fixed Tissue (1), Fixed Tissue Block (5), Frozen Tissue (16), Serum (1), Urine (1), Whole Blood (2) | |
| COG | Osteosarcoma | 7921: Trial of ADR, CDDP and MTX With and Without Ifos, With and Without MTP-PE for Treatment of Osteogenic Sarcoma(POG-9351) | 793 | DNA (2), Fixed Tissue (5), Fixed Tissue Block (15), Frozen Tissue (26), RNA (3) |
| COG | Osteosarcoma | 7943: Topotecan for Metastatic Osteosarcoma | 28 | Frozen Tissue (4) |
| COG | Neuroblastoma | 8104: Comprehensive Care of the Child with Neuroblastoma: A Stage and Age Oriented Study - A Pediatric Oncology Group Phase III Study | Buffy Coat (1), Frozen Tissue (93) | |
| COG | Neuroblastoma | 8742: Phase III portion of 8741 for Neuroblastoma | Fixed Tissue (1), Fixed Tissue Block (1), Frozen Tissue (72), Serum (15) | |
| COG | Neuroblastoma | 8743: Treatment in "Better Risk" Neuroblastoma: POG Stage B (All Ages) and POG Stage C, D and DS (IVS) <365 Days - A Phase III Study | 204 | Frozen Tissue (76), Serum (2) |
| COG | Sarcoma - NOS | 8850: Evaluation of Vincristine, Adriamycin, Cyclophosphamide and Dactinomycin with or without the Addition of Ifosfamide and Etoposide in the Treatment of Patients with Newly Diagnosed Isolated Ewing's Sarcoma or Pri | 591 | Cell Slide (2), Fixed Tissue Block (2), Frozen Tissue (1), Serum (2), Urine (1), Whole Bone Marrow (1) |
| COG | Germ cell tumor | 8882: A Study of High Risk Malignant Germ Cell Tumors in Children (POG-9049) | Fixed Tissue Block (3), Frozen Tissue (3) | |
| COG | Germ cell tumor | 8891: Treatment of Children With Localized Malignant Germ Cell Tumors (POG-9048) | 243 | Fixed Tissue (1), Frozen Tissue (2) |
| COG | Neuroblastoma | 9047: Neuroblastoma Biology Protocol | 2,429 | Buffy Coat (776), Cell Slide (2), Cells (5), DNA (1), Fixed Tissue (67), Fixed Tissue Block (46), Frozen Tissue (1,222), Plasma (9), RNA (4), Serum (660), Whole Blood (5), Whole Bone Marrow (36) |
| COG | Hematologic - NOS | 9082: Protocol for the Development of Intervention Strategies to Reduce the Time Between Symptom Onset and Diagnosis of Childhood Cancer - A Pediatric Oncology Group Cancer Control Study | 2,509 | Buffy Coat (76), DNA (17), Fixed Tissue (19), Fixed Tissue Block (20), Frozen Tissue (237), Plasma (2), RNA (1), Serum (101), Urine (5), Whole Blood (3), Whole Bone Marrow (3) |
| COG | Neuroblastoma | 9340: Treatment of Patients >365 Days at Diagnosis with Stage IV NBL: Upfront Phase II Window - A Phase II Study | 102 | Buffy Coat (54), Cell Slide (1), Fixed Tissue (2), Fixed Tissue Block (1), Frozen Tissue (28), Serum (16), Whole Bone Marrow (3) |
| COG | Neuroblastoma | 9341: Treatment of Patients >365 Days at Diagnosis with Stage IV and Stage IIB/III (N-myc) NBL - A Phase III Study | 146 | Buffy Coat (85), Cell Slide (1), Fixed Tissue (3), Fixed Tissue Block (1), Frozen Tissue (38), Serum (23), Whole Bone Marrow (6) |
| COG | CNS | 9881: Evaluation of VP-16 With and Without Mannitol for the Treatment of Recurrent of Unresponsive Brain Tumors | 143 | Fixed Tissue Block (2), Frozen Tissue (1) |
| COG | CNS | 9892: Treatment of Medulloblastoma/PNET in Children Greater Than 36 Months to 10 Years of Age With Reduced Neuraxis RT and Adjuvant Chemotherapy | 85 | Cells (1), Fixed Tissue (1), Fixed Tissue Block (1), Frozen Tissue (1), Whole Bone Marrow (1) |
| COG | CNS | 9921: Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors | 299 | Fixed Tissue Block (16), Frozen Tissue (13), Serum (1), Whole Bone Marrow (1) |
| COG | CNS | 9942: A Phase II Groupwide Trial of Pre-Irradiation Vincristine, Cisplatin, Cyclophosphamide, and Etoposide Chemotherapy for Children Aged 3 to 21 with Newly Diagnosed Intracranial Ependymoma and Radiologic Evidence o | 84 | Buffy Coat (1), DNA (1), Fixed Tissue (1), Fixed Tissue Block (5), Frozen Tissue (12) |
| COG | Lymphoma - Hodgkin's | 59704: Pilot Study for the Treatment of Children with Newly Diagnosed Advanced Stage Hodgkin's Disease: Upfront Dose Intensive Chemotherapy. | 99 | Buffy Coat (26), DNA (8), Fixed Tissue (1), Fixed Tissue Block (44), Frozen Tissue (12), Plasma (4), Serum (4), Whole Blood (2), Whole Bone Marrow (4) |
| COG | CNS | 99701: A Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed By Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors | 168 | Buffy Coat (21), Fixed Tissue (33), Fixed Tissue Block (9), Frozen Tissue (33), Whole Blood (1) |
| COG | CNS | 99703: A Pilot Study of Intensive Chemotherapy with Peripheral Stem Cell Support for Infants with Malignant Brain Tumors | 94 | Buffy Coat (16), Fixed Tissue (6), Fixed Tissue Block (3), Frozen Tissue (18), Serum (1) |
| COG via Navigator | Leukemia - Acute myelocytic | A2971: Treatment of Children with Down Syndrome and Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Transient Myeloproliferative Disorder. | 254 | Buffy Coat (3), Cell Slide (15), Serum (1), Whole Bone Marrow (2) |
| COG | Leukemia - Acute myelocytic | A2971 : Treatment of Children with Down Syndrome and Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Transient Myeloproliferative Disorder. | 254 | Buffy Coat (4), Serum (1), Whole Bone Marrow (2) |
| COG via Navigator | Neuroblastoma | A3961: Treatment for Infants and Children with Intermediate Risk Neuroblastoma | 573 | Buffy Coat (18), Fixed Tissue Block (1), Whole Blood (1), Whole Bone Marrow (21) |
| COG | Neuroblastoma | A3961 : Treatment for Infants and Children with Intermediate Risk Neuroblastoma | 573 | Buffy Coat (51), Fixed Tissue (17), Fixed Tissue Block (19), Frozen Tissue (281), Plasma (46), Serum (29), Whole Bone Marrow (25) |
| COG via Navigator | Neuroblastoma | A3973: A Randomized Study of Purged vs. Unpurged PBSC Transplant Following Dose Intensive Induction Therapy for High Risk NBL | 495 | Buffy Coat (7), Fixed Tissue Block (3), Frozen Tissue (4), Whole Bone Marrow (25) |
| COG | Neuroblastoma | A3973 : A Randomized Study of Purged vs. Unpurged PBSC Transplant Following Dose Intensive Induction Therapy for High Risk NBL | 495 | Buffy Coat (26), Fixed Tissue (10), Fixed Tissue Block (8), Frozen Tissue (187), Plasma (89), Serum (59), Whole Bone Marrow (39) |
| COG via Navigator | Lymphoma - NOS | A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma | 393 | Fixed Tissue Block (35), Frozen Tissue (2), RNA (1), Serum (1), Whole Bone Marrow (3) |
| COG | Lymphoma - NOS | A5971 : A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma | 393 | Buffy Coat (5), Fixed Tissue (49), Fixed Tissue Block (3), Frozen Tissue (33), Whole Blood (1), Whole Bone Marrow (16) |
| COG via Navigator | CNS | A9952: Chemotherapy For Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old | 428 | Buffy Coat (2), Cell Slide (2), Fixed Tissue Block (5), Whole Bone Marrow (1) |
| COG | CNS | A9952 : Chemotherapy For Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old | 428 | Fixed Tissue (2), Fixed Tissue Block (2), Frozen Tissue (17) |
| COG via Navigator | CNS | A9961: Phase III Prospective Randomized Study of Craniospinal RT Followed by 1 of 2 Adjuvant Chemo Regimens for Newly-Diagnosed Average Risk Medulloblastoma | 421 | Buffy Coat (14), Whole Blood (2) |
| COG | CNS | A9961 : Phase III Prospective Randomized Study of Craniospinal RT Followed by 1 of 2 Adjuvant Chemo Regimens for Newly-Diagnosed Average Risk Medulloblastoma | 421 | Buffy Coat (15), Fixed Tissue (5), Fixed Tissue Block (9), Frozen Tissue (52), Serum (1), Whole Bone Marrow (2) |
| COG | Multiple (not organ based) | AADM01P1: Protocol for Registration and Consent to the Childhood Cancer Research Network: A limited Institution Pilot | 2,242 | Buffy Coat (96), DNA (4), Fixed Tissue (8), Fixed Tissue Block (26), Frozen Tissue (269), Plasma (48), RNA (1), Serum (72), Urine (1), Whole Bone Marrow (123) |
| COG via Navigator | Leukemia - Acute lymphocytic | AALL0232: High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) | 3,154 | Buffy Coat (2,457), Cells (15), DNA (2,468), RNA (737), Whole Blood (3), Whole Bone Marrow (2,567) |
| COG | Leukemia - Acute lymphocytic | AALL0232 : High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) | 3,154 | Buffy Coat (1), DNA (1), Fixed Tissue (1), Plasma (2), Serum (21), Urine (1) |
| COG | Leukemia - Acute lymphocytic | AALL02P2: Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1>/=18 months) | 168 | Buffy Coat (35), DNA (137), Fixed Tissue Block (1), Frozen Tissue (1), RNA (7), Serum (2), Urine (1), Whole Bone Marrow (100) |
| COG via Navigator | Leukemia - Acute lymphocytic | AALL0331: Standard Risk B-precursor Acute Lymphoblastic Leukemia | 5,377 | Buffy Coat (3,971), Cells (133), DNA (4,109), RNA (1,852), Whole Bone Marrow (4,362) |
| COG | Leukemia - Acute lymphocytic | AALL0331 : Standard Risk B-precursor Acute Lymphoblastic Leukemia | 5,377 | Buffy Coat (3), Fixed Tissue Block (2), Frozen Tissue (2), Plasma (2), Serum (9), Urine (1), Whole Bone Marrow (63) |
| COG | Leukemia - Acute lymphocytic | AALL03B1: Classification of Acute Lymphoblastic Leukemia | 11,196 | Buffy Coat (8,413), Cells (133), DNA (8,680), Fixed Tissue (1), Fixed Tissue Block (2), Frozen Tissue (4), Plasma (10), RNA (2,794), Serum (37), Urine (3), Whole Blood (29), Whole Bone Marrow (8,759) |
| COG via Navigator | Leukemia - Acute lymphocytic | AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies | 275 | Buffy Coat (45), Cells (1), DNA (10), RNA (3), Whole Blood (1), Whole Bone Marrow (156) |
| COG | Leukemia - Acute lymphocytic | AALL0433 : Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies | 275 | Buffy Coat (2), Plasma (2), Serum (2), Whole Bone Marrow (5) |
| COG via Navigator | Leukemia - Acute lymphocytic | AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Ly | 1,895 | Buffy Coat (1,573), Cell Slide (3), Cells (1), DNA (1,458), Fixed Tissue Block (58), Frozen Tissue (26), RNA (32), Whole Blood (22), Whole Bone Marrow (1,632) |
| COG | Leukemia - Acute lymphocytic | AALL0434 : Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Ly | 1,895 | Fixed Tissue Block (3), Frozen Tissue (1) |
| COG | Leukemia - Acute lymphocytic | AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens | 814 | Buffy Coat (535), Cells (4), DNA (40), Frozen Tissue (3), Plasma (1), RNA (11), Serum (2), Whole Blood (2), Whole Bone Marrow (662) |
| COG via Navigator | Leukemia - Acute lymphocytic | AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#764 | 218 | Buffy Coat (206), DNA (36), Whole Blood (22), Whole Bone Marrow (159) |
| COG | Leukemia - Acute lymphocytic | AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL | 148 | Buffy Coat (90), Cells (1), DNA (5), RNA (5), Whole Bone Marrow (81) |
| COG | Leukemia - Acute lymphocytic | AALL07P4: A Pilot Study of Intravenous EZN-2285 (SC-PEG E. coli L-asparaginase, IND# 100594) or Intravenous Oncaspar® in the Treatment of Patients with High-Risk Acute Lymphoblastic Leukemia (ALL) | 166 | Buffy Coat (176), DNA (150), RNA (1), Whole Blood (1), Whole Bone Marrow (193) |
| COG | Leukemia - Acute lymphocytic | AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | 17,462 | Buffy Coat (16,369), Cell Slide (3), Cells (1,174), DNA (14,879), Fixed Tissue Block (4), Frozen Tissue (1), Plasma (1), RNA (4,904), Serum (8), Whole Blood (47), Whole Bone Marrow (16,677) |
| COG | Leukemia - Acute lymphocytic | AALL08P1: Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study | 104 | Buffy Coat (105), DNA (93), RNA (2), Whole Bone Marrow (111) |
| COG via Navigator | Leukemia - Acute lymphocytic | AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy) | 9,350 | Buffy Coat (9,183), Cell Slide (1), Cells (97), DNA (8,598), Fixed Tissue (1), Fixed Tissue Block (9), Frozen Tissue (3), RNA (863), Whole Blood (5), Whole Bone Marrow (9,487) |
| COG | Leukemia - Acute lymphocytic | AALL0932 : Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy) | 9,350 | Buffy Coat (5), Fixed Tissue Block (2), Plasma (1), RNA (3), Serum (5), Whole Bone Marrow (1) |
| COG | Leukemia - Acute lymphocytic | AALL1122: A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66,971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblast | Buffy Coat (7), Cells (1), DNA (80), RNA (78), Whole Bone Marrow (78) | |
| COG via Navigator | Leukemia - Acute lymphocytic | AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | 5,949 | Buffy Coat (4,838), Cell Slide (3), Cells (1,449), DNA (4,839), RNA (4,387), Serum (2), Whole Blood (15), Whole Bone Marrow (5,207) |
| COG | Leukemia - Acute lymphocytic | AALL1131 : A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | 5,949 | Buffy Coat (1), RNA (17), Serum (2) |
| COG via Navigator | Leukemia - Acute lymphocytic | AALL1231: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | 847 | Buffy Coat (656), Cell Slide (6), Cells (7), DNA (559), Fixed Tissue Block (25), Frozen Tissue (13), RNA (10), Serum (3), Whole Blood (3), Whole Bone Marrow (692) |
| COG | Leukemia - Acute lymphocytic | AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) | 669 | Buffy Coat (556), Cell Slide (1), Cells (8), DNA (29), RNA (13), Whole Bone Marrow (556) |
| COG | Leukemia - Acute lymphocytic | AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement | 78 | Buffy Coat (25), Cell Slide (1), DNA (6), Whole Blood (3), Whole Bone Marrow (60) |
| COG via Navigator | Leukemia - Acute myelocytic | AAML03P1: Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study | 350 | Buffy Coat (51), DNA (1), RNA (1), Whole Bone Marrow (221) |
| COG | Leukemia - Acute myelocytic | AAML03P1 : Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study | 350 | Buffy Coat (1), Fixed Tissue Block (1), Frozen Tissue (1), Plasma (1), Serum (3) |
| COG via Navigator | Leukemia - Acute myelocytic | AAML0431: The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years | 205 | Buffy Coat (15), Cell Slide (2), DNA (128), RNA (129), Serum (1), Whole Bone Marrow (66) |
| COG | Leukemia - Acute myelocytic | AAML0431 : The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years | 205 | DNA (2), Fixed Tissue Block (1), Whole Bone Marrow (1) |
| COG via Navigator | Leukemia - Acute myelocytic | AAML0531: A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults | 1,070 | Buffy Coat (837), Cell Slide (78), DNA (449), Fixed Tissue Block (19), RNA (10), Whole Bone Marrow (947) |
| COG | Leukemia - Acute myelocytic | AAML0531 : A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults | 1,070 | Frozen Tissue (1), Serum (3), Urine (1) |
| COG | Leukemia - Acute lymphocytic | AAML08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | 17,462 | Buffy Coat (146), Cell Slide (4), DNA (42), Plasma (151), RNA (43), Serum (1), Whole Bone Marrow (2) |
| COG via Navigator | Leukemia - Acute myelocytic | AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD | 1,645 | Buffy Coat (1,349), Cell Slide (629), Fixed Tissue Block (16), Frozen Tissue (1), Serum (2), Whole Bone Marrow (1,381) |
| COG | Leukemia - Acute myelocytic | AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid | 158 | Buffy Coat (141), DNA (49), Plasma (2), Serum (1), Whole Blood (1), Whole Bone Marrow (144) |
| COG via Navigator | Leukemia - Acute myelocytic | AAML1421: A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML) | 38 | Buffy Coat (4), DNA (25), Plasma (30), Serum (29), Whole Blood (1), Whole Bone Marrow (1) |
| COG | Hematologic - NOS | AB9804: Clinical and Biological Predictors of Therapy-Related Leukemia | 294 | Buffy Coat (51), DNA (7), Fixed Tissue (6), Fixed Tissue Block (5), Frozen Tissue (56), Plasma (1), RNA (1), Serum (52), Whole Blood (2), Whole Bone Marrow (13) |
| COG | Multiple (not organ based) | ABTR01B1: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors | 2,579 | Buffy Coat (803), Cell Slide (9), DNA (87), Fixed Tissue (23), Fixed Tissue Block (621), Frozen Tissue (1,365), Plasma (15), RNA (48), Serum (635), Urine (1), Whole Blood (16), Whole Bone Marrow (435) |
| COG | Leukemia - Acute myelocytic | ACCL0933: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) | 517 | Frozen Tissue (2), Serum (427) |
| COG | Hematologic - NOS | ACCL1131: A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT) | 292 | Buffy Coat (268), DNA (1), Plasma (266), Serum (1), Whole Bone Marrow (2) |
| COG via Navigator | CNS | ACNS0121: A Phase II Trial of Conformal RT for Pediatric Patients with Localized Ependymoma, Chemotherapy prior to 2nd Surgery for Incompletely Resected Ependymoma and Observations for Completely Resected, Differentiated, | 378 | Buffy Coat (18), Cell Slide (2), Fixed Tissue Block (47), Frozen Tissue (43), Whole Bone Marrow (1) |
| COG | CNS | ACNS0121 : A Phase II Trial of Conformal RT for Pediatric Patients with Localized Ependymoma, Chemotherapy prior to 2nd Surgery for Incompletely Resected Ependymoma and Observations for Completely Resected, Differentiated, | 378 | Buffy Coat (183), Fixed Tissue (1), Frozen Tissue (84), Plasma (2), Serum (2), Whole Blood (3), Whole Bone Marrow (1) |
| COG | CNS | ACNS0122: A Phase II Study to Assess the Ability of Neoadjuvant Chemotherapy +/- Second Look Surgery To Eliminate All Measurable Disease Prior to Radiotherapy For NGGCT | 104 | Buffy Coat (2), Fixed Tissue (4), Fixed Tissue Block (8), Frozen Tissue (4) |
| COG | CNS | ACNS0126: A Phase II Study of Temozolomide in the Treatment of Children with High Grade Glioma or Diffuse Intrinsic Pontine Gliomas | 170 | Buffy Coat (6), DNA (1), Fixed Tissue (33), Fixed Tissue Block (7), Frozen Tissue (6), RNA (1) |
| COG | CNS | ACNS0221: A Phase II Study of Conformal Radiotherapy in Patients with Low Grade Gliomas | 92 | Buffy Coat (2), Fixed Tissue Block (3), Frozen Tissue (3) |
| COG | CNS | ACNS0231 : A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence with a Single High Dose Chemotherapy and Autologous Stem Cell Transplant vs Three Courses of Intermediate Dose C | 1 | Fixed Tissue (1) |
| COG via Navigator | CNS | ACNS0232: Radiotherapy Alone vs. Chemotherapy Followed By Response-based Radiotherapy For Newly Diagnosed Primary CNS Germinoma | 24 | Fixed Tissue Block (1) |
| COG | CNS | ACNS0232 : Radiotherapy Alone vs. Chemotherapy Followed By Response-based Radiotherapy For Newly Diagnosed Primary CNS Germinoma | 24 | Frozen Tissue (1) |
| COG | CNS | ACNS02B3: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens | 3,663 | Buffy Coat (1,540), Cell Slide (4), DNA (23), Fixed Tissue (7), Fixed Tissue Block (849), Frozen Tissue (3,150), Plasma (2), RNA (22), Serum (14), Urine (2), Whole Blood (34), Whole Bone Marrow (3) |
| COG via Navigator | CNS | ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double | 549 | Cell Slide (1), DNA (14), Fixed Tissue (3), Fixed Tissue Block (78), Frozen Tissue (36), RNA (12) |
| COG | CNS | ACNS0331 : A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double | 549 | Buffy Coat (2), Fixed Tissue (24), Frozen Tissue (107), Serum (3) |
| COG via Navigator | CNS | ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients | 379 | Buffy Coat (71), Cell Slide (3), Fixed Tissue Block (25), Frozen Tissue (39), Plasma (1), Whole Blood (2) |
| COG | CNS | ACNS0332 : Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients | 379 | Buffy Coat (1), Frozen Tissue (31) |
| COG via Navigator | CNS | ACNS0333: Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation | 70 | Cell Slide (1), Fixed Tissue Block (6), Frozen Tissue (51) |
| COG | CNS | ACNS0333 : Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation | 70 | Frozen Tissue (3) |
| COG via Navigator | CNS | ACNS0334: A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by | 91 | Buffy Coat (64), Fixed Tissue Block (14), Frozen Tissue (19), Plasma (3), Serum (2), Whole Blood (2) |
| COG | CNS | ACNS0334 : A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by | 91 | Buffy Coat (4), Frozen Tissue (5), Plasma (1), Serum (1), Whole Blood (1) |
| COG via Navigator | CNS | ACNS0423: Concurrent Radiation and Temozolomide Followed By Temozolomide and Lomustine in the Treatment of High-Grade Gliomas. | 118 | DNA (6), Fixed Tissue Block (15), Frozen Tissue (5), RNA (6) |
| COG | CNS | ACNS0423 : Concurrent Radiation and Temozolomide Followed By Temozolomide and Lomustine in the Treatment of High-Grade Gliomas. | 118 | Buffy Coat (23), Fixed Tissue (12), Frozen Tissue (3), Plasma (1), Serum (1), Whole Blood (2), Whole Bone Marrow (1) |
| COG | CNS | ACNS0621: Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma | 30 | Buffy Coat (1), Fixed Tissue (1), Fixed Tissue Block (3), Frozen Tissue (5) |
| COG via Navigator | CNS | ACNS0822: A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Te | 101 | Buffy Coat (54), Cell Slide (2), DNA (19), Fixed Tissue (2), Fixed Tissue Block (25), Frozen Tissue (23), RNA (19), Whole Blood (1) |
| COG | CNS | ACNS0822 : A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Te | 101 | Fixed Tissue (2) |
| COG | CNS | ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years | 479 | Buffy Coat (283), Cell Slide (2), DNA (1), Fixed Tissue (68), Fixed Tissue Block (67), Frozen Tissue (129), Plasma (7), Serum (3), Whole Blood (3) |
| COG via Navigator | CNS | ACNS1221: A Phase II Study For The Treatment Of Non-Metastatic Desmoplastic Medulloblastoma In Children Less Than 4 Years of Age | 26 | Buffy Coat (23), Cell Slide (1), Fixed Tissue (18), Fixed Tissue Block (5), Frozen Tissue (11) |
| COG | Multiple (not organ based) | ADVL0122: A Phase II Study of Gleevec (Imatinib mesylate, NSC 716051 formerly STI571) in Children with Refractory or Relapsed Solid Tumors | 71 | Buffy Coat (2), Cell Slide (1), Fixed Tissue Block (20), Frozen Tissue (11), Serum (2) |
| COG | Leukemia - Acute lymphocytic | ADVL04P2: A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL) | 134 | Buffy Coat (19), DNA (17), Serum (2), Whole Bone Marrow (61) |
| COG | Multiple (not organ based) | ADVL0821: A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, IND# 100947, NSC# 742460) in Children With Relapsed/Refractory Solid Tumors | 116 | Buffy Coat (4), DNA (2), Fixed Tissue Block (10), Frozen Tissue (20), Plasma (4), RNA (1), Serum (104), Urine (2), Whole Bone Marrow (2) |
| COG | Germ cell tumor | AE22: A Case Control Study Of Malignant Germ Cell Tumors in Children | 515 | Buffy Coat (3), Fixed Tissue Block (25), Frozen Tissue (48), Plasma (2), Serum (2) |
| COG | Lymphoma - NOS | AE25: Pesticide Exposure and Markers of VDJ Recombination in Children with Lymphoma | 165 | Buffy Coat (2), Fixed Tissue Block (3), Frozen Tissue (15), Serum (5), Whole Bone Marrow (6) |
| COG | Liver | AEPI04C1: Low Birth Weight and Other Risk Factors for Hepatoblastoma | 408 | Buffy Coat (5), Fixed Tissue Block (9), Frozen Tissue (39), Serum (4), Whole Bone Marrow (2) |
| COG via Navigator | Ewing's sarcoma | AEWS0031: Trial of Chemotherapy Intensification through Interval Compression in Ewing's Sarcoma and Related Tumors | 587 | Buffy Coat (10), Cell Slide (3), DNA (134), Fixed Tissue (32), Fixed Tissue Block (57), Frozen Tissue (25), RNA (51), Serum (74), Whole Blood (10), Whole Bone Marrow (13) |
| COG | Ewing's sarcoma | AEWS0031 : Trial of Chemotherapy Intensification through Interval Compression in Ewing's Sarcoma and Related Tumors | 587 | Buffy Coat (23), Fixed Tissue (104), Fixed Tissue Block (8), Frozen Tissue (79), Plasma (2), Serum (151), Whole Blood (1), Whole Bone Marrow (2) |
| COG | Ewing's sarcoma | AEWS02B1: A Groupwide Biology and Banking Study for Ewing Sarcoma | 637 | Buffy Coat (152), Cell Slide (1), Cells (4), DNA (10), Fixed Tissue (205), Fixed Tissue Block (92), Frozen Tissue (183), Plasma (9), RNA (15), Serum (531), Urine (3), Whole Blood (8), Whole Bone Marrow (63) |
| COG | Ewing's sarcoma | AEWS02P1: A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination with Standard Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors | 38 | Buffy Coat (1), Fixed Tissue (6), Fixed Tissue Block (2), Frozen Tissue (12), Plasma (15), Serum (14), Urine (17), Whole Blood (2) |
| COG via Navigator | Ewing's sarcoma | AEWS0331: European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) | 110 | Buffy Coat (2), Cell Slide (1), Fixed Tissue Block (14), Frozen Tissue (1), Plasma (2), Serum (8), Whole Bone Marrow (1) |
| COG | Ewing's sarcoma | AEWS0331 : European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) | 110 | Buffy Coat (11), Cells (2), Fixed Tissue (31), Frozen Tissue (22), Plasma (1), Serum (24), Whole Bone Marrow (7) |
| COG | Ewing's sarcoma | AEWS07B1: A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens | 908 | Buffy Coat (494), Cell Slide (25), DNA (636), Fixed Tissue (3), Fixed Tissue Block (149), Frozen Tissue (275), Plasma (751), RNA (263), Serum (789), Urine (1), Whole Blood (22), Whole Bone Marrow (730) |
| COG via Navigator | Ewing's sarcoma | AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma | 642 | Buffy Coat (6), Cell Slide (3), DNA (40), Fixed Tissue Block (44), Frozen Tissue (6), Plasma (10), RNA (140), Serum (9), Whole Blood (1), Whole Bone Marrow (12) |
| COG | Ewing's sarcoma | AEWS1031 : A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma | 642 | Serum (1), Whole Bone Marrow (1) |
| COG via Navigator | Ewing's sarcoma | AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarc | 312 | Buffy Coat (87), Cell Slide (1), DNA (301), Fixed Tissue Block (42), Frozen Tissue (3), Plasma (28), Serum (286), Whole Blood (31), Whole Bone Marrow (6) |
| COG via Navigator | Germ cell tumor | AGCT0132: A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors | 302 | Buffy Coat (19), DNA (37), Fixed Tissue Block (70), Frozen Tissue (61), RNA (37), Serum (35), Whole Blood (2) |
| COG | Germ cell tumor | AGCT0132 : A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors | 302 | Buffy Coat (15), Fixed Tissue (33), Fixed Tissue Block (6), Frozen Tissue (36), Plasma (2), Serum (107), Whole Blood (1) |
| COG via Navigator | Liver | AHEP0731: Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment | 236 | Fixed Tissue Block (35), Frozen Tissue (22) |
| COG | Liver | AHEP0731 : Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment | 236 | Serum (1) |
| COG via Navigator | Lymphoma - Hodgkin's | AHOD0031: A Phase III Study of Dose-Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease | 1,734 | Buffy Coat (238), Cell Slide (10), DNA (183), Fixed Tissue (78), Fixed Tissue Block (302), Frozen Tissue (4), Plasma (253), RNA (3), Serum (281), Whole Blood (2), Whole Bone Marrow (22) |
| COG | Lymphoma - Hodgkin's | AHOD0031 : A Phase III Study of Dose-Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease | 1,734 | Buffy Coat (1,113), Fixed Tissue (225), Fixed Tissue Block (2), Frozen Tissue (325), Plasma (1,068), Serum (11,132), Urine (1), Whole Blood (14), Whole Bone Marrow (18) |
| COG | Lymphoma - Hodgkin's | AHOD00P1: A Pilot Study of Re-Induction Chemotherapy with Ifosfamide, and Vinorelbine (IV) in Children with Refractory/Relapsed Hodgkin Disease | 66 | Buffy Coat (3), Fixed Tissue (9), Fixed Tissue Block (6), Frozen Tissue (13), Plasma (2), Serum (20) |
| COG | Lymphoma - Hodgkin's | AHOD0121 : A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy with Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease | 24 | Serum (18) |
| COG | Lymphoma - Hodgkin's | AHOD0321: A Phase II Study of Weekly Gemcitabine and Vinorelbine in Children with Recurrent or Refractory Hodgkin Disease | 33 | Buffy Coat (8), Cell Slide (2), Fixed Tissue Block (3), Frozen Tissue (4), Plasma (7), Serum (9), Whole Bone Marrow (1) |
| COG | Lymphoma - Hodgkin's | AHOD03P1: Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD) | 188 | Buffy Coat (130), Fixed Tissue (21), Fixed Tissue Block (54), Frozen Tissue (22), Plasma (7), Serum (149), Urine (1) |
| COG via Navigator | Lymphoma - Hodgkin's | AHOD0431: Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low-Risk Hodgkin Disease | 287 | Buffy Coat (8), Fixed Tissue Block (42), Frozen Tissue (2), Serum (9) |
| COG | Lymphoma - Hodgkin's | AHOD0431 : Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low-Risk Hodgkin Disease | 287 | Buffy Coat (51), Fixed Tissue (46), Frozen Tissue (38), Plasma (8), Serum (58), Urine (1), Whole Bone Marrow (1) |
| COG | Lymphoma - Hodgkin's | AHOD04B1: Hodgkin Disease Banking Study | 1,272 | Buffy Coat (1,092), Cell Slide (1), DNA (1), Fixed Tissue Block (219), Frozen Tissue (473), Plasma (137), Serum (1,124), Urine (2), Whole Blood (29), Whole Bone Marrow (10) |
| COG | Lymphoma - Hodgkin's | AHOD0521: A Phase II Study of Bortezomib (Velcade, PS-341, IND # 58443) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with Refractory/Recurrent Hodgkin Disease | 26 | Buffy Coat (11), Fixed Tissue Block (2), Frozen Tissue (2), Plasma (30), Serum (10) |
| COG | Lymphoma - Hodgkin's | AHOD0831: A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma | 166 | Buffy Coat (68), Fixed Tissue Block (16), Frozen Tissue (27), Plasma (1), Serum (68), Whole Blood (1), Whole Bone Marrow (1) |
| COG | Lymphoma - Hodgkin's | AHOD1331: A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults | 600 | Buffy Coat (524), DNA (33), Fixed Tissue Block (80), Frozen Tissue (97), Plasma (467), RNA (1), Serum (4), Whole Blood (12), Whole Bone Marrow (3) |
| COG | Multiple (not organ based) | ALTE03N1: Key Adverse Events after Childhood Cancer | 4,162 | Buffy Coat (99), Cells (1), DNA (3), Fixed Tissue (4), Fixed Tissue Block (20), Frozen Tissue (273), Plasma (29), Serum (96), Urine (1), Whole Blood (5), Whole Bone Marrow (178) |
| COG | Multiple (not organ based) | ALTE05N1: Umbrella Long-term Follow-up Protocol | 3,969 | Buffy Coat (83), DNA (3), Fixed Tissue (1), Fixed Tissue Block (15), Frozen Tissue (203), Plasma (90), RNA (2), Serum (132), Urine (5), Whole Blood (1), Whole Bone Marrow (56) |
| COG | Neuroblastoma | ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study | 377 | Buffy Coat (9), DNA (306), Fixed Tissue (1), Frozen Tissue (238), Plasma (313), Serum (57), Whole Blood (8), Whole Bone Marrow (38) |
| COG via Navigator | Neuroblastoma | ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue | 1,449 | Buffy Coat (2), Fixed Tissue Block (1), Frozen Tissue (1), Plasma (1), Whole Bone Marrow (5) |
| COG | Neuroblastoma | ANBL0032 : Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue | 1,449 | Buffy Coat (31), Fixed Tissue (1), Fixed Tissue Block (3), Frozen Tissue (719), Plasma (140), Serum (223), Whole Bone Marrow (216) |
| COG via Navigator | Neuroblastoma | ANBL00P3: A Phase III randomized trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone | 53 | Buffy Coat (48), Cells (6), DNA (1), Fixed Tissue Block (1), Frozen Tissue (6), Plasma (7), RNA (1), Serum (48), Whole Blood (3), Whole Bone Marrow (4) |
| COG | Neuroblastoma | ANBL00P3 : A Phase III randomized trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone | 53 | Frozen Tissue (25), Serum (1) |
| COG via Navigator | Neuroblastoma | ANBL0532: Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma | 665 | Buffy Coat (1), Cell Slide (1), DNA (1), Fixed Tissue Block (1), Frozen Tissue (2), RNA (498), Whole Bone Marrow (1) |
| COG | Neuroblastoma | ANBL0532 : Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma | 665 | Fixed Tissue Block (1), Frozen Tissue (404), Serum (74), Whole Bone Marrow (6) |
| COG | Neuroblastoma | ANBL12P1: Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma | 150 | Buffy Coat (3), DNA (2), Frozen Tissue (53), Plasma (16), RNA (2), Serum (42), Whole Bone Marrow (114) |
| COG | Neuroblastoma | ANBL17P1: A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, dinutuximab) (NSC# 764038, IND# 4308) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma | 42 | Buffy Coat (2), Cell Slide (35), Frozen Tissue (1), Plasma (7), RNA (15), Serum (35), Whole Blood (29), Whole Bone Marrow (31) |
| COG via Navigator | Lymphoma - NOS | ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine | 129 | Buffy Coat (14), DNA (19), Fixed Tissue Block (22), Frozen Tissue (29), Plasma (2), RNA (8), Serum (58), Whole Blood (1), Whole Bone Marrow (2) |
| COG | Lymphoma - NOS | ANHL0131 : A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine | 129 | Buffy Coat (18), Fixed Tissue (22), Frozen Tissue (3), Plasma (3), Serum (57), Whole Blood (3), Whole Bone Marrow (1) |
| COG | Lymphoma - NOS | ANHL01P1: A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-C | 97 | Buffy Coat (3), Fixed Tissue (4), Fixed Tissue Block (5), Frozen Tissue (1), Plasma (1), Serum (28), Whole Bone Marrow (1) |
| COG | Lymphoma - NOS | ANHL0221: A Phase II Study of the Combination of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults with CD20 Positive Post-Transplant Lymphoproliferative Disease (PTLD) following S | 55 | Buffy Coat (11), DNA (8), Fixed Tissue Block (3), Frozen Tissue (4), Serum (17), Whole Blood (22), Whole Bone Marrow (2) |
| COG | Lymphoma - Non-Hodgkin's | ANHL04B1: Rare and Cutaneous Non-Hodgkin Lymphoma Registry | 174 | Buffy Coat (71), Fixed Tissue (4), Fixed Tissue Block (22), Frozen Tissue (28), RNA (1), Serum (67), Whole Blood (2), Whole Bone Marrow (33) |
| COG via Navigator | Lymphoma - Non-Hodgkin's | ANHL1131: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B-AL: Evaluation of Rituximab (IND #10385) Efficacy and Safety in High Risk Patients | 164 | Buffy Coat (14), Cell Slide (1), DNA (15), Fixed Tissue Block (32), Frozen Tissue (19), Serum (1), Whole Bone Marrow (15) |
| COG | Lymphoma - Non-Hodgkin's | ANHL1131 : Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B-AL: Evaluation of Rituximab (IND #10385) Efficacy and Safety in High Risk Patients | 164 | Plasma (1), Serum (1), Whole Bone Marrow (1) |
| COG | Lymphoma - NOS | ANHL12P1: A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117 | 137 | Cell Slide (3), Fixed Tissue Block (12), Frozen Tissue (13), Whole Bone Marrow (11) |
| COG via Navigator | Osteosarcoma | AOST0121: A Groupwide Phase II Study of Trastuzumab ( Herceptin) in Metastatic Osteosarcoma Patients with Tumors that Overexpress HER2 | 101 | Cell Slide (5), DNA (4), Fixed Tissue Block (20), Frozen Tissue (14), RNA (2), Serum (4), Whole Blood (2) |
| COG | Osteosarcoma | AOST0121 : A Groupwide Phase II Study of Trastuzumab ( Herceptin) in Metastatic Osteosarcoma Patients with Tumors that Overexpress HER2 | 101 | Buffy Coat (9), Fixed Tissue (1), Fixed Tissue Block (4), Frozen Tissue (15), Serum (44) |
| COG | Osteosarcoma | AOST0221: A Phase II Study of Aerosolized GM-CSF (NSC# 613795, IND # 11042) in Osteosarcoma Patients with First Pulmonary Recurrence of Osteosarcoma | 49 | Buffy Coat (2), Fixed Tissue Block (17), Frozen Tissue (32), Plasma (1), Serum (9) |
| COG via Navigator | Osteosarcoma | AOST0331: A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy | 1,164 | Buffy Coat (11), Cell Slide (3), DNA (143), Fixed Tissue Block (185), Frozen Tissue (48), Plasma (44), RNA (74), Serum (51), Whole Blood (6), Whole Bone Marrow (8) |
| COG | Osteosarcoma | AOST0331 : A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy | 1,164 | Buffy Coat (28), DNA (1), Fixed Tissue (58), Fixed Tissue Block (26), Frozen Tissue (103), Plasma (56), Serum (188), Whole Blood (2) |
| COG | Osteosarcoma | AOST06B1: A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens | 957 | Buffy Coat (675), Cell Slide (1), DNA (645), Fixed Tissue Block (196), Frozen Tissue (251), Plasma (821), RNA (12), Serum (843), Urine (4), Whole Blood (37) |
| COG | Osteosarcoma | AOST06P1: Feasibility and Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma | 24 | Buffy Coat (1), DNA (4), Fixed Tissue Block (4), Frozen Tissue (4), Plasma (4), Serum (18), Urine (16) |
| COG | Osteosarcoma | AOST1421: A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcom | 41 | Buffy Coat (12), DNA (12), Fixed Tissue Block (6), Frozen Tissue (2), Plasma (18), Whole Blood (1) |
| COG via Navigator | Head & Neck | ARAR0331: Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy | 111 | Buffy Coat (48), Fixed Tissue Block (7), Frozen Tissue (21), Plasma (73), Serum (24) |
| COG | Head & Neck | ARAR0331 : Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy | 111 | Buffy Coat (2), Fixed Tissue (2), Frozen Tissue (1), Plasma (1), Serum (2) |
| COG via Navigator | Adrenal | ARAR0332: Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy | 78 | Buffy Coat (11), DNA (5), Fixed Tissue Block (42), Frozen Tissue (17), Serum (1), Whole Bone Marrow (1) |
| COG | Adrenal | ARAR0332 : Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy | 78 | Buffy Coat (2), Fixed Tissue Block (1), Frozen Tissue (29) |
| COG | Kidney | AREN0321: Treatment of High Risk Renal Tumors | 291 | Buffy Coat (11), DNA (1), Fixed Tissue Block (1), Frozen Tissue (133), Serum (9), Urine (8) |
| COG | Wilm's Tumor | AREN0532: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor | 808 | Buffy Coat (23), DNA (4), Fixed Tissue Block (3), Frozen Tissue (381), Serum (71), Urine (55), Whole Blood (1) |
| COG via Navigator | Wilm's Tumor | AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor | 249 | Buffy Coat (4), DNA (6), Fixed Tissue Block (1), Frozen Tissue (9), RNA (6), Serum (2), Urine (2) |
| COG | Wilm's Tumor | AREN0534 : Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor | 249 | Frozen Tissue (11), Serum (4), Urine (3) |
| COG | Retinoblastoma | ARET0321: A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma | 60 | Buffy Coat (3), Fixed Tissue Block (2), Frozen Tissue (3), Plasma (20), RNA (5), Whole Blood (1), Whole Bone Marrow (11) |
| COG via Navigator | Retinoblastoma | ARET0332: A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy | 331 | Buffy Coat (10), Frozen Tissue (4) |
| COG | Retinoblastoma | ARET0332 : A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy | 331 | Buffy Coat (31), Fixed Tissue Block (1), Frozen Tissue (16), Plasma (1), Serum (2) |
| COG | Multiple (not organ based) | ARST0121 : A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination with Vincristine and Pilot Assessment of Safety and Efficacy of Tirapazamine Combined with Multiagent Chemothe | 139 | DNA (5), Fixed Tissue (2), Fixed Tissue Block (3), Frozen Tissue (3), RNA (4), Whole Bone Marrow (1) |
| COG | Multiple (not organ based) | ARST0121 : A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination with Vincristine and Pilot Assessment of Safety and Efficacy of Tirapazamine Combined with Multiagent Chemothe | 139 | Buffy Coat (11), Fixed Tissue (6), Fixed Tissue Block (7), Frozen Tissue (33), Serum (4), Whole Bone Marrow (15) |
| COG | Sarcoma - NOS | ARST0321: A Phase II Study of Sulindac and Tamoxifen in Patients with Desmoid Tumors that are Recurrent or Not Amenable to Standard Therapy | 70 | Buffy Coat (2), Fixed Tissue (4), Fixed Tissue Block (11), Frozen Tissue (3), Serum (3) |
| COG via Navigator | Rhabdomyosarcoma | ARST0331: Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma | 390 | Buffy Coat (1), Cell Slide (1), DNA (81), Fixed Tissue (9), Fixed Tissue Block (30), Frozen Tissue (4), RNA (60), Serum (21), Whole Bone Marrow (11) |
| COG | Rhabdomyosarcoma | ARST0331 : Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma | 390 | Buffy Coat (19), Fixed Tissue (1), Fixed Tissue Block (8), Frozen Tissue (198), Serum (64), Urine (1), Whole Blood (2), Whole Bone Marrow (26) |
| COG via Navigator | Sarcoma - NOS | ARST0332: Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Patients Under 30 Years of Age | 588 | Buffy Coat (20), DNA (187), Fixed Tissue (2), Fixed Tissue Block (98), Frozen Tissue (39), RNA (186), Serum (17), Whole Bone Marrow (3) |
| COG | Sarcoma - NOS | ARST0332 : Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Patients Under 30 Years of Age | 588 | Buffy Coat (26), Fixed Tissue (1), Fixed Tissue Block (8), Frozen Tissue (107), Serum (52), Urine (3), Whole Blood (1), Whole Bone Marrow (5) |
| COG via Navigator | Rhabdomyosarcoma | ARST0431: Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma | 109 | Buffy Coat (2), Cell Slide (2), DNA (43), Fixed Tissue (1), Fixed Tissue Block (15), Frozen Tissue (13), RNA (32), Serum (9), Whole Bone Marrow (13) |
| COG | Rhabdomyosarcoma | ARST0431 : Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma | 109 | Buffy Coat (6), Fixed Tissue Block (1), Frozen Tissue (27), Serum (23), Whole Bone Marrow (13) |
| COG via Navigator | Rhabdomyosarcoma | ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS). | 481 | Buffy Coat (8), DNA (127), Fixed Tissue (25), Fixed Tissue Block (66), Frozen Tissue (28), RNA (113), Serum (22), Whole Blood (3), Whole Bone Marrow (17) |
| COG | Rhabdomyosarcoma | ARST0531 : Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk RhaD374:D379MS). | 481 | Buffy Coat (5), Fixed Tissue Block (3), Frozen Tissue (78), Serum (17), Whole Bone Marrow (9) |
| COG | Multiple (not organ based) | ARST08P1: A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy fo | 175 | Buffy Coat (25), DNA (19), Fixed Tissue (2), Fixed Tissue Block (12), Frozen Tissue (17), Plasma (3), RNA (41), Serum (93), Whole Bone Marrow (17) |
| COG | Rhabdomyosarcoma | ARST0921: A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabd | 87 | Buffy Coat (2), DNA (6), Fixed Tissue (8), Fixed Tissue Block (10), Frozen Tissue (6), RNA (7), Serum (1), Whole Bone Marrow (1) |
| COG | Rhabdomyosarcoma | ARST0921 : A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabd | 87 | Fixed Tissue Block (1), Frozen Tissue (6), Serum (3) |
| COG via Navigator | Sarcoma - NOS | ARST1321: Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, | 140 | Cell Slide (1), DNA (75), Fixed Tissue (28), Fixed Tissue Block (50), Frozen Tissue (15), RNA (123), Serum (2), Whole Blood (97) |
| COG via Navigator | Stem Cell Transplant | ASCT0431: A Randomized Trial of Sirolimus-Based Graft versus Host Disease (GVHD) Prophylaxis after Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL | 146 | Buffy Coat (143), DNA (10), Whole Blood (6), Whole Bone Marrow (140) |
| COG | Stem Cell Transplant | ASCT0521: Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation. | 39 | Serum (1), Whole Blood (1) |
| COG via Navigator | Stem Cell Transplant | ASCT0631: A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source in Matched Sibling Donor Transplantation | 27 | Buffy Coat (19), DNA (1), Whole Bone Marrow (7) |
| COG via Navigator | Stem Cell Transplant | ASCT0631D: A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors with and without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631 | 13 | Buffy Coat (1), Whole Bone Marrow (9) |
| COG via Navigator | Hematologic - NOS | ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML) | 30 | Buffy Coat (19), Cell Slide (22), Whole Bone Marrow (20) |
| COG | Multiple (not organ based) | B903: Childhood Cancer Genetics | 2,183 | Buffy Coat (10), DNA (1), Fixed Tissue (2), Fixed Tissue Block (27), Frozen Tissue (57), Plasma (1), Serum (7), Urine (1), Whole Blood (2), Whole Bone Marrow (99) |
| COG | Multiple (not organ based) | B904: IRS Laboratory Evaluation of Tumor Tissue | 295 | Buffy Coat (13), Fixed Tissue (1), Fixed Tissue Block (43), Frozen Tissue (75), Plasma (1), Serum (2), Urine (2), Whole Blood (21), Whole Bone Marrow (8) |
| COG | Lymphoma - NOS | B944: Biology Studies in Childhood Hodgkin's and Non-Hodgkin's Lymphoma | 542 | Buffy Coat (12), DNA (5), Fixed Tissue (4), Fixed Tissue Block (41), Frozen Tissue (158), RNA (1), Serum (101), Whole Blood (5), Whole Bone Marrow (10) |
| COG | Multiple (not organ based) | B947: Protocol for Collection of Biology Specimens for Research Studies | 11,101 | Buffy Coat (755), Cell Slide (3), Cells (1), DNA (993), Fixed Tissue (39), Fixed Tissue Block (806), Frozen Tissue (2,569), Plasma (29), RNA (821), Serum (392), Urine (34), Whole Blood (25), Whole Bone Marrow (3,519) |
| COG | Neuroblastoma | B973: Laboratory-Clinical Studies of Neuroblastoma | 496 | Buffy Coat (4), Fixed Tissue (4), Fixed Tissue Block (25), Frozen Tissue (146), Serum (2), Urine (2), Whole Bone Marrow (2) |
| COG via Navigator | Leukemia - Acute myelocytic | C9710: Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy with or without Arsenic Trioxide (AS2O3) (NSC #706363) as Initial Consolidation Therapy Followed by Maintenance Therapy with Intermittent Tretinoin Therapy Versus Intermittent Tretinoin Plus Mercaptopurine and Methotresate for Patients with Untreated Acute Promylocytic Leukemia | 107 | Whole Bone Marrow (2) |
| COG | Leukemia - Acute myelocytic | C9710 : Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy with or without Arsenic Trioxide (AS2O3) (NSC #706363) as Initial Consolidation Therapy Followed by Maintenance Therapy with Intermittent Tretinoin Therapy Versus Intermittent Tretinoin Plus Mercaptopurine and Methotresate for Patients with Untreated Acute Promylocytic Leukemia | 107 | Buffy Coat (2) |
| COG via Navigator | Leukemia - Acute lymphocytic | CCG-1951: Extramedullary Relapse and Occult Marrow Involvement in Childhood ALL | 125 | Whole Bone Marrow (1) |
| COG | Leukemia - Acute lymphocytic | CCG-1951 : Extramedullary Relapse and Occult Marrow Involvement in Childhood ALL | 125 | Buffy Coat (14), Fixed Tissue Block (1), Whole Bone Marrow (53) |
| COG via Navigator | Leukemia - Acute lymphocytic | CCG-1952: Randomized comparisons of oral mercaptopurine vs oral thioguanine and IT methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia | 2,185 | DNA (1), Frozen Tissue (1), RNA (1), Whole Bone Marrow (20) |
| COG | Leukemia - Acute lymphocytic | CCG-1952 : Randomized comparisons of oral mercaptopurine vs oral thioguanine and IT methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia | 2,185 | Buffy Coat (27), Fixed Tissue Block (4), Frozen Tissue (5), Serum (1), Whole Bone Marrow (854) |
| COG via Navigator | Leukemia - Acute lymphocytic | CCG-1961: Treatment of Patients with A.L.L. with Unfavorable Features | 2,078 | Buffy Coat (6), DNA (4), Frozen Tissue (1), RNA (5), Whole Bone Marrow (67) |
| COG | Leukemia - Acute lymphocytic | CCG-1961 : Treatment of Patients with A.L.L. with Unfavorable Features | 2,078 | Buffy Coat (523), DNA (1), Fixed Tissue (1), Fixed Tissue Block (3), Frozen Tissue (7), Plasma (1), Serum (2), Whole Bone Marrow (1,108) |
| COG via Navigator | Leukemia - Acute lymphocytic | CCG-1962: A Randomized Comparison of PEG and Native E. coli Asparaginases in the Standard Arm of CCG-1952 for Standard Risk ALL | 118 | Whole Bone Marrow (3) |
| COG | Leukemia - Acute lymphocytic | CCG-1962 : A Randomized Comparison of PEG and Native E. coli Asparaginases in the Standard Arm of CCG-1952 for Standard Risk ALL | 118 | Buffy Coat (3), Fixed Tissue Block (1), Whole Bone Marrow (41) |
| COG via Navigator | Leukemia - Acute lymphocytic | CCG-1991: Escalating Dose Intravenous Methotrexate without Leucovorin Rescue vs. Oral Methotrexate and Single vs. Double Delayed Intensification for Children with Standard Risk Acute Lymphoblastic Leukemia | 3,054 | Buffy Coat (122), Cells (3), DNA (691), Frozen Tissue (1), RNA (786), Whole Bone Marrow (1,039) |
| COG | Leukemia - Acute lymphocytic | CCG-1991 : Escalating Dose Intravenous Methotrexate without Leucovorin Rescue vs. Oral Methotrexate and Single vs. Double Delayed Intensification for Children with Standard Risk Acute Lymphoblastic Leukemia | 3,054 | Buffy Coat (90), Fixed Tissue Block (5), Frozen Tissue (8), Serum (4), Whole Bone Marrow (935) |
| COG via Navigator | Leukemia - Acute myelocytic | CCG-2961: A Phase III Study in Children with Untreated Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | 1,010 | Buffy Coat (1), Whole Bone Marrow (4) |
| COG | Leukemia - Acute myelocytic | CCG-2961 : A Phase III Study in Children with Untreated Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | 1,010 | Buffy Coat (2), Fixed Tissue Block (2), Frozen Tissue (2), Serum (3), Whole Bone Marrow (21) |
| COG via Navigator | Lymphoma - Hodgkin's | CCG-5942: Comprehensive Study of Clinically Staged Hodgkin's Disease | 834 | DNA (1), Fixed Tissue Block (2), Frozen Tissue (5), Serum (44) |
| COG | Lymphoma - Hodgkin's | CCG-5942 : Comprehensive Study of Clinically Staged Hodgkin's Disease | 834 | Fixed Tissue (7), Fixed Tissue Block (59), Frozen Tissue (109), Serum (33), Whole Bone Marrow (1) |
| COG via Navigator | Lymphoma - NOS | CCG-5961: FAB LMB 96 Treatment of Mature B-Cell Lymphoma/Leukaemia (A SFOP/CCG/UKCCSG Cooperative Study) | 561 | Buffy Coat (5), Cell Slide (46), DNA (8), Fixed Tissue Block (77), Frozen Tissue (13), Serum (30), Whole Blood (1), Whole Bone Marrow (72) |
| COG | Lymphoma - NOS | CCG-5961 : FAB LMB 96 Treatment of Mature B-Cell Lymphoma/Leukaemia (A SFOP/CCG/UKCCSG Cooperative Study) | 561 | Buffy Coat (5), Fixed Tissue (14), Fixed Tissue Block (13), Frozen Tissue (83), Serum (13), Whole Bone Marrow (8) |
| COG | Rhabdomyosarcoma | D9501: Topotecan and CPM, Followed by Multimodal, Multiagent Therapy with Newly Diagnosed Stage 4/Clinical Group 4 Rhabdomyosarcoma, IRS-V Pilot Study | 67 | Buffy Coat (11), Fixed Tissue (1), Fixed Tissue Block (17), Frozen Tissue (24), Serum (1), Whole Blood (6), Whole Bone Marrow (12) |
| COG via Navigator | Rhabdomyosarcoma | D9502: IRS V Pilot Study of VCR, AMD, and Escalating Dose CTX Therapy for Children With Rhabdomyosarcoma at Increased Risk of Relapse | 125 | Buffy Coat (18), Cell Slide (1), Fixed Tissue Block (18), Frozen Tissue (36), Whole Blood (14), Whole Bone Marrow (17) |
| COG via Navigator | Rhabdomyosarcoma | D9602: Actinomycin D and VCR with or without CPM and RT, for Newly Diagnosed Patients with Low-Risk Embryonal/Botryoid Rhabdomyosarcoma: IRS-V Protocol | 484 | Buffy Coat (10), Cell Slide (4), DNA (14), Fixed Tissue (3), Fixed Tissue Block (18), Frozen Tissue (13), Whole Blood (7), Whole Bone Marrow (22) |
| COG | Rhabdomyosarcoma | D9602 : Actinomycin D and VCR with or without CPM and RT, for Newly Diagnosed Patients with Low-Risk Embryonal/Botryoid Rhabdomyosarcoma: IRS-V Protocol | 484 | Buffy Coat (26), Fixed Tissue (71), Fixed Tissue Block (57), Frozen Tissue (105), Serum (1), Whole Blood (5), Whole Bone Marrow (29) |
| COG via Navigator | Multiple (not organ based) | D9802: D9802, A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Combined with Vincristine followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents with Newly Diagnosed Stage 4/Clinical | 127 | Buffy Coat (14), Cell Slide (2), DNA (13), Fixed Tissue (6), Fixed Tissue Block (20), Frozen Tissue (39), Plasma (1), RNA (5), Serum (1), Whole Bone Marrow (34) |
| COG via Navigator | Rhabdomyosarcoma | D9803: Randomized Study of VCR, Actinomycin-D, and CPM (VAC) vs. VAC alternating with VCR, Topotecan, and CPM (VTC) for Patients with Intermediate Risk RMS | 702 | Buffy Coat (18), Cell Slide (9), DNA (24), Fixed Tissue (78), Fixed Tissue Block (101), Frozen Tissue (15), RNA (5), Serum (11), Whole Blood (4), Whole Bone Marrow (41) |
| COG | Rhabdomyosarcoma | D9803 : Randomized Study of VCR, Actinomycin-D, and CPM (VAC) vs. VAC alternating with VCR, Topotecan, and CPM (VTC) for Patients with Intermediate Risk RMS | 702 | Buffy Coat (50), Fixed Tissue (92), Fixed Tissue Block (19), Frozen Tissue (198), Serum (19), Whole Blood (1), Whole Bone Marrow (99) |
| COG | Sarcoma - NOS | D9902: A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol | 2,660 | Buffy Coat (1,272), Cell Slide (21), DNA (1,724), Fixed Tissue (175), Fixed Tissue Block (1,177), Frozen Tissue (2,164), Plasma (13), RNA (1,593), Serum (1,879), Urine (6), Whole Blood (73), Whole Bone Marrow (1,180) |
| COG | Leukemia - Acute lymphocytic | E15: Case Control Study of A.L.L. | 3,264 | Buffy Coat (43), Cell Slide (5), Fixed Tissue Block (7), Frozen Tissue (4), Plasma (1), Serum (9), Urine (3), Whole Bone Marrow (364) |
| COG | CNS | E21: Case Control Study of Primitive Neuroectodermal Tumor of Brain In Young Children | 657 | Fixed Tissue Block (22), Frozen Tissue (21), Whole Bone Marrow (1) |
| COG via Navigator | Neuroblastoma | P9641: Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma | 968 | Buffy Coat (25), Fixed Tissue Block (7), Frozen Tissue (18), Serum (1), Whole Bone Marrow (18) |
| COG | Neuroblastoma | P9641 : Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma | 968 | Buffy Coat (98), Fixed Tissue (22), Fixed Tissue Block (32), Frozen Tissue (598), Plasma (69), Serum (58), Whole Bone Marrow (32) |
| COG via Navigator | Liver | P9645: Phase III Protocol for the Treatment of Children with Hepatoblastoma | 289 | Buffy Coat (1), Fixed Tissue Block (17), Frozen Tissue (54) |
| COG | Liver | P9645 : Phase III Protocol for the Treatment of Children with Hepatoblastoma | 289 | Buffy Coat (2), Fixed Tissue (10), Fixed Tissue Block (9), Frozen Tissue (2), Serum (1), Whole Bone Marrow (1) |
| COG | Germ cell tumor | P9749: Pilot Intergroup Study of High-dose Cisplatin, Etoposide and Bleomycin (HD-PEB) Combined with Amifostine in Children with High-Risk Malignant Germ Cell Tumors | 27 | Buffy Coat (19), DNA (4), Fixed Tissue (4), Fixed Tissue Block (5), Frozen Tissue (10), Plasma (8), RNA (4), Serum (15), Whole Bone Marrow (1) |
| COG | Osteosarcoma | P9754: Protocol for Patients with Newly-Diagnosed, Non-metastatic Osteosarcoma: A Pilot Study | 253 | Buffy Coat (14), Cell Slide (4), DNA (59), Fixed Tissue (24), Fixed Tissue Block (41), Frozen Tissue (45), Plasma (1), RNA (48), Serum (107), Whole Blood (2) |
| COG | Osteosarcoma | P9851: Osteosarcoma Biology Protocol: Companion to Group -Wide Therapeutic Studies | 1,110 | Buffy Coat (133), Cell Slide (8), DNA (76), Fixed Tissue (1), Fixed Tissue Block (184), Frozen Tissue (380), Plasma (7), RNA (21), Serum (791), Urine (1), Whole Blood (19), Whole Bone Marrow (3) |
| COG via Navigator | CNS | P9934: Systemic Chemotherapy, Second Look Surgery and Involved Field Radiation for Children >= 8 months and <=36 months with Non-metastatic (MO) Medulloblastoma | 82 | Buffy Coat (9), Fixed Tissue Block (4), Serum (2) |
| COG | CNS | P9934 : Systemic Chemotherapy, Second Look Surgery and Involved Field Radiation for Children >= 8 months and <=36 months with Non-metastatic (MO) Medulloblastoma | 82 | Buffy Coat (23), Fixed Tissue (2), Fixed Tissue Block (1), Frozen Tissue (27), Serum (1) |
| COG via Navigator | Hematologic - NOS | POG-9900: ALinC 17, Classification (C), B-Precursor Induction Treatment (I) Protocol. | 3,762 | Buffy Coat (151), DNA (320), RNA (5), Whole Bone Marrow (193) |
| COG | Hematologic - NOS | POG-9900 : ALinC 17, Classification (C), B-Precursor Induction Treatment (I) Protocol. | 3,762 | Buffy Coat (4), Fixed Tissue Block (2), Frozen Tissue (4), Serum (1), Whole Bone Marrow (3) |
| COG via Navigator | Leukemia - Acute lymphocytic | POG-9904: ALinC 17 Treatment for Patients with Low Risk Acute Lymphoblastic Leukemia - A Phase III Study | 838 | Buffy Coat (86), DNA (57), Whole Bone Marrow (84) |
| COG | Leukemia - Acute lymphocytic | POG-9904 : ALinC 17 Treatment for Patients with Low Risk Acute Lymphoblastic Leukemia - A Phase III Study | 838 | Whole Bone Marrow (1) |
| COG via Navigator | Leukemia - Acute lymphocytic | POG-9905: ALinC 17: Protocol for Patients with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study | 1,076 | Buffy Coat (102), DNA (266), RNA (1), Whole Bone Marrow (100) |
| COG | Leukemia - Acute lymphocytic | POG-9905 : ALinC 17: Protocol for Patients with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study | 1,076 | Fixed Tissue Block (1), Serum (1), Whole Bone Marrow (1) |
| COG via Navigator | Leukemia - Acute lymphocytic | POG-9906: ALinC 17: Protocol for Patients with Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study | 276 | Buffy Coat (17), DNA (36), Whole Bone Marrow (18) |
| COG via Navigator | Leukemia - Acute lymphocytic | POG-9906: ALinC 17: Protocol for Patients with Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study | 276 | Whole Bone Marrow (1) |
| COG | Wilm's Tumor | Q9401 (4941): National Wilms Tumor Study V - Therapeutic Trial & Biology Study | 3,036 | Buffy Coat (3), DNA (2,462), Fixed Tissue (5), Fixed Tissue Block (1,591), Frozen Tissue (367), Plasma (5), RNA (96), Serum (505), Urine (1,821), Whole Blood (5) |
| COG | Wilm's Tumor | Q9401 (4941) : National Wilms Tumor Study V - Therapeutic Trial & Biology Study | 3,036 | Buffy Coat (1), DNA (37), Fixed Tissue (18), Fixed Tissue Block (101), Frozen Tissue (1,921), Plasma (11), Serum (1,122), Urine (11), Whole Blood (7), Whole Bone Marrow (1) |
| COG | Wilm's Tumor | Q9402 (4942): NWTS-5: Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study | 203 | DNA (149), Fixed Tissue Block (2), Frozen Tissue (6), RNA (1), Urine (134) |
| COG | Wilm's Tumor | Q9402 (4942) : NWTS-5: Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study | 203 | DNA (39), Fixed Tissue (77), Fixed Tissue Block (10), Frozen Tissue (157), Plasma (1), Serum (101) |
| COG | Ewing's sarcoma | SWOG-7942 (7942): Evaluation of Intensified VCR, DOXO, CPM, IFOS, and VP16 in the Treatment of Newly-Diagnosed Ewing's Sarcoma or PNET of Bone or Soft Tissue (POG-9354) | 492 | Fixed Tissue Block (4), Frozen Tissue (2) |
| COG | Ewing's sarcoma | SWOG-7942 (7942) : Evaluation of Intensified VCR, DOXO, CPM, IFOS, and VP16 in the Treatment of Newly-Diagnosed Ewing's Sarcoma or PNET of Bone or Soft Tissue (POG-9354) | 492 | Buffy Coat (1), Fixed Tissue (2), Fixed Tissue Block (3), Frozen Tissue (17), Serum (1), Whole Blood (1) |
| ECOG-ACRIN via Navigator | Breast | E1105: E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or Without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer | 96 | Cells (73), Fixed Tissue Block (55), Fixed Tissue Slide (3), Plasma (71), Serum (1), Urine (36) |
| ECOG-ACRIN via Navigator | Breast | E1199: A Phase III study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High Risk Node-Negative Breast Cancer | 5,052 | DNA (119), Fixed Tissue Block (3,696) |
| ECOG-ACRIN via Navigator | Head & Neck | E1302: Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer | 270 | Fixed Tissue Block (83), Fixed Tissue Slide (132), Plasma (2), Serum (1), Whole Blood (101) |
| ECOG-ACRIN via Navigator | Head & Neck | E1305: A Phase III Randomized Trial of Chemotherapy with or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer | 403 | Cells (160), Fixed Tissue Block (135), Fixed Tissue Slide (68), Plasma (248), Serum (218), Whole Blood (49) |
| ECOG-ACRIN via Navigator | Head & Neck | E1395: A Randomized Phase III Evaluation of Paclitaxel + Cisplatin Versus Cisplatin + 5-FU in Advanced Head and Neck Cancer | 218 | Fixed Tissue Block (38), Fixed Tissue Slide (10) |
| ECOG-ACRIN via Navigator | Lymphoma - NOS | E1496: Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy | 516 | Fixed Tissue Slide (172) |
| ECOG-ACRIN via Navigator | Lung | E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with or Without Bevacizumab for Patients with Completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) | 1,501 | Cells (1,047), Fixed Tissue Block (1,129), Fixed Tissue Slide (102), Plasma (1,088), Serum (999), Urine (1), Whole Blood (1,041) |
| ECOG-ACRIN via Navigator | Melanoma | E1694: A Phase III study of adjuvant Ganglioside vaccination GM2-KLH/QS-21 therapy vs. high-dose Interferon Alfa-2B (Introna) for high-risk melanoma (T4.>4MM primary or regional lymph node metastasis) | 877 | Fixed Tissue Block (159), Fixed Tissue Slide (208) |
| ECOG-ACRIN via Navigator | Melanoma | E1697: Phase III Randomized Study of Four Weeks High Dose IFN-alpha2b in Stage T2b N0, T3a-bN0, T4a-b N0, and T1-4, N1a, 2a (Microscopic) Melanoma | 1,150 | Fixed Tissue Block (12), Fixed Tissue Slide (376) |
| ECOG-ACRIN via Navigator | Leukemia - Acute myelocytic | E1900: A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation | 657 | Cell Slide (512), Cells (385), DNA (541), Fixed Tissue Slide (26), Plasma (239), RNA (583), Serum (541), Whole Blood (463), Whole Bone Marrow (516) |
| ECOG-ACRIN via Navigator | Leukemia - Chronic lymphocytic | E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | 529 | Cells (457), Fixed Tissue Block (443), Plasma (457), Saliva (418), Serum (457), Whole Blood (449), Whole Bone Marrow (115) |
| ECOG-ACRIN via Navigator | Myeloma | E1A00: A Randomized Phase III Trial of Thalidomide (NSC #66847) Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma | 207 | Cell Slide (113), Cells (98), Plasma (123), Whole Bone Marrow (92) |
| ECOG-ACRIN via Navigator | Myeloma | E1A05: Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) - Lenalidomide (Revlimid®) - Dexamethasone (VRD) Versus Bortezomib (Velcade®) - Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen | 48 | Cells (32), Plasma (32), Whole Bone Marrow (23) |
| ECOG-ACRIN via Navigator | Myeloma | E1A06: An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients who are not Candidates for High-Dose Therapy | 306 | Cell Slide (95), Cells (135), Plasma (141), Whole Bone Marrow (94) |
| ECOG-ACRIN via Navigator | Myeloma | E1A95: A Phase III Study of PSC-833 in Combination with Vincristine, Doxorubicin and Dexamethasone (psc-833/vad) Versus Vad Alone in Patients with Relapsing or Refractory Multiple Myeloma | 100 | Cell Slide (38), Cells (41) |
| ECOG-ACRIN via Navigator | Breast | E2100: A Randomized Phase III Trial of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer | 722 | Cell Slide (1), Fixed Tissue Block (391), Fixed Tissue Slide (480) |
| ECOG-ACRIN via Navigator | CNS | E2394: A Phase III study comparing three cycles of infusional bcnu/cisplatin followed by radiation therapy with radiation therapy and concurrent bcnu for patients with newly diagnosed supratentorial glioblastoma multiforme | 223 | Fixed Tissue Block (56), Fixed Tissue Slide (11) |
| ECOG-ACRIN via Navigator | Lymphoma - Diffuse large B-cell | E2499: Randomized Phase III Trial of Rituximab (NSC #687451) and Autologous Stem Cell Transplantation for B Cell Diffuse Large Cell Lymphoma | 38 | Fixed Tissue Block (22), Fixed Tissue Slide (9) |
| ECOG-ACRIN via Navigator | Melanoma | E2603: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma | 823 | Fixed Tissue Block (352), Fixed Tissue Slide (93), Plasma (12), Whole Blood (1) |
| ECOG-ACRIN via Navigator | Kidney | E2805: ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma | 1,943 | Cells (514), Fixed Tissue Block (359), Fixed Tissue Slide (124), Plasma (530), Serum (77), Urine (1,134), Whole Blood (4) |
| ECOG-ACRIN via Navigator | Leukemia - Acute myelocytic | E2995: Phase III Randomized Trial Comparing MEC Chemotherapy with MEC Plus PSC 833 (PSC-MEC) in Patients with Relapsed and Refractory AML | 144 | Cells (41), RNA (69), Whole Blood (8), Whole Bone Marrow (60) |
| ECOG-ACRIN via Navigator | Leukemia - Chronic lymphocytic | E2997: Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia | 278 | Cells (202), DNA (225), RNA (240) |
| ECOG-ACRIN via Navigator | Breast | E3193: Phase III comparison of Tamoxifen versus Tamoxifen with Ovarian Ablation in premenopausal women with axillary node-negative receptor-positive Breast cancer < or = to 3 cm. | 345 | Fixed Tissue Block (102) |
| ECOG-ACRIN via Navigator | Colon | E3200: Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients with Advanced Colorectal Cancer | 829 | Fixed Tissue Block (280), Fixed Tissue Slide (245) |
| ECOG-ACRIN via Navigator | Rectum | E3201: Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5 Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients with Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil | 225 | Fixed Tissue Block (136), Fixed Tissue Slide (121) |
| ECOG-ACRIN via Navigator | Head & Neck | E3311: Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer. | 519 | Cells (104), Fixed Tissue Block (396), Plasma (102), Saliva (1), Serum (42) |
| ECOG-ACRIN via Navigator | Lung | E3598: A Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, with or without Thalidomide, in Patients with Stage III NSCLC | 589 | Fixed Tissue Block (46), Fixed Tissue Slide (36) |
| ECOG-ACRIN via Navigator | Melanoma | E3697: A prospective randomized Phase III clinical trial assessing the role of post-operative Radiotherapy plus adjuvant Interferon Alpha-2B in patients with Cervical, Axillary and Inguinal nodal metastasis from cutaneous Melanoma | 15 | Fixed Tissue Block (1), Fixed Tissue Slide (6) |
| ECOG-ACRIN via Navigator | Prostate | E3805: CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer | 790 | Fixed Tissue Block (269), Fixed Tissue Slide (276), Plasma (163), Serum (161), Whole Blood (151) |
| ECOG-ACRIN via Navigator | Prostate | E3886: Randomized Phase III Evaluation of Hormonal Therapy Versus Observation in Patients with Stage D1 Adenocarcinoma of the Prostate Following Pelvic Lymphadenectomy and Radical Prostatectomy | 100 | Fixed Tissue Block (4) |
| ECOG-ACRIN via Navigator | Lymphoma - Non-Hodgkin's | E4402: Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin's Lymphoma | 544 | Fixed Tissue Block (173), Fixed Tissue Slide (349) |
| ECOG-ACRIN via Navigator | Lymphoma - Non-Hodgkin's | E4494: Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma | 632 | Fixed Tissue Block (251), Fixed Tissue Slide (141) |
| ECOG-ACRIN via Navigator | Lung | E4599: Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin with or without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC | 878 | Plasma (161) |
| ECOG-ACRIN via Navigator | Melanoma | E4697: A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GMCSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with 'No Evidence of Disease' After Complete Surgical Resection of 'Locally Advanced' and/or Stage IV Melanoma | 815 | Cells (692), Plasma (1), Serum (712) |
| ECOG-ACRIN via Navigator | Myeloma | E4A03: A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders | 452 | Cells (197), Plasma (249), RNA (141), Whole Bone Marrow (126) |
| ECOG-ACRIN via Navigator | Myeloma | E4A08: A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-Chain (AL) Amyloidosis Ineligible for Autologous Stem-Cell Transplantation | 11 | Cell Slide (5), Cells (4), Plasma (5), Serum (7), Whole Bone Marrow (1) |
| ECOG-ACRIN via Navigator | Breast | E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer | 4,994 | Plasma (3,445), Serum (3,487) |
| ECOG-ACRIN via Navigator | Head & Neck | E5397: Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Patients with Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck | 123 | Fixed Tissue Block (26), Fixed Tissue Slide (66) |
| ECOG-ACRIN via Navigator | Pancreas | E6201: A Phase III, Randomized Study of Gemcitabine [Fixed-Dose Rate Infusion] and Oxaliplatin (NSC 266046) Versus Gemcitabine [Fixed-Dose Rate Infusion] Versus Gemcitabine [30-Minute Infusion] in Pancreatic Carcinoma | 832 | Cell Slide (3), Fixed Tissue Block (10), Fixed Tissue Slide (26) |
| ECOG-ACRIN via Navigator | Breast | EST-4181: Adjuvant therapy for postmenopausal women with Breast cancer (CTX, MTX,5-FU, Pred, Tam) | 951 | Fixed Tissue Slide (712) |
| ECOG-ACRIN via Navigator | Leukemia - Acute lymphocytic | INT-032: Phase III Randomized Trial of Autologous and Allogeneic Bone Marrow Transplantation versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission | 736 | Whole Blood (74), Whole Bone Marrow (33) |
| ECOG-ACRIN via Navigator | Breast | PACCT-1: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial | 10,273 | Cells (188), Fixed Tissue Block (5), Plasma (4,996), Serum (81), Whole Blood (18) |
| NRG | Cervix | GOG-0076HH: Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | 37 | Fixed Tissue Block (4), Fixed Tissue Slide (24) |
| NRG | Uterus | GOG-0086P: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | 349 | Fixed Tissue Block (135), Fixed Tissue Slide (34), Frozen Tissue (1), Plasma (273), Whole Blood (1) |
| NRG | Cervix | GOG-0109: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix | 268 | Fixed Tissue Block (176), Fixed Tissue Slide (159), Serum (1) |
| NRG | Cervix | GOG-0127V: ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | 37 | Fixed Tissue Block (2), Fixed Tissue Slide (8), Plasma (1) |
| NRG | Ovary | GOG-0158: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer | 792 | Buffy Coat (3), Fixed Tissue Block (6), Fixed Tissue Slide (10), Frozen Tissue (5), Plasma (124), Serum (22), Whole Blood (3) |
| NRG | Ovary | GOG-0170R: Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | 30 | DNA (28), Fixed Tissue Block (10), Fixed Tissue Slide (3), Plasma (29) |
| NRG via Navigator | Ovary | GOG-0172: A Phase III randomized trial of intravenous Paclitaxel and Cisplatin versus intravenous Paclitaxel, intraperitoneal Cisplatin and intraperitoneal Paclitaxel in patients with optimal stage III Epithelial Ovarian Carcinoma or primary | 429 | Buffy Coat (1), Whole Blood (2) |
| NRG | Ovary | GOG-0175: A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q21 days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q21 days x 3 Courses Plus | 507 | Fixed Tissue Slide (15), Plasma (13), Serum (16), Whole Blood (2) |
| NRG | Uterus | GOG-0177: A Randomized Study of Doxorubicin plus Cisplatin Versus Doxorubicin plus Cisplatin plus 3-hour Paclitaxel with G-CSF Support in Patients with Primary Stage III & IV or Recurrent Endometrial Carcinoma (PHASE III) | 273 | Fixed Tissue Block (73), Fixed Tissue Slide (125) |
| NRG | Ovary | GOG-0182: A Phase III Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma | 3,882 | Fixed Tissue Block (27), Plasma (2), Serum (2), Whole Blood (1) |
| NRG | Ovary | GOG-0186K: Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | 111 | Fixed Tissue Block (43), Fixed Tissue Slide (61) |
| NRG | Ovary | GOG-0190: An Exploratory Evaluation of Fenretinide (4-HPR) (IND #39,812) as a Chemopreventive Agent for Ovarian Carcinoma | 71 | Plasma (4) |
| NRG | Uterus | GOG-0191: A Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 G/L with Erythropoietin Versus Above 100 G/L without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer | 114 | Fixed Tissue Block (50), Fixed Tissue Slide (50), Serum (91) |
| NRG | Ovary | GOG-0198: A Randomized Study of Tamoxifen Versus Thalidomide (NSC# 66847) in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy | 139 | Serum (108), Whole Blood (1) |
| NRG | Ovary | GOG-0199: Prospective Study of Risk-Reducing Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer | 2,605 | Fixed Tissue Slide (1,246), Frozen Tissue (1,246), Plasma (2,651), Serum (2,674) |
| NRG | Cervix | GOG-0207: A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3) | 130 | Cells (1), Fixed Tissue Slide (129), Serum (115) |
| NRG | Uterus | GOG-0210: A Molecular Staging Study of Endometrial Carcinoma | 6,124 | DNA (128), Fixed Tissue Block (3,375), Fixed Tissue Slide (2,400), Serum (2,666), Urine (1,496) |
| NRG | Ovary | GOG-0212: A randomized phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or ct-2103 (ind# 70177) versus no treatment until documented relapse in women with advanced ovarian, primary peritoneal or fallopian tube cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy | 1,159 | DNA (830), Fixed Tissue Block (159), Fixed Tissue Slide (513), Serum (535) |
| NRG | Ovary | GOG-0213: A Phase III Randomized Controlled Clinical Trial Of Carboplatin and Paclitaxel or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrenovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912) | 1,059 | DNA (591), Fixed Tissue Block (123), Fixed Tissue Slide (104), Plasma (76), Serum (75), Whole Blood (37) |
| NRG | Ovary | GOG-0214: Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND# 79,610) | 60 | Fixed Tissue Slide (64), Frozen Tissue (60), Plasma (63), Serum (63) |
| NRG | Ovary | GOG-0218: A phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab (nsc #704865, ind #7921) followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women newly diagnosed, previously untreated, stage III or IV, epithelial ovarian, primary peritoneal or fallopian tube cancer nci-supplied agent(s): bevacizumab/ placebo | 1,873 | DNA (1,033), Fixed Tissue Block (1,130), Fixed Tissue Slide (748), Plasma (242), Serum (64) |
| NRG | Uterus | GOG-0219: A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine (IND# 46525) and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis | 402 | Fixed Tissue Block (104), Fixed Tissue Slide (28), Plasma (13), Serum (26) |
| NRG | Ovary | GOG-0220: Pelvic Mass Study to Develop Serum Proteomic Profiles (Signatures) for Epithelial Ovarian Cancer Diagnosis and Prognosis | 2,288 | Serum (7), Whole Blood (1) |
| NRG | Uterus | GOG-0221: Glycoprotein and Glycan Profiling in Patients with Locally Advanced Cervical Cancer (STAGE IB2, IIA > 4 CM, IIB to IVA) Undergoing Pelvic and Para-Aortic (Abdominal) Lymphadenectomy | 159 | Fixed Tissue Block (85), Fixed Tissue Slide (87), Serum (75) |
| NRG | Ovary | GOG-0225: Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival? | 1,070 | Plasma (985), Serum (867), Whole Blood (765) |
| NRG | Cervix | GOG-0227G: Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | 31 | Serum (24) |
| NRG | Uterus | GOG-0229E: Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer | 56 | Fixed Tissue Block (9), Fixed Tissue Slide (32), Plasma (25) |
| NRG | Cervix | GOG-0229N: Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | 28 | DNA (28), Fixed Tissue Block (7), Fixed Tissue Slide (17), Plasma (26) |
| NRG | Uterus | GOG-0229O: A randomized phase II study with a phase I lead-in to assess the antitumor efficacy of the MEK inhibitor Trametinib alone or in combination with GSK2141795, an AKT inhibitor in patients with recurrent or persistent endometrial cancer. | 26 | DNA (22), Fixed Tissue Block (5), Fixed Tissue Slide (14) |
| NRG | Ovary | GOG-0235: A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy | 686 | Serum (641) |
| NRG | Cervix | GOG-0237: Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC) | 1,053 | Cells (581), Fixed Tissue Slide (710) |
| NRG | Ovary | GOG-0239: Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | 52 | Fixed Tissue Block (3), Fixed Tissue Slide (7), Plasma (46) |
| NRG | Uterus | GOG-0240: A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and Without NCI-Supplied Bevacizumab (NSC #704865, IND #113912) Versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, with and Without NCI-Supplied | 452 | DNA (324), Fixed Tissue Block (135), Fixed Tissue Slide (354), Plasma (336), RNA (27), Whole Blood (1) |
| NRG | Ovary | GOG-0241: A GCIG intergroup multicenter phase III trial of open label carboplatin and paclitaxel +/- NCI-supplied agent: bevacizumab (nsc #704865, ind #113912) compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous epithelial ovarian or fallopian tube cancer (MEOC) | 16 | DNA (14), Fixed Tissue Block (9), Fixed Tissue Slide (12) |
| NRG | Uterus | GOG-0248: Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer | 73 | DNA (25), Fixed Tissue Block (31), Fixed Tissue Slide (19), Whole Blood (54) |
| NRG | Uterus | GOG-0249: A phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high risk, early stage endometrial carcinoma | 601 | DNA (460), Fixed Tissue Block (349), Fixed Tissue Slide (252), Whole Blood (1) |
| NRG | Uterus | GOG-0250: A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865, IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus | 107 | Fixed Tissue Block (26), Fixed Tissue Slide (66) |
| NRG | Ovary | GOG-0252: A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab | 1,560 | DNA (1,446), Fixed Tissue Block (491), Fixed Tissue Slide (700) |
| NRG | Ovary | GOG-0254: Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer | 35 | Fixed Tissue Block (1), Fixed Tissue Slide (28), Plasma (29), Serum (29) |
| NRG | Ovary | GOG-0255: OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission | 171 | Serum (167) |
| NRG | Uterus | GOG-0258: A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. Carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma | 813 | DNA (667), Fixed Tissue Block (373), Fixed Tissue Slide (345) |
| NRG via Navigator | Gyn - NOS | GOG-0261: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary | 637 | DNA (530), Fixed Tissue Block (228), Fixed Tissue Slide (337) |
| NRG | Ovary | GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (NSC #704865, IND #113912) in the | 804 | DNA (599), Fixed Tissue Block (479), Fixed Tissue Slide (312), Plasma (555), Serum (560), Whole Blood (1) |
| NRG | Ovary | GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary | 63 | Fixed Tissue Block (11), Fixed Tissue Slide (56) |
| NRG | Cervix | GOG-0265: Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | 54 | Fixed Tissue Block (4), Fixed Tissue Slide (39), Serum (45) |
| NRG | Ovary | GOG-0268: A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary | 90 | Fixed Tissue Block (15), Fixed Tissue Slide (23) |
| NRG via Navigator | Ovary | GOG-0271: A Study of the Local and Systemic Effects of Intraperitoneal Chemotherapy in the Treatment of Previously-Untreated, Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | 14 | Fixed Tissue Block (2), Fixed Tissue Slide (9) |
| NRG | Ovary | GOG-0273: Chemotherapy toxicity in elderly women with ovarian, primary peritoneal or fallopian tube cancer | 318 | Plasma (189) |
| NRG | Uterus | GOG-0274/RTOG-1174: A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL | 900 | DNA (287), Fixed Tissue Block (139), Fixed Tissue Slide (384), Plasma (508), Whole Blood (227) |
| NRG | Ovary | GOG-0280: A Phase II Eval of the Poly(ADP-Ribose)Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888)(NSC #737644) in the tx of Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Ca in Patients who carry a germline BRCA 1 or 2 Mutation | 52 | DNA (43), Fixed Tissue Block (9), Fixed Tissue Slide (26), Frozen Tissue (1), Serum (43) |
| NRG via Navigator | Ovary | GOG-0281: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer | 260 | Fixed Tissue Block (42), Fixed Tissue Slide (94), Plasma (167) |
| NRG | Ovary | GOG-0283: A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #73969) In Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, Endometrial, or Endometriosis-Associated Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expsion | 35 | DNA (24), Fixed Tissue Block (17), Fixed Tissue Slide (17), Whole Blood (3) |
| NRG via Navigator | Uterus | GOG-0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer | 469 | DNA (369), Fixed Tissue Block (167), Fixed Tissue Slide (165), Plasma (175), Whole Blood (8) |
| NRG | Cervix | GOG-9918: Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer | 64 | Fixed Tissue Block (1), Fixed Tissue Slide (60) |
| NRG | Ovary | GOG-9923: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | 431 | Whole Blood (3) |
| NRG | Ovary | GOG-9924: Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | 33 | Plasma (32) |
| NRG | Ovary | GOG-9925: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | 20 | DNA (19), Plasma (20) |
| NRG | Ovary | GOG-9927: Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | 41 | Fixed Tissue Block (11), Fixed Tissue Slide (25) |
| NRG | Ovary | GOG-9928: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | 16 | Plasma (15) |
| NRG via Navigator | Esophageal | INT-0113: A Phase III intergroup trial: a prospective randomized comparison of combined modality therapy for squamous carcinoma of the esophagus: chemotherapy plus surgery versus surgery alone for patients with local regional disease | 467 | Fixed Tissue Block (34), Fixed Tissue Slide (80) |
| NRG | Rectum | NRG GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer | 363 | Buffy Coat (296), Fixed Tissue (22), Fixed Tissue Block (205), Fixed Tissue Slide (130), Plasma (265), Serum (297) |
| NRG | CNS | NRG-CC001: A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases | 518 | Serum (312), Whole Blood (288) |
| NRG | Lung | NRG-CC003: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer | 380/392 | Serum (194), Whole Blood (163) |
| NRG | Prostate | NRG-GU003: A Randomized Phase III Trial Of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT) | 296 | Fixed Tissue Block (188), Fixed Tissue Slide (190), Plasma (221), Sputum (221), Whole Blood (213) |
| NRG | Ovary | NRG-GY001: A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum | 13 | Fixed Tissue Block (9), Fixed Tissue Slide (129) |
| NRG | Cervix | NRG-GY002: A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer | 26 | Fixed Tissue Block (7), Serum (24) |
| NRG via Navigator | Ovary | NRG-GY004: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 579 | DNA (348), Fixed Tissue Block (214), Fixed Tissue Slide (254), Plasma (500), Whole Blood (477) |
| NRG | Uterus | NRG-GY008: A Phase II Evaluation of Copanlisib BAY 80-6946 IND #130822, A Selective Inhibitor of PI3KCA, in patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations | 53 | Fixed Tissue Block (4), Fixed Tissue Slide (6) |
| NRG | Uterus | NRG-GY011: A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus | 50 | Fixed Tissue Block (12), Fixed Tissue Slide (33), Frozen Tissue (20) |
| NRG | Ovary | NRG-GY016: A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary | 14/25 | Fixed Tissue Block (6), Fixed Tissue Slide (8), Plasma (14) |
| NRG via Navigator | Breast | NSABP-B-20: A Clinical Trial to Compare Tamoxifen (TAM) with Sequential Methotrexate, 5-Fluorouracil and TAM (M-F+T) or CMF and TAM (CMF+T) in Patients with Primary Breast Cancer, Negative Axillary Nodes and Estrogen Receptor Positive Tumors | 2,363 | Cell Slide (29), Fixed Tissue Block (827), Fixed Tissue Slide (2,098), Whole Blood (1) |
| NRG via Navigator | Breast | NSABP-B-27: A Randomized Trial Comparing Preoperative Doxorubicin (Adriamycin) Cyclophosphamide (AC) to Preoperative AC Followed by Preoperative Docetaxel (Taxotere) and to Preoperative AC Followed by Postoperative Docetaxel | 2,411 | Cell Slide (216), Fixed Tissue Block (1,529), Fixed Tissue Slide (1,415), Whole Blood (1) |
| NRG | Breast | NSABP-B-27 (not in navigator): A Randomized Trial Comparing Preoperative Doxorubicin (Adriamycin) Cyclophosphamide (AC) to Preoperative AC Followed by Preoperative Docetaxel (Taxotere) and to Preoperative AC Followed by Postoperative Docetaxel | 2,411 | Buffy Coat (13), Plasma (3), Serum (593) |
| NRG via Navigator | Breast | NSABP-B-28: A Randomized Trial Evaluating the Worth of Paclitaxel (Taxol) Following Doxorubicin (Adriamycin)/Cyclophosphamide in Breast Cancer Patients with Positive Axillary Nodes | 3,060 | Cell Slide (48), Fixed Tissue Block (2,092), Fixed Tissue Slide (2,511), Whole Blood (1) |
| NRG | Breast | NSABP-B-29: A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 pa LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Patients with Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer | 893 | Cell Slide (2), Fixed Tissue Block (615), Fixed Tissue Slide (373), Whole Blood (1) |
| NRG via Navigator | Breast | NSABP-B-30: A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC->T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer | 5,351 | Fixed Tissue Block (4,208), Fixed Tissue Slide (1,378) |
| NRG | Breast | NSABP-B-31: A Randomized Trial Comparing The Safety And Efficacy Of Adriamycin And Cyclophosphamide Followed By Taxol (AC?T) To That Of Adriamycin And Cyclophosphamide Followed By Taxol Plus Herceptin (AC?T + H) In Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2 | 2,130 | Cell Slide (2), DNA (1,115), Fixed Tissue Block (1,802), Fixed Tissue Slide (1,837), RNA (8) |
| NRG | Breast | NSABP-B-31 (not in navigator): A Randomized Trial Comparing The Safety And Efficacy Of Adriamycin And Cyclophosphamide Followed By Taxol (AC?T) To That Of Adriamycin And Cyclophosphamide Followed By Taxol Plus Herceptin (AC?T + H) In Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2 | 2,130 | Buffy Coat (1,736), Serum (1,795) |
| NRG | Breast | NSABP-B-34: A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy | 3,323 | Fixed Tissue Block (2,497), Fixed Tissue Slide (1,219) |
| NRG | Breast | NSABP-B-34 (not in navigator): A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy | 3,323 | Buffy Coat (2,418), Serum (2,438) |
| NRG via Navigator | Breast | NSABP-B-39/RTOG-0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer | 4,216 | Cell Slide (9), Fixed Tissue Block (2,710), Fixed Tissue Slide (2,667) |
| NRG | Breast | NSABP-B-39/RTOG-0413 (not in navigator): A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer | 4,216 | Buffy Coat (2,884), Serum (2,959) |
| NRG | Breast | NSABP-B-40: A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens | 1,206 | Fixed Tissue Block (1,189), Fixed Tissue Slide (471), RNA (81) |
| NRG | Breast | NSABP-B-40 (not in navigator): A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens | 1,206 | Buffy Coat (1,052), Serum (1,105) |
| NRG | Breast | NSABP-B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer | 3,966 | Fixed Tissue Block (3,107), Fixed Tissue Slide (2,115) |
| NRG | Breast | NSABP-B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy | 2,014 | Fixed Tissue Block (1,821), Fixed Tissue Slide (119), RNA (32) |
| NRG | Breast | NSABP-B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer | 3,270 | Fixed Tissue Block (2,926), Fixed Tissue Slide (812), RNA (239), Whole Bone Marrow (1) |
| NRG | Breast | NSABP-B-47 (not in navigator): A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer | 3,270 | Buffy Coat (2,803), Plasma (1,396), RNA (1,395), Serum (2,868) |
| NRG | Breast | NSABP-B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | 1,870 | Fixed Tissue Block (1,680), Fixed Tissue Slide (546) |
| NRG | Breast | NSABP-B-52: A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation | 313 | Buffy Coat (283), DNA (290), Fixed Tissue Block (295), Fixed Tissue Slide (277), Plasma (275), RNA (243), Serum (294), Whole Blood (284) |
| NRG | Colon | NSABP-C-08: A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Stage II/III Colon Cancer | 2,710 | Fixed Tissue Block (2,132), Fixed Tissue Slide (2,180), RNA (63) |
| NRG | Colon | NSABP-C-08 (not in navigator): A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Stage II/III Colon Cancer | 2,710 | Buffy Coat (2,190), Serum (2,263) |
| NRG | Rectum | NSABP-R-04: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum | 1,608 | Fixed Tissue Block (751), Fixed Tissue Slide (367) |
| NRG | Rectum | NSABP-R-04 (not in navigator): A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum | 1,608 | Buffy Coat (1,290), Serum (1,306) |
| NRG | Prostate | RTOG 0126: A Phase III Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3DCRT/IMRT in Patients Treated for Localized Prostate Cancer | 1,532 | Buffy Coat (374), Fixed Tissue Block (381), Fixed Tissue Slide (1,392), Plasma (208), Serum (99) |
| NRG | Head & Neck | RTOG 0129: A Phase III Trial of Concurrent Radiation and Chemotherapy (Followed by Surgery for Residual Primary/N2-3 Nodal Disease) for Advanced Head and Neck Carcinomas | 743 | Fixed Tissue Block (220), Fixed Tissue Slide (635), Plasma (1), Serum (4), Whole Blood (235) |
| NRG | Prostate | RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation And Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone For Selected Patients With Intermediate Risk Prostatic Carcinoma | 588 | Fixed Tissue Block (162), Fixed Tissue Slide (475), Frozen Tissue (13) |
| NRG via Navigator | Lung | RTOG 0412/SWOG-S0332: Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients with Stage IIIA (N2) Non-Small Cell Lung Cancer | 19 | Buffy Coat (10), Fixed Tissue Block (6), Fixed Tissue Slide (10), Frozen Tissue (3), Plasma (11), Serum (5) |
| NRG | Prostate | RTOG 0415: A Phase III Randomized Study of Hypofractionated 3DCRT/IMRT versus Conventionally Fractionated 3DCRT/IMRT in Patients Treated for Favorable-Risk Prostate Cancer | 1,115 | Buffy Coat (553), Fixed Tissue Block (401), Fixed Tissue Slide (922), Plasma (525), Serum (525) |
| NRG via Navigator | Head & Neck | RTOG 0421: A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy versus Chemotherapy Alone | 15 | Buffy Coat (6), Plasma (7), Serum (7) |
| NRG | Esophageal | RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery | 344 | Buffy Coat (506), Fixed Tissue Block (176), Fixed Tissue Slide (648), Plasma (1,589), Serum (1,589), Urine (488), Whole Blood (246) |
| NRG | Head & Neck | RTOG 0514: Establishment of a Head and Neck Cancer Tissue/Specimen Repository | 351 | Buffy Coat (163), Fixed Tissue Block (225), Fixed Tissue Slide (230), Frozen Tissue (57), Plasma (168), Saliva (137), Serum (168) |
| NRG | Prostate | RTOG 0521: A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer | 612 | Buffy Coat (238), Fixed Tissue Block (278), Fixed Tissue Slide (431), Plasma (226), Serum (226), Whole Blood (10) |
| NRG | Head & Neck | RTOG 0522: A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab C225 [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas | 942 | Buffy Coat (277), Fixed Tissue Block (388), Fixed Tissue Slide (631), Plasma (504), Serum (504), Whole Blood (33) |
| NRG | CNS | RTOG 0525: Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma | 1,174 | Fixed Tissue Block (696), Fixed Tissue Slide (805) |
| NRG | Prostate | RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy | 1,792 | Buffy Coat (722), Fixed Tissue Block (588), Fixed Tissue Slide (1,561), Plasma (1,274), Serum (1,273), Urine (1,260) |
| NRG | Prostate | RTOG 0612: Investigating Markers of Radiation Outcome in Patients with Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study | 13 | Fixed Tissue Block (6), Fixed Tissue Slide (6), Frozen Tissue (13) |
| NRG | Lung | RTOG 0617: A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer | 544 | Buffy Coat (243), Fixed Tissue Block (235), Fixed Tissue Slide (309), Plasma (376), Serum (376), Whole Blood (149) |
| NRG | Prostate | RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer | 1,538 | Buffy Coat (188), Fixed Tissue Block (447), Fixed Tissue Slide (1,021), Plasma (972), Serum (164), Whole Blood (764) |
| NRG | CNS | RTOG 0825: Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in | 978 | Buffy Coat (83), Fixed Tissue Block (607), Fixed Tissue Slide (631), Plasma (472), Serum (417), Urine (500), Whole Blood (171) |
| NRG | Pancreas | RTOG 0848: A Phase IIR and a Phase III Trial Evaluating Both Erlotinib (Ph IIR) And Chemoradiation (Ph III) As Adjuvant Treatment For Patients With Resected Head Of Pancreas Adenocarcinoma | 545 | Buffy Coat (19), Fixed Tissue Block (421), Fixed Tissue Slide (438), Plasma (437), Urine (395), Whole Blood (419) |
| NRG | Head & Neck | RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer | 627 | Buffy Coat (16), Fixed Tissue Block (655), Fixed Tissue Slide (670), Plasma (435), Serum (429), Whole Blood (420) |
| NRG | Prostate | RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial | 2,590 | Fixed Tissue Block (700), Fixed Tissue Slide (1,655), Plasma (1,717), Serum (1,059), Urine (1,611), Whole Blood (1,667) |
| NRG | Breast | RTOG 1005: A Phase III Trial Of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer | 2,353 | Buffy Coat (4), Fixed Tissue Block (1,261), Fixed Tissue Slide (1,449), Plasma (1,404), Whole Blood (1,393) |
| NRG | Esophageal | RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma | 273 | Fixed Tissue Block (243), Fixed Tissue Slide (472), Plasma (160), Urine (161), Whole Blood (161) |
| NRG | Liver | RTOG 1112: Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma | 193 | Fixed Tissue Block (2), Fixed Tissue Slide (9), Plasma (52), Serum (52), Whole Blood (49) |
| NRG | Prostate | RTOG 1115: Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer | 239 | Buffy Coat (74), Fixed Tissue Block (91), Fixed Tissue Slide (180), Plasma (211), Serum (217), Whole Blood (203) |
| NRG | CNS | RTOG 7401/ECOG 1374: Comparison of postoperative radiotherapy and chemotherapy in the multidisciplinary management of ma- lignant gliomas | 639 | Fixed Tissue Slide (117) |
| NRG | CNS | RTOG 7918: A randomized comparison of misonida- zole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery | 318 | Fixed Tissue Block (29), Fixed Tissue Slide (73) |
| NRG | Prostate | RTOG 8610: Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer | 456 | Fixed Tissue Block (126), Fixed Tissue Slide (160) |
| NRG | Head & Neck | RTOG 9003: Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck | 1,113 | Fixed Tissue Block (576), Fixed Tissue Slide (838) |
| NRG | CNS | RTOG 9305: Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme | 200 | Fixed Tissue Block (24), Fixed Tissue Slide (72) |
| NRG | CNS | RTOG-0614: A Randomized Phase III Double-Blind, Placebo Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy | 554 | Buffy Coat (181), CSF (2), Fixed Tissue Block (4), Fixed Tissue Slide (4), Plasma (250), Serum (268), Urine (274) |
| NRG | CNS | RTOG-0631: Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis | 399 | Buffy Coat (5), Plasma (158), Serum (158), Urine (155), Whole Blood (150) |
| NRG | Prostate | RTOG-0831: A Randomized, Double-Blinded, Placebo-Controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated with Radiotherapy for Prostate Cancer | 242 | Buffy Coat (9), Fixed Tissue Block (1), Fixed Tissue Slide (1), Plasma (111), Serum (110), Whole Blood (101) |
| NRG | CNS | RTOG-0925: Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery | 82 | Fixed Tissue Block (34), Fixed Tissue Slide (74), Plasma (40), Urine (43), Whole Blood (41) |
| NRG | CNS | RTOG-0933: A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases--RTOG CCOP Study | 113 | Plasma (67), Serum (67), Whole Blood (60) |
| NRG | Head & Neck | RTOG-1008: A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | 252 | Buffy Coat (2), Fixed Tissue Block (166), Fixed Tissue Slide (233), Plasma (177), Serum (177), Whole Blood (167) |
| NRG | Gyn - NOS | RTOG-1203: A Randomized Phase III Study Of Standard Vs. IMRT Pelvic Radiation For Post-Operative Treatment Of Endometrial And Cervical Cancer (TIME-C)--RTOG CCOP Study | 289 | Buffy Coat (1), Fixed Tissue Block (142), Fixed Tissue Slide (208), Plasma (209), Serum (209), Whole Blood (203) |
| NRG via Navigator | CNS | RTOG-83-02: Randomized Phase II protocol: hyperfractionated radiation therapy and BCNU for Supratentorial Malignant Glioma | 304 | Fixed Tissue Block (54), Fixed Tissue Slide (189) |
| NRG via Navigator | CNS | RTOG-90-06: Phase III comparison of hyperfractionated Radiation Therapy (RT) with BCNU and conventional RT with BCNU for Supratentorial Malignant Glioma | 712 | Fixed Tissue Block (83), Fixed Tissue Slide (258) |
| NRG via Navigator | CNS | RTOG-94-04: A Phase III randomized study of radiotherapy with or without BUDR plus Procarbazine, CCNU, and Vincristine (PCV) for the treatment of Anaplastic Astrocytomas | 293 | Fixed Tissue Block (18), Fixed Tissue Slide (66) |
| NRG | Prostate | RTOG-94-13: A Phase III Trial Comparing Whole Pelvic Irradiation Followed by a Conedown Boost to Boost Irradiation Only and Comparing Neoadjuvant to Adjuvant Total Androgen Suppression (TAS) | 1,322 | Fixed Tissue Block (495), Fixed Tissue Slide (1,190) |
| NRG | Head & Neck | RTOG-95-01: Phase III intergroup trial of surgery followed by (1) radiotherapy vs. (2) radiochemotherapy for resectable high risk Squamous Cell Carcinoma of the Head and Neck | 459 | Fixed Tissue Block (196), Fixed Tissue Slide (431) |
| NRG | Head & Neck | RTOG-95-12: A Randomized Study of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord | 250 | Fixed Tissue Block (109), Fixed Tissue Slide (236) |
| NRG | Sarcoma - NOS | RTOG-9514: Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma | 66 | Fixed Tissue Block (47), Fixed Tissue Slide (65) |
| NRG | Prostate | RTOG-96-01: A Phase III Trial of Radiation Therapy with or without Casodex in Patients with PSA Elevation Following Radical Prostatectomy for pT3N0 Carcinoma of the Prostate | 840 | Fixed Tissue Block (400), Fixed Tissue Slide (673) |
| NRG | Prostate | RTOG-96-08: A Phase III trial of total androgen suppression versus total androgen suppression plus definitive external beam irradiation for pathologic lymph node positive (pn+) adenocarcinoma of the prostate | 5 | Fixed Tissue Block (2), Fixed Tissue Slide (2) |
| NRG | Lung | RTOG-97-01: Phase III randomized trial of radiation therapy alone versus concurrent chemotherapy plus radiation therapy for poor-risk stage iii non-small-cell lung carcinoma | 13 | Fixed Tissue Block (8), Fixed Tissue Slide (6) |
| NRG | Pancreas | RTOG-97-04: A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma | 538 | Fixed Tissue Block (245), Fixed Tissue Slide (300), Serum (329), Whole Blood (1) |
| NRG | Lung | RTOG-98-01: A Phase III Study of Amifostine Mucosal Protection for Patients With Favorable Prognosis Inoperable stage II-IIIA/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Pacitaxel and Carboplatin | 243 | Fixed Tissue Slide (2) |
| NRG | CNS | RTOG-9802: A Phase II Study of Observation in Favorable Low-Grade Glioma and Phase III Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma | 370 | Fixed Tissue Block (119), Fixed Tissue Slide (42) |
| NRG | Breast | RTOG-98-04: Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Ductal Carcinoma In Situ (DCIS) of the Female Breast | 633 | Fixed Tissue Block (12), Fixed Tissue Slide (18) |
| NRG | Anus | RTOG-98-11: A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal | 682 | Fixed Tissue Block (305), Fixed Tissue Slide (384) |
| NRG | CNS | RTOG-98-13: A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND #60,265) Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) | 230 | Fixed Tissue Block (102), Fixed Tissue Slide (105), Serum (141) |
| NRG | Prostate | RTOG-99-02: A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) Versus AS and RT Followed by Chemotherapy with Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer | 397 | Fixed Tissue Block (140), Fixed Tissue Slide (268) |
| NRG | Head & Neck | RTOG-99-03: A Randomized Phase III Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated with Radiotherapy for Carcinoma of the Head and Neck | 148 | Fixed Tissue Block (39), Fixed Tissue Slide (99) |
| NRG via Navigator | Gyn - NOS | RTOG-99-05: A Phase III Study of Adjuvant Postoperative Irradiation with or without Cisplatin/Paclitaxel Chemotherapy Following TAH/BSO for Patients with Endometrial Cancer | 50 | Fixed Tissue Block (13), Fixed Tissue Slide (26) |
| NRG | Prostate | RTOG-99-10: A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer | 1,579 | Fixed Tissue Block (582), Fixed Tissue Slide (1,154) |
| NRG via Navigator | Prostate | RTOG-P-0011: Phase III Randomized Study of Adjuvant Therapy for High Risk pT2-3NO Prostate Cancer | 57 | Fixed Tissue Block (26), Fixed Tissue Slide (48) |
| SWOG | Leukemia - Acute lymphocytic | C10001: A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC #716051, IND #61135), and Transplantation for Adults with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG | 2 | Buffy Coat (1), Plasma (1), Whole Bone Marrow (2) |
| SWOG | Leukemia - Acute lymphocytic | C10403: An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL) | 90 | Buffy Coat (19), Whole Bone Marrow (16) |
| SWOG | Leukemia - Chronic lymphocytic | C10404: A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia | 34 | Buffy Coat (9), Cell Slide (5), Plasma (4), Whole Bone Marrow (12) |
| SWOG | Leukemia - Acute lymphocytic | C19801: A Phase II Study of 506U78 in Patients with Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | 11 | Buffy Coat (4), Whole Bone Marrow (4) |
| SWOG | GI - NOS | C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum | 647 | Buffy Coat (55), DNA (48), Fixed Tissue Block (1,920), Fixed Tissue Slide (2,260), Plasma (1,914), Serum (1,919), Whole Blood (453) |
| SWOG via Navigator | Leukemia - Acute myelocytic | C9710: Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy with or without Arsenic Trioxide (As2O3) (NSC #706363) as Initial Consolidation Therapy Followed by Maintenance Therapy with Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients with Untreated Acute Promyelocytic Leukemia | 111 | Buffy Coat (107), Plasma (2), Serum (1), Whole Bone Marrow (109) |
| SWOG | Leukemia - Acute myelocytic | E1905: A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia with Multilineage Dysplasia | 23 | Buffy Coat (12), Whole Bone Marrow (15) |
| SWOG | Leukemia - Chronic lymphocytic | E2997: Phase III Randomized Trial of Fludarabine and Cyclophosphamide versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia | 23 | Buffy Coat (5), Serum (1), Whole Bone Marrow (4) |
| SWOG | Leukemia - Acute myelocytic | E2998: A Phase III Study of Flt3 Ligand (Flt3L) (NSC# 696599) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission | 3 | Buffy Coat (2), Whole Bone Marrow (2) |
| SWOG | Breast | JMA17R: A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study) | 352 | Fixed Tissue Slide (5) |
| SWOG | Prostate | JPR3: Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate | 42 | Serum (2) |
| SWOG | Prostate | JPR7: A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients with Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer | 172 | Fixed Tissue Slide (1), Serum (2) |
| SWOG | Lung | LUNGMAP: | Buffy Coat (899), Fixed Tissue Block (1,410), Fixed Tissue Slide (827), Plasma (923), Serum (2), Whole Blood (2) | |
| SWOG | CNS | S0001: A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma | 183 | Fixed Tissue Block (3), Fixed Tissue Slide (5), Serum (1) |
| SWOG | Lung | S0003: Randomized Phase III Trial of Carboplatin and Paclitaxel plus Tirapazamine versus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer Cisplatin, Paclitaxel, Tirapazamine vs. Cisplatin, Paclitaxel Specimen submission per S | 397 | Fixed Tissue Block (11), Fixed Tissue Slide (1), Serum (1) |
| SWOG | Lymphoma - Non-Hodgkin's | S0014: Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High Risk Localized Aggressive Histologies of Non-Hodgkin’s Lymphoma, Phase II | 71 | Serum (15) |
| SWOG via Navigator | Lymphoma - Non-Hodgkin's | S0016: A Phase III Trial of CHOP vs. CHOP + Rituximab vs. CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) For Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas | 571 | Serum (336), Whole Bone Marrow (117) |
| SWOG | Hematologic - NOS | S0020: A PHASE II STUDY OF ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORINE FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) | 23 | Buffy Coat (11), Whole Bone Marrow (10) |
| SWOG | Lung | S0023: A Phase III Trial of Cisplatin/Etoposide/Radiotherapy with Consolidation Docetacel followed by Maintenance Therapy with ZD1839 (NSC-715055) or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer | 620 | Fixed Tissue Block (11), Fixed Tissue Slide (5), Plasma (10), Serum (4) |
| SWOG | Prostate | S0032: Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate | 41 | Serum (16) |
| SWOG | Gastrointestinal stromal tumor | S0033: Phase III Randomized, Intergroup Trial Assessing the Clinical Activity of STI-571 at Two Dose Levels in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the KIT Receptor Tyrosine Kinase (CD117) | 746 | Serum (9) |
| SWOG | Breast | S0102: Docetaxel and Vinorelbine Plus Filgrastim for HER-2 Negative, Stage IV Breast Cancer, Phase II | 95 | Fixed Tissue Block (5), Fixed Tissue Slide (24) |
| SWOG via Navigator | Leukemia - Acute myelocytic | S0106: A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy for Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) | 637 | Buffy Coat (415), Whole Bone Marrow (390) |
| SWOG | Lymphoma - Non-Hodgkin's | S0108: Bevacizumab (rhuMAb) (NSC 704865) Therapy For Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma | 52 | Cell Slide (1), Fixed Tissue Block (2), Fixed Tissue Slide (25), Serum (1) |
| SWOG | Prostate | S0111: A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients with Hormone Refractory Prostate Cancer | 48 | Serum (4) |
| SWOG | Leukemia - Acute myelocytic | S0112: S0112, A Phase II Study Of Daunomycin And Ara-C, Both Given By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older. | 71 | Buffy Coat (58), Whole Bone Marrow (45) |
| SWOG | Myeloma | S0115: A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) And Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) For Patients with AL Amyloidosis or High Risk (greater than or equal to Age 70 or Poor Renal Function)Patients With Multiple Myeloma(A BMT Study) | 104 | Cell Slide (1), Serum (29), Whole Bone Marrow (1) |
| SWOG | Leukemia - Acute myelocytic | S0117: A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg™) and Standard Dose Ara-C for Patients With Relapsed Acute Myeloid Leukemia (AML) | 33 | Buffy Coat (20), Whole Bone Marrow (17) |
| SWOG via Navigator | Lung | S0124: Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer | 671 | Buffy Coat (140), Fixed Tissue Block (15), Fixed Tissue Slide (10), Plasma (183), Serum (1), Whole Blood (6) |
| SWOG | Leukemia - Acute myelocytic | S0125: A Phase II Study of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Older Patients With Acute Myeloid Leukemia (AML) in First Complete Remission (A BMT Study) | 5 | Buffy Coat (4), Whole Bone Marrow (4) |
| SWOG | Lung | S0126: Phase II Trial of Chronic Oral ZD1839 (Iressa) in Both Previously-Untreated and Previously-Treated Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) | 145 | Buffy Coat (1), Fixed Tissue Slide (1), Plasma (2) |
| SWOG | Gastric | S0127: A Phase II Study of OSI-774 (NSC #718781) in Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction | 70 | Cell Slide (1), Fixed Tissue Block (30), Fixed Tissue Slide (67), Plasma (1) |
| SWOG | GI - NOS | S0202: A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients with Unresectable or Metastatic Gallbladder or Cholangiocarcinoma | 57 | Buffy Coat (10), Fixed Tissue Block (3), Fixed Tissue Slide (8), Plasma (9), Serum (2) |
| SWOG | Myeloma | S0204: A Phase II Trial of Thalidomide/Dexamethasone Induction Followed by Tandem Melphalan Transplant and Prednisone/Thalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients, (A BMT Study) | 147 | Cell Slide (2), Fixed Tissue Block (15), Fixed Tissue Slide (39), Serum (12), Whole Bone Marrow (10) |
| SWOG via Navigator | Pancreas | S0205: A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer | 766 | Cell Slide (1), Fixed Tissue Block (323), Fixed Tissue Slide (763) |
| SWOG | Lymphoma - NOS | S0213: Pilot Trial of Hyper-CVAD and Methotrexate/ARA C+ Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | 56 | Buffy Coat (1), Cell Slide (1), Fixed Tissue Block (13), Fixed Tissue Slide (51), Serum (12), Whole Bone Marrow (4) |
| SWOG | Breast | S0215: Docetaxel and Vinorelbine Plus Filgrastim with Weekly Trastuzumab for HER-2 Positive, Stage IV Breast Cancer, Phase II Pilot | 76 | Fixed Tissue Block (1), Fixed Tissue Slide (35) |
| SWOG | Lung | S0218: A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) In Patients with Malignant Pleural Mesothelioma | 64 | Fixed Tissue Block (28), Fixed Tissue Slide (47) |
| SWOG | Lung | S0220: A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors) | 46 | Buffy Coat (13), Fixed Tissue Block (8), Fixed Tissue Slide (5), Plasma (15), Serum (4) |
| SWOG via Navigator | Breast | S0221: Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High -Risk Node Negative Breast Cancer | 3,294 | Buffy Coat (11), DNA (1,949), Fixed Tissue (15), Fixed Tissue Block (1,968), Fixed Tissue Slide (729), Plasma (31), Serum (1,957), Whole Blood (10) |
| SWOG | Lung | S0222: A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer | 72 | Buffy Coat (2), Fixed Tissue Block (18), Fixed Tissue Slide (13), Plasma (27), Serum (27), Whole Blood (1) |
| SWOG via Navigator | Breast | S0226: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer. | 707 | Buffy Coat (109), Fixed Tissue (2), Fixed Tissue Block (295), Fixed Tissue Slide (166), Plasma (342), Serum (512), Whole Blood (12) |
| SWOG via Navigator | Myeloma | S0232: Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Previously Untreated Multiple Myeloma who are Not Immediately Undergoing Autologous Stem Cell Transplant | 198 | Serum (82) |
| SWOG | Leukemia - Acute myelocytic | S0301: A Phase II Study of Induction With Daunorubicin, Cytarabine, and Cyclosporine All By Continuous IV Infusion for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older. | 69 | Buffy Coat (66), Whole Bone Marrow (56) |
| SWOG | Colon | S0303: A Phase III Trial of Modified FOLFOX6 versus CAPOX, with Bevacizumab (NSC-704865) or Placebo*, as First-Line Therapy in Patients with Previously Untreated Advanced Colorectal Cancer | 33 | Buffy Coat (20), Fixed Tissue Block (15), Fixed Tissue Slide (17) |
| SWOG via Navigator | Breast | S0307: Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer | 6,097 | Buffy Coat (2,445), Fixed Tissue (4), Fixed Tissue Block (3,300), Fixed Tissue Slide (1,191), Plasma (2,477), Serum (4,319), Whole Blood (15) |
| SWOG | Myeloma | S0309: Myeloma Specimen Repository Protocol, Ancillary | 190 | Frozen Tissue (1), Serum (25), Whole Blood (1) |
| SWOG | Lung | S0310: Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC). | 19 | Fixed Tissue Slide (1), Plasma (1), Serum (2) |
| SWOG | Lymphoma - Non-Hodgkin's | S0313: Evaluation of CHOP Plus Involved Field Radiotherapy followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE and non-bulky Stages II and IIE, CD20 Positive, High-risk Localized, Aggressive Histologies of Non-Hodgkin's Lymphoma, Phase II | 46 | Serum (8) |
| SWOG | Kidney | S0317: A Phase II Study of OSI-774 (NSC-718781) in Patients with Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer | 52 | Fixed Tissue Block (3), Fixed Tissue Slide (39) |
| SWOG | Hematologic - NOS | S0325: A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase. | 403 | Buffy Coat (12), Plasma (141), Whole Bone Marrow (4) |
| SWOG | Lung | S0327: A Phase II Trial of PS-341 (NSC-681239) in Patients with Platinum-Treated Extensive Stage Small Cell Lung Cancer. | 60 | Buffy Coat (1), Plasma (1) |
| SWOG | Sarcoma - NOS | S0330: U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II | 24 | Fixed Tissue Block (6), Fixed Tissue Slide (23) |
| SWOG | Leukemia - Acute lymphocytic | S0333: A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy | 79 | Buffy Coat (78), Plasma (78), Whole Bone Marrow (68) |
| SWOG via Navigator | Bladder | S0337: A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer | 416 | Fixed Tissue (1), Fixed Tissue Block (113), Fixed Tissue Slide (283) |
| SWOG | Breast | S0338: Phase II Trial of Imatinib Mesylate (Gleevec) (NSC-716051) In Combination With Capecitabine (Xeloda) (NSC-712807) In Metastatic Breast Cancer | 27 | Fixed Tissue Block (8), Fixed Tissue Slide (8) |
| SWOG | Myeloma | S0340: A Prospective Observational Study of Patients with Solitary Plasmacytoma Using a Modified Staging System Supplemented by an MRI and Whole Body FDG-PET Scan | 2 | Serum (2) |
| SWOG | Lung | S0341: Phase II Trial of OSI-774 (NSC-718781) in Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status of 2 | 81 | Buffy Coat (37), Fixed Tissue Block (12), Fixed Tissue Slide (32), Plasma (35), Serum (4), Whole Blood (2) |
| SWOG | Lung | S0342: Phase II Selection Design Trial of Concurrent Chemotherapy + Cetuximab vs. Chemotherapy Followed by Cetuximab in Advanced Non-Small Cell Lung Cancer (NSCLC) | 242 | Buffy Coat (56), Fixed Tissue Block (71), Fixed Tissue Slide (62), Plasma (59), Serum (4), Whole Blood (1) |
| SWOG | Sarcoma - NOS | S0344: A Phase II Surgical Trial of Intralesional Resection of Low-Grade Intracompartmental Chondrosarcoma of Bone | 20 | Fixed Tissue Slide (19) |
| SWOG | Sarcoma - NOS | S0345: A Phase II Study of Imatinib (NSC-716051) in Patients with Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans | 8 | Fixed Tissue Block (3), Fixed Tissue Slide (4) |
| SWOG | Lymphoma - Diffuse large B-cell | S0349: Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (< Age 60) with Advanced Stage Diffuse Large B-cell NHL of Low and Low-Intermediate IPI Risk | 8 | Serum (1) |
| SWOG | Lymphoma - Non-Hodgkin's | S0350: Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma | 34 | Fixed Tissue (3), Fixed Tissue Block (17), Fixed Tissue Slide (34), Serum (19) |
| SWOG | Bladder | S0353: Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG | 58 | Buffy Coat (23), Fixed Tissue Block (5), Fixed Tissue Slide (20), Plasma (24), Serum (1), Whole Blood (1) |
| SWOG | Prostate | S0354: A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6) in Patients with Hormone Refractory Prostate Cancer | 62 | Buffy Coat (52), Fixed Tissue Block (22), Fixed Tissue Slide (17), Plasma (51) |
| SWOG | Esophageal | S0356: Oxaliplatin Plus Protracted Infusion 5-Fluorouracil and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial with Molecular Correlates | 98 | Buffy Coat (41), Fixed Tissue Block (74), Fixed Tissue Slide (81), Plasma (86), Whole Blood (5) |
| SWOG | Lymphoma - Hodgkin's | S0410: Tandem Autologous Stem Cell Transplantation For Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II | 98 | Fixed Tissue Slide (2), Serum (10) |
| SWOG | Kidney | S0412: A Phase II Study of the RAF-Kinase Inhibitor BAY 43-9006 (NSC-724772, IND-69,896) in Combination with Interferon Alpha 2b in Patients wtih Advanced Renal Cancer | 67 | Buffy Coat (47), Fixed Tissue Slide (1), Plasma (50), Serum (1), Whole Blood (1) |
| SWOG | Gastric | S0413: Phase II Study of GW572016 (NSC #727989) as First Line Therapy in Patients with Advanced or Metastatic Gastric Cancer | 47 | Buffy Coat (29), Fixed Tissue Block (37), Fixed Tissue Slide (37), Plasma (34), Whole Blood (8) |
| SWOG | Esophageal | S0414: Cetuximab Plus Cisplatin, Irinotecan and Thoracic Radiotherapy (TRT) for Locally Advanced (Non-Metastatic), Clinically Unresectable Esophageal Cancer: A Phase II Trial with Molecular Correlates | 22 | Buffy Coat (21), Fixed Tissue Block (16), Fixed Tissue Slide (9), Plasma (22) |
| SWOG | Esophageal | S0415: Cetuximab as a Second Line Therapy in Patients with Metastatic Esophageal Cancer - Phase II | 63 | Buffy Coat (35), Fixed Tissue Block (28), Fixed Tissue Slide (48), Plasma (48), Whole Blood (5) |
| SWOG | Myeloma | S0417: A Phase II Study of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma | 7 | Serum (7) |
| SWOG | Prostate | S0418: A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer | 25 | Serum (8) |
| SWOG via Navigator | Prostate | S0421: Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer | 1,038 | Buffy Coat (4), DNA (3), Fixed Tissue Block (349), Fixed Tissue Slide (336), Plasma (8), Serum (872), Whole Blood (198) |
| SWOG | Sarcoma - NOS | S0423: Phase II Trial of Pemetrexed for Advanced Chondrosarcomas | 14 | Fixed Tissue Block (5), Fixed Tissue Slide (10) |
| SWOG | Gastric | S0425: Neoadjuvant Chemoradiation Therapy with Oxaliplatin and Capecitabine for Patients with Surgically Resectable Gastric Cancer: A Pilot Phase II Trial with Molecular Correlates | 7 | Buffy Coat (6), Fixed Tissue Block (5), Fixed Tissue Slide (4), Plasma (6), Whole Blood (1) |
| SWOG | Head & Neck | S0427: A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin, with and without Docetaxel, Cisplatin, and 5-Fluorouracil Induction Chemotherapy, in Patients with Advanced Oropharyngeal Squamous Cell Cancer | 6 | Fixed Tissue Block (4), Fixed Tissue Slide (2), Plasma (1), Serum (5) |
| SWOG | Lung | S0429: A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer | 24 | Buffy Coat (21), Fixed Tissue Block (7), Fixed Tissue Slide (14), Plasma (22), Serum (1) |
| SWOG | Breast | S0430: Phase II Trial of Simple Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients With Metastatic Breast Cancer | 112 | Buffy Coat (76), Fixed Tissue Slide (1), Plasma (83), Serum (83), Whole Blood (4) |
| SWOG | Head & Neck | S0431: Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma | 3 | Fixed Tissue Block (1), Fixed Tissue Slide (2) |
| SWOG | Leukemia - Acute myelocytic | S0432: Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra®, NSC-702818)for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older. | 348 | Buffy Coat (101), Whole Bone Marrow (91) |
| SWOG | Lymphoma - Diffuse large B-cell | S0433: Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study | 86 | Cell Slide (1), Fixed Tissue Block (23), Fixed Tissue Slide (83), Serum (42), Whole Bone Marrow (1) |
| SWOG | Myeloma | S0434: A Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients with Relapsing or Resistant Multiple Myeloma | 23 | Serum (12) |
| SWOG | Lung | S0435: A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients with Platinum-Treated Extensive Stage Small Cell Lung Cancer | 89 | Buffy Coat (58), Fixed Tissue Block (29), Fixed Tissue Slide (23), Plasma (66), Serum (1), Whole Blood (3) |
| SWOG via Navigator | Breast | S0500: A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment | 624 | Buffy Coat (9), DNA (2), Fixed Tissue Block (2), Fixed Tissue Slide (1), Plasma (13), Serum (583), Whole Blood (4) |
| SWOG | Gastrointestinal stromal tumor | S0502: A Phase III Randomized Study of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors | 12 | Plasma (12), Serum (12), Whole Blood (8) |
| SWOG | Sarcoma - NOS | S0505: Phase II Trial of BAY 43-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas | 51 | Fixed Tissue Block (16), Fixed Tissue Slide (51) |
| SWOG | Lung | S0509: A Phase II Study of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma | 54 | Buffy Coat (3), Fixed Tissue Block (13), Fixed Tissue Slide (19), Plasma (21), Serum (7), Whole Blood (1) |
| SWOG | Melanoma | S0512: Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma | 25 | Buffy Coat (3), Fixed Tissue Block (2), Fixed Tissue Slide (5), Plasma (4), Whole Blood (4) |
| SWOG | GI - NOS | S0514: Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma | 36 | Buffy Coat (30), Fixed Tissue Block (19), Fixed Tissue Slide (24), Plasma (30), Serum (3), Whole Blood (6) |
| SWOG | Lymphoma - Diffuse large B-cell | S0515: Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL | 73 | Fixed Tissue Block (54), Fixed Tissue Slide (70), Serum (23), Whole Bone Marrow (3) |
| SWOG via Navigator | GI - NOS | S0518: Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients | 427 | Buffy Coat (336), Fixed Tissue Block (205), Fixed Tissue Slide (200), Plasma (281), Serum (9), Whole Blood (5) |
| SWOG via Navigator | Leukemia - Acute myelocytic | S0521: A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III | 105 | Buffy Coat (33), Whole Bone Marrow (32) |
| SWOG | Lung | S0526: Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) | 27 | Buffy Coat (22), Fixed Tissue Block (13), Fixed Tissue Slide (10), Plasma (22), Serum (2) |
| SWOG | Leukemia - Acute lymphocytic | S0530: A Phase II Trial of Cytarabine and Clofarabine in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | 37 | Buffy Coat (30), Plasma (1), Whole Bone Marrow (27) |
| SWOG | Lung | S0533: A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer | 29 | Buffy Coat (2), Fixed Tissue Block (2), Fixed Tissue Slide (8), Plasma (16), Serum (9), Whole Blood (1) |
| SWOG | Leukemia - Acute myelocytic | S0535: A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia | 78 | Buffy Coat (7), Whole Bone Marrow (9) |
| SWOG | Lung | S0536: A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed by Cetuximab and Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer | 110 | Buffy Coat (71), Fixed Tissue Block (49), Fixed Tissue Slide (64), Plasma (60), Saliva (1) |
| SWOG | Lymphoma - NOS | S0601: A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade®) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma | 68 | Fixed Tissue Block (34), Fixed Tissue Slide (63), Serum (37) |
| SWOG | Leukemia - Acute myelocytic | S0605: A Phase II Study of Lenalidomide (Revlimid®) (NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy | 41 | Buffy Coat (27), DNA (1), RNA (1), Whole Bone Marrow (29) |
| SWOG | Breast | S0622: Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer | 85 | Buffy Coat (1), Plasma (1), Serum (73) |
| SWOG | Lung | S0635: A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features | 84 | Buffy Coat (74), Fixed Tissue Block (44), Fixed Tissue Slide (48), Plasma (76), Serum (7), Whole Blood (3) |
| SWOG | Lung | S0636: A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas | 89 | Buffy Coat (82), Fixed Tissue Block (38), Fixed Tissue Slide (15), Plasma (81), Serum (11), Whole Blood (2) |
| SWOG | Multiple (not organ based) | S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment | 3,571 | Buffy Coat (2,222), DNA (1,691), Fixed Tissue Slide (3), Plasma (2,210), Serum (2,538), Urine (1), Whole Blood (39) |
| SWOG | Leukemia - Acute myelocytic | S0703: A Phase II Trial of Azacitidine Plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia | 142 | Buffy Coat (123), DNA (6), Plasma (26), RNA (17), Whole Blood (1), Whole Bone Marrow (86) |
| SWOG | Lung | S0709: A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected by Serum Proteomics | 59 | Buffy Coat (58), Fixed Tissue Block (19), Fixed Tissue Slide (28), Plasma (61), Serum (123) |
| SWOG | Rectum | S0713: A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-operative Therapy of Rectal Cancer | 83 | Buffy Coat (68), Fixed Tissue Block (52), Fixed Tissue Slide (40), Plasma (43), Serum (1) |
| SWOG | Multiple (not organ based) | S0715: Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane Induced Neuropathy | 437 | Buffy Coat (387), Plasma (394), Serum (7) |
| SWOG | Kidney | S0717: A Phase I and A Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) with or without MEDI-522 (NSC-719850) | 5 | Buffy Coat (4), Fixed Tissue Block (2), Fixed Tissue Slide (2), Plasma (4) |
| SWOG | Lung | S0720: Phase II ERCC 1and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) | 85 | Buffy Coat (67), Fixed Tissue Block (61), Fixed Tissue Slide (11), Plasma (67) |
| SWOG | Lung | S0722: A Phase II Trial of mTOR Inhibitor, Everolimus, (RAD001) in Malignant Pleural Mesothelioma (MPM) | 61 | Buffy Coat (43), Fixed Tissue Block (12), Fixed Tissue Slide (23), Plasma (44), Serum (3) |
| SWOG | Pancreas | S0727: A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First Line Treatment in Patients with Metastatic Pancreatic Cancer | 134 | Buffy Coat (12), Fixed Tissue Block (41), Fixed Tissue Slide (13), Plasma (104), Serum (1) |
| SWOG via Navigator | Myeloma | S0777: A Randomized Phase III Trial of CC-5013 (lenalidomide, NSD-703813) and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant | 525 | Buffy Coat (16), Cell Slide (4), Fixed Tissue Block (1), Fixed Tissue Slide (1), Plasma (1), Serum (258), Whole Bone Marrow (24) |
| SWOG | Breast | S0800: A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (Peg-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer | 215 | Buffy Coat (161), Fixed Tissue (6), Fixed Tissue Block (60), Fixed Tissue Slide (6), Frozen Tissue (3), Plasma (80), Serum (203), Whole Blood (7) |
| SWOG | Lymphoma - Non-Hodgkin's | S0801: A Phase II Study of Iodine-131 Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma | 87 | Fixed Tissue Block (43), Fixed Tissue Slide (79), Serum (57), Whole Bone Marrow (3) |
| SWOG | Lung | S0802: A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) | 192 | Buffy Coat (144), Fixed Tissue Block (93), Fixed Tissue Slide (46), Plasma (146), Serum (4), Whole Blood (1) |
| SWOG | Leukemia - Acute lymphocytic | S0805: Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) | 97 | Buffy Coat (29), Plasma (12), Whole Blood (3), Whole Bone Marrow (29) |
| SWOG | Lymphoma - Diffuse large B-cell | S0806: A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) | 83 | Fixed Tissue Block (2), Fixed Tissue Slide (1), Plasma (1) |
| SWOG | GI - NOS | S0809: A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) | 105 | Fixed Tissue Block (18), Fixed Tissue Slide (100) |
| SWOG | Breast | S0812: A Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer, Phase IIB | 208 | Buffy Coat (79), DNA (99), Fixed Tissue Block (36), Fixed Tissue Slide (53), Plasma (156), Serum (185), Whole Blood (5) |
| SWOG | Lymphoma - Hodgkin's | S0816: A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Interim FDG-PET Imaging | 371 | Buffy Coat (2), Cell Slide (1), Fixed Tissue Block (27), Fixed Tissue Slide (307), Serum (311), Whole Bone Marrow (6) |
| SWOG via Navigator | Lung | S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) | 1,333 | Buffy Coat (1,223), DNA (2), Fixed Tissue Block (417), Fixed Tissue Slide (986), Plasma (1,233), Serum (9), Whole Blood (6) |
| SWOG | Melanoma | S0826: A Phase II Trial of SCH 727965 (NSC 747135) in Patients with Stage IV Melanoma | 72 | Fixed Tissue Block (24), Fixed Tissue Slide (31) |
| SWOG | Gyn - NOS | S0904: Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel plus Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | 131 | Buffy Coat (65), Plasma (74), Serum (5) |
| SWOG | Lung | S0905: A Phase I / Randomized Phase II Study of Cediranib (NSC #732208) Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma | 117 | Buffy Coat (53), Fixed Tissue Block (18), Fixed Tissue Slide (97), Plasma (53), Serum (53), Whole Blood (45) |
| SWOG | Multiple (not organ based) | S0916: A Phase II Trial of the Anti-CCR2 Antibody MLN1202 in Patients with Bone Metastases | 44 | Buffy Coat (11), Plasma (38), Serum (43), Urine (1) |
| SWOG | Leukemia - Acute myelocytic | S0919: A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia (AML) | 115 | Buffy Coat (1), Whole Bone Marrow (1) |
| SWOG | Breast | S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness in Women with Early Stage Breast Cancer, Phase III | 262 | Buffy Coat (3), DNA (247), Plasma (3), Serum (247), Urine (250), Whole Blood (13) |
| SWOG | Kidney | S0931: EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study | 1,545 | Buffy Coat (1,344), Fixed Tissue Block (744), Fixed Tissue Slide (618), Plasma (1,343), Serum (16), Whole Blood (1,083) |
| SWOG | Melanoma | S0933: Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma | 36 | Fixed Tissue Block (10), Fixed Tissue Slide (5) |
| SWOG | GI - NOS | S0941: Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients with Advanced Gallbladder Carcinoma or Cholangiocarcinoma | 40 | Buffy Coat (27), Fixed Tissue Block (11), Fixed Tissue Slide (13), Plasma (27), Whole Blood (1) |
| SWOG | Lymphoma - Diffuse large B-cell | S1001: A Phase II Trial of PET-Directed Therapy for Early Stage Diffuse Large B-Cell Lymphoma (DLBCL) | 159 | Fixed Tissue (2), Fixed Tissue Block (64), Fixed Tissue Slide (157), Serum (128) |
| SWOG | Breast | S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less | 9,383 | Buffy Coat (3,281), Fixed Tissue (37), Fixed Tissue Block (1,765), Fixed Tissue Slide (1,884), Plasma (1,006), Serum (3,289), Whole Blood (90) |
| SWOG | Multiple (not organ based) | S1008: Feasibility Study of a Physical Activity and Dietary Change Weight Loss Intervention in Breast and Colorectal Cancer Survivors, Phase II | 50 | Buffy Coat (1), DNA (49), Plasma (50), Serum (50), Whole Blood (1) |
| SWOG | GU - NOS | S1011: A Phase III Surgical Trial to Evaluate The Benefit of A Standard versus An Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer | 658 | DNA (256), Fixed Tissue (1), Fixed Tissue Block (169), Fixed Tissue Slide (477), RNA (256) |
| SWOG | Breast | S1105: Randomized Trial of Text-Messaging Intervention to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer | 724 | Urine (716) |
| SWOG | Lymphoma - NOS | S1106: A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. R-Bendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients <= 65 Years of Age with Previous Untreated Mantle Cell Lymphoma | 53 | Fixed Tissue (1), Fixed Tissue Block (22), Fixed Tissue Slide (48), Whole Bone Marrow (4) |
| SWOG | Kidney | S1107: Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma | 55 | Fixed Tissue Block (10), Fixed Tissue Slide (28) |
| SWOG | Lymphoma - Non-Hodgkin's | S1108: Phase II Trial of The Aurora Kinase A Inhibitor MLN8237 in Relapsed Or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | 42 | Fixed Tissue Block (3), Frozen Tissue (1), Serum (16) |
| SWOG | Pancreas | S1115: Randomized Phase II Clinical Trial of AZD-6244 (NSC-741078) and MK-2206 (NSC-749607) vs mFOLFOX in Patients with Metastatic Pancreatic Cancer After Prior Chemotherapy | 137 | Buffy Coat (105), Fixed Tissue Block (63), Fixed Tissue Slide (43), Plasma (1), Whole Blood (5) |
| SWOG | Hematologic - NOS | S1117: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) | 282 | Buffy Coat (141), Cell Slide (3), DNA (1), Whole Blood (3), Whole Bone Marrow (120) |
| SWOG | Breast | S1200: Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer | 226 | DNA (218), Serum (223), Urine (223), Whole Blood (2) |
| SWOG | Gastric | S1201: A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 for Advanced/Metastatic Esophagus, Gastric Cancer or Gastroesophageal (GE) Junction Cancer | 264 | Buffy Coat (175), DNA (1), Fixed Tissue Block (126), Fixed Tissue Slide (11), Plasma (2), Whole Blood (1) |
| SWOG | Breast | S1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer | 299 | Buffy Coat (2), DNA (276), Plasma (3), Serum (276), Whole Blood (6) |
| SWOG | Leukemia - Acute myelocytic | S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy and Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) | 754 | Buffy Coat (924), Cell Slide (6), DNA (1), Plasma (4), Serum (3), Whole Blood (6), Whole Bone Marrow (707) |
| SWOG | Multiple (not organ based) | S1204: A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients | 3,092 | Serum (1,665), Whole Blood (1,665) |
| SWOG | S1206 (8811): | Buffy Coat (40), Fixed Tissue Block (21), Fixed Tissue Slide (30), Plasma (41), Serum (41) | ||
| SWOG | Breast | S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer | 1,939 | Buffy Coat (1,009), DNA (1,528), Fixed Tissue (22), Fixed Tissue Block (1,104), Fixed Tissue Slide (1,650), Plasma (88), RNA (964), Serum (1,836), Whole Blood (19), Whole Bone Marrow (4) |
| SWOG | Myeloma | S1211: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM) | 142 | Fixed Tissue (1), Fixed Tissue Block (7), Fixed Tissue Slide (3), Serum (95), Whole Blood (1), Whole Bone Marrow (57) |
| SWOG | Prostate | S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer | 1,313 | Buffy Coat (583), Fixed Tissue Block (364), Fixed Tissue Slide (530), Plasma (1,114), Serum (104), Whole Blood (5), Whole Bone Marrow (3) |
| SWOG | Multiple (not organ based) | S1221: Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib in Patients with BRAF Mutant Cancer | 27 | Buffy Coat (13), Fixed Tissue Slide (5), Frozen Tissue (2), Plasma (16) |
| SWOG | Breast | S1222: Fulvestrant Alone versus Fulvestrant and Everolimus versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients with Hormone-Receptor-Positive Stage IV Breast Cancer | 37 | Fixed Tissue Block (26), Fixed Tissue Slide (9) |
| SWOG | Myeloma | S1304: A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease | 143 | Cell Slide (2), DNA (1), Fixed Tissue Block (1), Fixed Tissue Slide (1), Serum (118), Whole Bone Marrow (113) |
| SWOG | GI - NOS | S1310: Randomized Phase II Trial of Single Agent MEK Inhibitor GSK1120212 vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer | 53 | Fixed Tissue Block (16), Fixed Tissue Slide (42), Plasma (49) |
| SWOG | Pancreas | S1313: A Phase Ib/II Randomized Study of Modified Folfirinox + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified Folfirinox Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma | 126 | Fixed Tissue Block (13), Fixed Tissue Slide (57), Plasma (27) |
| SWOG | Bladder | S1314: A Randomized Phase II Study of Co-expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-invasive Bladder Cancer | 237 | Buffy Coat (174), DNA (226), Fixed Tissue Block (40), Fixed Tissue Slide (231), RNA (223), Urine (226) |
| SWOG | S1318: | Buffy Coat (40), Cell Slide (1), DNA (4), Whole Bone Marrow (41) | ||
| SWOG | Melanoma | S1320: A Randomized Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib and Trametinib in BRAF V600E/K Mutant Melanoma | 249 | Buffy Coat (174), Fixed Tissue (12), Fixed Tissue Block (121), Fixed Tissue Slide (185), Plasma (3), Whole Blood (1) |
| SWOG | Lung | S1400: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (LUNG-MAP) | 1,864 | Buffy Coat (647), Cell Slide (1), DNA (44), Fixed Tissue Block (1,037), Fixed Tissue Slide (1,062), Plasma (686), RNA (68), Serum (2), Whole Blood (10) |
| SWOG | Lung | S1400A: A Phase II Study of MEDI4736 for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (LUNG-MAP SUB-STUDY) | 116 | Buffy Coat (77), Fixed Tissue Slide (1), Plasma (77), Whole Blood (20) |
| SWOG | Lung | S1400B: A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY) | 39 | Buffy Coat (28), Plasma (29) |
| SWOG | Lung | S1400C: A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (LUNG-MAP Sub-Study) | 53 | Buffy Coat (35), Plasma (36) |
| SWOG | Lung | S1400D: A Phase II Study of AZD4547 for Previously-Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer (LUNG MAP SUB-STUDY) | 43 | Buffy Coat (30), Plasma (32) |
| SWOG | Lung | S1400E: A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib versus Erlotinib as Second Line Therapy for Biomarker Selected Patients with Squamous Cell Lung Cancer | 9 | Buffy Coat (4), Plasma (4), Whole Blood (1) |
| SWOG | Lung | S1400F: A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study) | 67 | Buffy Coat (47), Fixed Tissue Block (5), Fixed Tissue Slide (1), Plasma (47), Whole Blood (2) |
| SWOG | Lung | S1400G: A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) | 51 | Buffy Coat (39), Plasma (40) |
| SWOG | Lung | S1400I: A Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study) | 275 | Buffy Coat (212), DNA (35), Fixed Tissue Block (3), Plasma (219), Whole Blood (3) |
| SWOG | Lung | S1400K: A Phase II Study of ABBV-399 (Process II) in Patients with c-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-Study) | 28 | Buffy Coat (22), Plasma (22), Serum (21), Whole Blood (1) |
| SWOG | Lung | S1403: A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naïve Patients with Advanced, EGFR Mutation Positive Non Small Lung Cancer (NSCLC) | 174 | Buffy Coat (166), Fixed Tissue Block (84), Fixed Tissue Slide (53), Frozen Tissue (3), Plasma (166), Whole Blood (1), Whole Bone Marrow (2) |
| SWOG | Melanoma | S1404: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma | 1,426 | Buffy Coat (1,078), DNA (111), Fixed Tissue Block (289), Fixed Tissue Slide (979), Plasma (1,101), RNA (112), Serum (1,103), Whole Blood (4) |
| SWOG | Colon | S1406: Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | 142 | Buffy Coat (19), Fixed Tissue Block (41), Fixed Tissue Slide (32), Plasma (40), Whole Blood (1) |
| SWOG | Breast | S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer | 344 | Fixed Tissue Block (201), Fixed Tissue Slide (311) |
| SWOG | Breast | S1418: S1418/BR006, A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy | 1,355 | Buffy Coat (981), Fixed Tissue Block (529), Fixed Tissue Slide (412), Plasma (517), Serum (988), Whole Blood (12) |
| SWOG | Kidney | S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors in Metastatic Papillary Renal Carcinoma (PAPMET) | 152 | Buffy Coat (131), Fixed Tissue Block (2), Fixed Tissue Slide (148), Plasma (135), Serum (135) |
| SWOG | Pancreas | S1505: A Randomized Phase II Study of Perioperative Mfolfirinox versus Gemcitabine/Nab-Paclitaxel As Therapy for Resectable Pancreatic Adenocarcinoma | 147 | Fixed Tissue Block (38), Fixed Tissue Slide (82) |
| SWOG | Melanoma | S1512: A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM) | 57 | Fixed Tissue Slide (2) |
| SWOG | Pancreas | S1513: Randomized Phase II Study of 2nd Line FOLFIRI vs Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib)(NSC-737664) In Metastatic Pancreatic Cancer | 123 | Cell Slide (1), DNA (109), Fixed Tissue (1), Fixed Tissue Block (81), Fixed Tissue Slide (112) |
| SWOG | Bladder | S1605: Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | 172 | Buffy Coat (1), Cell Slide (95), Fixed Tissue (65), Fixed Tissue Block (41), Fixed Tissue Slide (165), Serum (1), Urine (141), Whole Blood (143) |
| SWOG | Leukemia - Acute myelocytic | S1612: A Randomized Phase II/III Trial of ''Novel Therapeutic'' versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Age 60 or Older | 113 | Buffy Coat (55), Cell Slide (3), Whole Bone Marrow (43) |
| SWOG | S1613: | Buffy Coat (1), Fixed Tissue Block (15), Fixed Tissue Slide (154), Plasma (43) | ||
| SWOG | S1619: | Buffy Coat (17), Fixed Tissue Block (2), Fixed Tissue Slide (28), Plasma (17) | ||
| SWOG | Myeloma | S1702: A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis | 43 | Cell Slide (3), Serum (32), Whole Blood (37), Whole Bone Marrow (25) |
| SWOG | S1712: | Buffy Coat (77), Cell Slide (3), DNA (1), Plasma (78), Whole Bone Marrow (7) | ||
| SWOG | Multiple (not organ based) | S1714: A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients | 1,336 | Buffy Coat (14), DNA (1,222), Plasma (1,257), Serum (744), Whole Blood (2) |
| SWOG | Lung | S1800A: A Phase II Randomized Study of Ramucirumab plus Pembrolizumab (MK-3475) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) | 166 | Buffy Coat (132), Plasma (134), Whole Blood (2) |
| SWOG | GI - NOS | S1801: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers | 452 | Buffy Coat (282), Fixed Tissue Block (92), Fixed Tissue Slide (228), Plasma (283), Serum (276), Whole Blood (1) |
| SWOG | Lung | S1815: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) | 64 | Buffy Coat (340), Fixed Tissue Block (82), Fixed Tissue Slide (149), Plasma (340), Whole Blood (2) |
| SWOG | Lung | S1900A: A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) | 6 | Buffy Coat (52), Fixed Tissue Block (1), Plasma (52) |
| SWOG | Lung | S1900B: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-study) | 47 | Buffy Coat (4), Plasma (4) |
| SWOG | Gyn - NOS | S1900C: Chemoimmunotherapy in Stages III & IV Ovarian and Endometrial Carcinoma Adriamycin + Cyclophosphamide vs. Adriamycin + Cyclophosphamide + BCG | 279 | Buffy Coat (34), Plasma (34) |
| SWOG | Melanoma | S7524: The Treatment of Resected, Poor Prognosis Malignant Melanoma: Stage I: Surgical Excision Versus Surgical Excision + Vitamin A | 407 | Fixed Tissue Slide (4) |
| SWOG | Leukemia - Acute myelocytic | S8049: Treatment of Acute Non-Lymphocytic Leukemia with Conventional Induction, Consolidation Chemotherapy: Maintenance with Chemotherapy Versus Bone Marrow Transplantation Following Total Body Irradiation | 557 | Fixed Tissue Slide (1) |
| SWOG | Bladder | S8124: Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy versus Radical Cystectomy Alone | 140 | Buffy Coat (14) |
| SWOG | Lung | S8221: Treatment of Limited Small Cell Lung Cancer with VP-16/ Cis-Platinum, Alternating with Vincristine/Adriamycin/Cyclophosphamide and Radiation Therapy Versus Concurrent VP-16/Vincristine/Adriamycin/Cyclophosphamide and Radiation Therapy | 400 | Fixed Tissue Slide (1) |
| SWOG | Lung | S8232: Treatment of Advanced Non-Small Cell Lung Cancer: PVp Versus PVpM Versus PVe Versus PVeMI Versus FOMi/CAP | 740 | Fixed Tissue Slide (1) |
| SWOG | Leukemia - Acute myelocytic | S8241: Evaluation of Combination Chemotherapy Using High Dose Ara-C in Adult Acute Leukemia and Chronic Granulocytic Leukemia in Blastic Crisis | 544 | Fixed Tissue Slide (8) |
| SWOG | Breast | S8326: Cell Kinetic Measurement In Stage I and Stage II Node Negative or Node Positive (Pathological Stage T1-3, NO-1, MO) Breast Cancer, A Natural History Study | 842 | Buffy Coat (88), Plasma (1), Whole Bone Marrow (63) |
| SWOG | Leukemia - Acute lymphocytic | S8366: Evaluation of Two Consolidation Regimens in the Treatment of Adult Acute Lymphoblastic Leukemia | 404 | Fixed Tissue Slide (385) |
| SWOG | Ovary | S8417: Intraperitoneal Cis-Platinum/Intravenous Cyclophosphamide Versus Intravenous Cis-Platinum/ Intravenous Cyclophosphamide in Patients with Non-Measurable (Optimal) Disease Stage III Ovarian Cancer | 654 | Buffy Coat (47), Whole Bone Marrow (23) |
| SWOG | Lymphoma - Non-Hodgkin's | S8501: A Phase III Comparison of CHOP Versus m-BACOD Versus ProMACE-CytaBOM Versus MACOP-B in Patients with Intermediate or High-Grade Non-Hodgkin's Lymphoma | 1,138 | Fixed Tissue (2), Fixed Tissue Slide (449) |
| SWOG | Leukemia - Acute myelocytic | S8516: Treatment of Acute Non-Lymphocytic Leukemia Patients Over 50 Years | 33 | Fixed Tissue Block (33), Fixed Tissue Slide (85) |
| SWOG | Leukemia - Acute myelocytic | S8522: V-TAD for Patients Greater Than Fifty Years of Age With Acute Non-Lymphocytic Leukemia. | 35 | Buffy Coat (2) |
| SWOG | Leukemia - Acute myelocytic | S8561: A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-Lymphocytic Leukemia | 863 | Buffy Coat (2) |
| SWOG | Sarcoma - NOS | S8600: Intergroup Phase lll Randomized Study of Doxorubicin and Dacarbazine With or Without Ifosfamide and Mesna in Advanced Soft Tissue and Bone Sarcomas | 455 | Buffy Coat (185), Fixed Tissue (1), Fixed Tissue Slide (2), Whole Bone Marrow (138) |
| SWOG | Melanoma | S8616: Recombinant Human Interferon-Gamma for the Adjuvant Treatment of High Risk Malignant Melanoma After Surgical Excision of the Primary Lesion | 284 | Fixed Tissue (1) |
| SWOG | Hematologic - NOS | S8642: (INT-0073), A Randomized Comparison of Deoxycoformycin Versus Alpha-Interferon in Previously Untreated Patients With Hairy Cell Leukemia | 356 | Fixed Tissue Slide (22) |
| SWOG | Leukemia - Acute myelocytic | S8691: A Prospective Study of Three Post-Remission Therapies in Adult Acute Nonlymphocytic Leukemia: Allogeneic Transplantation vs. Autologous Transplantation vs. Consolidation Chemotherapy | 52 | Buffy Coat (29), Plasma (46), Whole Bone Marrow (22) |
| SWOG | Testicle | S8706: A Study of Reproductive Function in Patients with Testicular Cancer | 207 | Buffy Coat (20), Whole Bone Marrow (18) |
| SWOG | Uterus | S8711: Evaluation of Amonafide in Endometrial Carcinoma | 38 | Fixed Tissue (1) |
| SWOG | Hematologic - NOS | S8732: A Phase II Study of Recombinant Human Interferon- Alpha and Recombinant Human Interferon-Gamma in Previously Untreated Patients with Chronic Myelogenous Leukemia | 20 | Fixed Tissue Slide (31) |
| SWOG | Lymphoma - Non-Hodgkin's | S8735: Treatment of Localized Non-Hodgkin's Lymphoma: Comparison of Chemotherapy (CHOP) to Chemo-therapy Plus Radiation Therapy | 442 | Buffy Coat (15), Whole Bone Marrow (15) |
| SWOG | Uterus | S8736: A Phase II Study of Recombinant Tumor Necrosis (rTNF) in Patients with Endometrial Cancer | 5 | Fixed Tissue Slide (3) |
| SWOG | Ovary | S8752: A Randomized Trial of Adjuvant Intraperitoneal Recombinant Interferon Alpha-2 in Stage III Ovarian Carcinoma in Patients Who Have No Evidence of Disease After Surgery and Chemotherapy | 74 | Fixed Tissue Slide (3) |
| SWOG | Bladder | S8790: Randomized Prospective Comparison of Bacillus Calmette-Guerin and Mitomycin-C Therapy and Prophylaxis in Superficial Transitional Cell Carcinoma of the Bladder with DNA Flow Cytometric Analysis | 469 | Fixed Tissue Slide (12) |
| SWOG | Lymphoma - NOS | S8794: A Phase III Study of Alpha-Interferon Consolidation Following Intensive Chemotherapy with ProMACE- MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas | 571 | Fixed Tissue Block (14), Fixed Tissue Slide (24), Plasma (8), Serum (68) |
| SWOG | Breast | S8795: Phase lll Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors (Intergroup) | 1,558 | Fixed Tissue (1), Fixed Tissue Slide (1) |
| SWOG | Lymphoma - NOS | S8809: Central Lymphoma Repository Tissue Procurement Protocol | 457 | Fixed Tissue (1), Fixed Tissue Slide (5) |
| SWOG | Breast | S8814: Prognostic Value of Cytometry Measurements of Breast Cancer DNA From Postmenopausal Patients With Involved Nodes and Receptor Positive Tumors: A Companion Protocol to SWOG-8814 | 618 | Cell Slide (1), Fixed Tissue (1), Fixed Tissue Slide (36) |
| SWOG | Prostate | S8819: A Comparison of Bilateral Orchiectomy with or without Flutamide for the Treatment of Patients with Histologically Confirmed Stage D2 Prostate Cancer | 1,387 | Fixed Tissue Slide (4) |
| SWOG | Breast | S8854: Comparison of Adjuvant Chemotherapy With or Without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients, and a Natural History Follow-up Study in Low-Risk Node Negative Patients (to initially low risk patients) | 4,406 | Fixed Tissue (2) |
| SWOG | Colon | S8857: A Prospectively Randomized Trial of Low-Dose Leucovorin Plus 5-FU, High-Dose Leucovorin Plus 5-FU, Levamisole Plus 5-FU, or Low-Dose Leucovorin Plus 5-FU Plus Levamisole Following Curative Resection in Selected Patients with Duke's B or C Colon Cancer | 1,530 | Fixed Tissue (1), Fixed Tissue Slide (1) |
| SWOG | Lymphoma - Non-Hodgkin's | S8894: Phase I Trial of Promace-CytoBOM with GM-CSF for Treatment of Non-Hodgkin's Lymphoma | 28 | Fixed Tissue (1), Fixed Tissue Block (4), Fixed Tissue Slide (156), Plasma (2), Serum (71) |
| SWOG | Adrenal | S8897: Evaluations of Cisplatin + VP-16 Followed by Mitotane at Progression if No Prior Mitotane or Cisplatin + VP-16 Only if Prior Treatment with Mitotane in Advanced and Metastatic Adrenal Cortical Carcinoma | 47 | Fixed Tissue (131), Fixed Tissue Block (1), Fixed Tissue Slide (1,932) |
| SWOG | Pancreas | S8899: Evaluation of Piroxantrone in Pancreatic Adenocarcinoma | 42 | Fixed Tissue (1), Fixed Tissue Slide (4) |
| SWOG | Kidney | S8903: Evaluation of Piroxantrone in Patients with Advanced Renal Cell Carcinoma | 34 | Fixed Tissue (1), Fixed Tissue Slide (1) |
| SWOG | Lymphoma - NOS | S8925: Central Lymphoma Serum Repository Protocol | 940 | Fixed Tissue Block (18), Fixed Tissue Slide (5) |
| SWOG | Lymphoma - NOS | S8945: Evaluation of the L-17M Protocol in the Management of Patients with Lymphoblastic Lymphoma | 37 | Fixed Tissue (1) |
| SWOG | Prostate | S8947: Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5/Fluorouracil and Roferon-A®, Phase II | 23 | Fixed Tissue Block (3), Fixed Tissue Slide (5), Serum (33) |
| SWOG | Colon | S8955: Biomarkers of Colorectal Cancer Prognosis | 234 | Serum (2) |
| SWOG | Gastric | S8993: Trial of Adjuvant Chemoradiation After Gastric Resection For Adenocarcinoma, Phase III | 606 | Cell Slide (11), Fixed Tissue Block (2) |
| SWOG | Prostate | S9000: A Pilot Study of Combined Modality Therapy in T3, 4; N0, M0 Adenocarcinoma of the Prostate, Phase II | 31 | Fixed Tissue Slide (14) |
| SWOG | Leukemia - Acute lymphocytic | S9008: Phase II Study of High Dose ARA-C/Mitoxantrone for the Treatment of Relapsed/Refractory Acute Lymphocytic Leukemia | 33 | Fixed Tissue Block (345), Fixed Tissue Slide (576) |
| SWOG | Leukemia - Acute myelocytic | S9024: A Double Blind Placebo Controlled Trial of Daunomycin and Cytosine Arabinoside With or Without rhG-CSF in Elderly Patients With Acute Myeloid Leukemia | 234 | Fixed Tissue Block (2), Serum (6) |
| SWOG | Leukemia - Acute myelocytic | S9030: A Controlled Trial of Cyclosporine As A Chemotherapy-Resistance Modifier in Blast Phase-Chronic Myelogenous Leukemia | 82 | Buffy Coat (27), Whole Bone Marrow (25) |
| SWOG | Leukemia - Acute myelocytic | S9031: Phase III Study of Three Intensive Post-Remission Therapies in Adult Acute Non-Lymphocytic Leukemia: Comparison of Autologous Bone Marrow Transplantation, Intensive Chemotherapy and Allogeneic Bone Marrow Transplantation | 293 | Buffy Coat (86), Whole Bone Marrow (103) |
| SWOG | Melanoma | S9032: Randomized Trial of Adjuvant Immunotherapy with an Allogeneic Melanoma Vaccine for Patients with Intermediate Thickness, Node Negative Malignant Melanoma (T3N0M0), Phase III. | 689 | Buffy Coat (68), Whole Bone Marrow (48) |
| SWOG | Breast | S9034: Prediction of Recurrence and Survival in Node-Negative Breast Cancer Patients Using a Panel of Prognostic Factors: A Companion Protocol to SWOG-8897 (EST-2188, CALGB-8897, INT-0102) | 2,072 | Buffy Coat (199), Fixed Tissue Slide (1), Whole Bone Marrow (226) |
| SWOG | Colon | S9035: Chemoprevention of Recurrent Adenomas and Second Primary Colorectal Carcinoma, A Phase III Pilot Study | 280 | Fixed Tissue Block (39), Fixed Tissue Slide (289) |
| SWOG | Leukemia - Chronic lymphocytic | S9037: A Phase III Comparison of Fludarabine Phosphate (NSC #312887) vs Chlorambucil vs Fludarabine Phosphate Plus Chlorambucil in Previously Untreated B-cell Chronic Lymphocytic Leukemia | 158 | Fixed Tissue (357), Fixed Tissue Slide (4) |
| SWOG | Prostate | S9041: Neoadjuvant Zoladex and Flutamide in Bulky and Non-Bulky Clinical Stage C Carcinoma of the Prostate, Phase II | 62 | Fixed Tissue Block (14), Fixed Tissue Slide (268) |
| SWOG | Hematologic - NOS | S9108: Investigation of G-CSF and Trans-Retinoic Acid in the Treatment of Myelodysplastic Syndrome, Phase I | 7 | Buffy Coat (82), Whole Bone Marrow (64) |
| SWOG | Leukemia - Acute myelocytic | S9109: A Controlled Trial of Cyclosporine as a Chemotherapy- Resistance Modifier in High Risk Acute Myeloid Leukemia, Phase III | 231 | Fixed Tissue Block (4), Plasma (1), Serum (20) |
| SWOG | Leukemia - Acute myelocytic | S9120: Phase III Randomized Study of All-Trans Retinoic Acid versus Cytosine Arabinoside and Daunorubicin as Induction Therapy for Patients with Previously Untreated Acute Promyelocytic Leukemia | 92 | Buffy Coat (3), Whole Bone Marrow (8) |
| SWOG | Lymphoma - Hodgkin's | S9126: Randomized Trial of Subtotal Nodal Irradiation Versus Doxorubicin Plus Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease, Phase III | 348 | Buffy Coat (144), DNA (1), Whole Bone Marrow (179) |
| SWOG | Bladder | S9129: Phase II Study of Oral Bropirimine Combined with Intravesical Bacillus Calmette - Guerin (Tice) in Patients with Carcinoma in Situ of the Bladder | 51 | Buffy Coat (27), Whole Bone Marrow (47) |
| SWOG | CNS | S9133: A Phase II Study of Cisplatin Preceded by a 12-Hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (Ara-C) for Adult Patients with Malignant Gliomas | 76 | Fixed Tissue Block (164), Fixed Tissue Slide (188) |
| SWOG | Prostate | S9149: Central Prostate Cancer Serum Repository Protocol | 1,291 | Fixed Tissue Slide (1) |
| SWOG | Prostate | S9205: Phase II Trial of Casodex in Advanced Prostate Cancer Patients Who Failed Conventional Hormonal Manipulation | 53 | Plasma (9), Serum (67) |
| SWOG | Lymphoma - NOS | S9235: Phase II Trial of Sequential Modification of Immunosuppression, Interferon Alpha, and ProMACE-CytaBOM for Treatment of Post-Organ Transplant Lymphoproliferation | 20 | Plasma (1), Serum (25) |
| SWOG | Lymphoma - Non-Hodgkin's | S9239: A Phase II Trial of CVAD for Treatment of Non-Hodgkin's Lymphoma | 112 | Fixed Tissue Block (3), Fixed Tissue Slide (13), Serum (5) |
| SWOG | Hematologic - NOS | S9240: A Randomized Phase II Evaluation of All Trans-Retinoic Acid (ATRA) with Interferon-Alfa 2a (IFN-alfa 2a) or All Trans-Retinoic Acid with Hydroxyurea (HU) in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase | 116 | Fixed Tissue Block (10), Fixed Tissue Slide (85) |
| SWOG | Rectum | S9304: Postoperative Evaluation of 5-FU by Bolus Injection versus 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT Versus Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT in Patients with Rectal Cancer, Phase III, Intergroup | 1,917 | Buffy Coat (111), Whole Bone Marrow (96) |
| SWOG | Bladder | S9304: Phase II Evaluation of Cisplatin + 5-FU + Radiation Therapy in Patients with Locally Advanced/Inoperable Bladder Cancer | 60 | Fixed Tissue Block (698), Fixed Tissue Slide (878) |
| SWOG | Breast | S9312: Phase III Comparison of Adjuvant Chemotherapy with High-Dose Cyclophosphamide plus Doxorubicin (AC) versus Sequential Doxorubicin followed by Cyclophosphamide (A’C) in High-Risk Breast Cancer Patients with 0 - 3 Positive Nodes (Intergroup) | 3,176 | Fixed Tissue Block (3) |
| SWOG | Breast | S9313: Biologic Factors Predicting Response to Tamoxifen in Patients Registered to SWOG-8228, Ancillary | 227 | Fixed Tissue Block (446), Fixed Tissue Slide (21), Serum (1) |
| SWOG | Lymphoma - NOS | S9314: Study of ProMACE-CytaBOM with Trimethoprim Sulfamethoxazole, Granulocyte Colony Stimulating Factor (G-CSF) and Antiretroviral Therapy in Patients with AIDS Related Lymphoma, Phase II | 52 | Fixed Tissue Block (10) |
| SWOG | Myeloma | S9320: Standard Dose Versus Myeloablative Therapy For Previously Untreated Symptomatic Multiple Myeloma | 899 | Fixed Tissue Block (7), Fixed Tissue Slide (25), Serum (1) |
| SWOG | Leukemia - Acute myelocytic | S9321: Autologous Stem Cell Transplantation for Patients with Acute Myeloid Leukemia Beyond First Remission: A Randomized Trial of Post-Transplant Therapy with Interleukin-2 Versus Observation Phase III | 12 | Cell Slide (14), Fixed Tissue Block (2), Fixed Tissue Slide (492), Whole Bone Marrow (15) |
| SWOG | Leukemia - Acute myelocytic | S9328: A Randomized Controlled Trial of Mitoxantrone and Etoposide versus Daunomycin and Cytosine Arabinoside as Induction Therapy in Patients Over Age 55 With Previously Untreated Acute Myeloid Leukemia, Phase III | 334 | Buffy Coat (4), Whole Bone Marrow (9) |
| SWOG | Breast | S9333: A Study of the Late Cardiac Effects of Two Different Adjuvant Chemotherapy Regimens in Women With Node Negative Breast Cancer Treated on SWOG-8897 | 180 | Buffy Coat (231), Whole Bone Marrow (265) |
| SWOG | Prostate | S9342: Evaluation of Combined Androgen Suppression and Fixed Schedule Suramin in Patients with Newly Diagnosed Metastatic Prostate Cancer, Phase II | 62 | Fixed Tissue (3) |
| SWOG | S9343: | Serum (26) | ||
| SWOG via Navigator | Prostate | S9346: Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III | 3,040 | Buffy Coat (1), DNA (319), Fixed Tissue Slide (3), Plasma (9), Serum (648), Whole Blood (252) |
| SWOG | Breast | S9347: Phase III Comparison of Tamoxifen versus Tamoxifen with Ovarian Ablation in Premenopausal Women with Axillary Node-Negative Receptor-Positive Breast Cancer < 3 cm, Intergroup | 119 | Fixed Tissue Block (86), Fixed Tissue Slide (2) |
| SWOG | Leukemia - Acute lymphocytic | S9400: Treatment of Adult Lymphoblastic Leukemia: A Phase II Trial of An Induction Regimen Including PEG-L-Asparaginase in Previously Untreated Patients, Followed By Allogeneic Bone Marrow Transplantation or Further Chemotherapy In First Complete Remission | 218 | Buffy Coat (142), Plasma (1), Whole Bone Marrow (130) |
| SWOG | CNS | S9402: Phase III Intergroup Randomized Comparison of Radiation Alone Vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas | 41 | Fixed Tissue Block (2) |
| SWOG | Prostate | S9407: Evaluation of Oral Estramustine and Oral Etoposide in Patients with Hormone Refractory Adenocarcinoma of the Prostate, Phase II | 55 | Serum (16) |
| SWOG | Breast | S9410: Doxorubicin Dose Escalation, with or without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen for Node Positive Breast Cancer: A Phase III Intergroup Study | 804 | Fixed Tissue Slide (11) |
| SWOG | Lung | S9424: Phase II Trial of High Dose Tamoxifen Plus Cisplatin Chemotherapy in Metastatic Non-Small Cell Lung Cancer | 82 | Fixed Tissue Block (2) |
| SWOG | Prostate | S9426: A Phase II Trial of Antiandrogen Withdrawal In Patients with Progressive Prostate Cancer | 259 | Serum (56) |
| SWOG | GU - NOS | S9428: Evaluation of DNA Ploidy and p53 in Patients Registered to SWOG-8794 and SWOG-9024, Ancillary | 201 | Fixed Tissue Block (122), Fixed Tissue Slide (44) |
| SWOG | Melanoma | S9431: Cytogenetic, Molecular and Cellular Biology Studies in Metastatic Melanoma Patients, Ancillary | 91 | Buffy Coat (73), Fixed Tissue Block (37), Fixed Tissue Slide (29), Serum (75) |
| SWOG | Lymphoma - Non-Hodgkin's | S9432: Induction Chemotherapy Followed by High Dose Chemoradiotherapy with Autologous Stem Cell Rescue for Patients with Newly Diagnosed Ki67 Diffuse Aggressive Lymphoma, A BMT Study, Phase II | 3 | Fixed Tissue Block (1), Fixed Tissue Slide (2) |
| SWOG | Gastrointestinal stromal tumor | S9444: Gastrointestinal Tumor Repository Protocol, Ancillary | 416 | Fixed Tissue Block (250), Fixed Tissue Slide (377) |
| SWOG | Prostate | S9452: A Phase III Study of Three Different Doses of Suramin (NSC# 34936) Administered with a Fixed Dosing Schedule in Patients with Advanced Prostate Cancer | 26 | Serum (3) |
| SWOG | Leukemia - Acute myelocytic | S9500: A Phase II Study of 7 + 3 and High Dose Ara-C Induction Therapy with Sequential High-Dose Ara-C Consolidation Therapy for Adults with De Novo Acute Myeloid Leukemia | 104 | Buffy Coat (78), Whole Bone Marrow (99) |
| SWOG | Lymphoma - Non-Hodgkin's | S9501: A Phase II Trial of Fludarabine and Mitoxantrone (FN) for Treatment of Non-Hodgkin's Lymphoma | 92 | Fixed Tissue Block (64), Fixed Tissue Slide (55), Whole Bone Marrow (1) |
| SWOG | Lung | S9509: A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Vinorelbine and Cisplatin in Untreated Advanced Non-Small Cell Lung Cancer | 444 | Fixed Tissue Block (9), Fixed Tissue Slide (1) |
| SWOG | Prostate | S9510: Evaluation of Topotecan in Hormone Refractory Prostate Cancer, Phase II | 31 | Plasma (1), Serum (7) |
| SWOG | Breast | S9514: Phase III Double-Blind, Placebo Controlled, Prospective Randomized Comparison of Adjuvant Therapy with Tamoxifen vs. Tamoxifen and Fenretinide in Postmenopausal Women with Positive Receptors, Intergroup | 144 | Fixed Tissue Block (103), Fixed Tissue Slide (3) |
| SWOG | Prostate | S9615: Neoadjuvant Hormonal Therapy Prior to Radical Prostatectomy for T1 - 2 Adenocarcinoma of the Prostate, Phase III | 38 | Plasma (5), Serum (20) |
| SWOG | Leukemia - Acute myelocytic | S9617: A Phase I Study of PSC833 As Chemotherapy – Resistance Modifier in Patients Over Age 55 With Previously Untreated Myeloid Leukemia (AML). | 31 | Buffy Coat (22), Whole Bone Marrow (29) |
| SWOG | Breast | S9623: A Comparison of Intensive Sequential Chemotherapy using Doxorubicin plus Paclitaxel plus Cyclophosphamide with High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women with >= 4 Involved Axillary Lymph | Fixed Tissue Block (198), Fixed Tissue Slide (2) | |
| SWOG | Lymphoma - NOS | S9704: A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas(with Possible Late Autologous Stem Cell Transplant) for Patien | 419 | Serum (23) |
| SWOG | Leukemia - Chronic lymphocytic | S9706: A Phase II Trial of High Dose Cyclophosphamide Followed by Fludarabine in Patients with Previously Untreated B-Cell Chronic Lymphocytic Leukemia | 51 | Buffy Coat (43), Whole Bone Marrow (40) |
| SWOG | Breast | S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Pilot Study Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence, Ancillary to S9623 | 29 | Buffy Coat (17), Whole Blood (1), Whole Bone Marrow (4) |
| SWOG | Lymphoma - Non-Hodgkin's | S9800: A Phase II Pilot Trial of CHOP Followed by Rituximab Chimeric Monoclonal Anti-CD20 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas | 104 | Cell Slide (2), Fixed Tissue Block (47), Fixed Tissue Slide (44), Serum (1) |
| SWOG | Lung | S9900: A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB(T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC). | 354 | Fixed Tissue Block (22), Fixed Tissue Slide (1) |
| SWOG | Lymphoma - Hodgkin's | S9901: A Randomized Phase III Trial Comparing Early High Dose Chemotherapy and an Autologous Stem Cell Transplant to Conventional Dose ABVD Chemotherapy for Patients with Advanced Stage Poor Prognosis Hodgkin’s Disease as Defined by the International Prognostic | 11 | Fixed Tissue Block (8), Fixed Tissue Slide (8), Whole Bone Marrow (1) |
| SWOG via Navigator | Hematologic - NOS | S9910: Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary | 1,294 | Buffy Coat (133), DNA (2), Plasma (263), RNA (3), Whole Bone Marrow (114) |
| SWOG | Lymphoma - Non-Hodgkin's | S9911: A Phase II Pilot Trial of CHOP Followed By Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas | 102 | Fixed Tissue Block (4), Fixed Tissue Slide (8), Serum (2) |
| SWOG | Prostate | S9916: Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer, Phase III. | 770 | Serum (90) |
| SWOG | Leukemia - Acute myelocytic | S9918: A Phase II Study of Daunomycin and Ara-C Given by Continuous IV Infusion with PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older | 18 | Buffy Coat (17), Whole Bone Marrow (17) |
| SWOG via Navigator | Prostate | S9921: Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III. | 983 | Buffy Coat (2), Fixed Tissue Block (46), Fixed Tissue Slide (70), Plasma (66), Serum (279), Whole Blood (61) |
| SWOG | Lung | S9925: Lung Cancer Specimen Repository Protocol, Ancillary | 2,260 | Buffy Coat (1), Fixed Tissue Block (22), Fixed Tissue Slide (3), Plasma (1) |
| SWOG | Breast | S9927: Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes, Phase III | 98 | Fixed Tissue Block (31) |